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Abstract 
 
Neutrophil function in the pathogenesis of chronic periodontitis was investigated. A case-
controlled longitudinal intervention study of patients with chronic periodontitis and matched 
healthy controls was performed. Peripheral blood neutrophils from patients released more IL-
8, IL-6, IL-1β and TNF-α in response to periodontally-relevant bacteria than controls. Hyper-
reactive Fusobacterium nucleatum-stimulated neutrophil IL-8, IL-6 and TNF-α release from 
patient cells normalised to control levels following successful therapy. Hyper-reactive FcγR-
stimulated IL-8, IL-6, IL-1β and TNF-α and Porphyromonas gingivalis-stimulated IL-1β 
release by patient cells persisted after therapy. Patient neutrophils displayed hyper-active and 
hyper-reactive superoxide release that normalised to healthy control levels post-therapy. 
Although neutrophil extracellular trap release was unchanged in periodontitis, patient 
neutrophils demonstrated impaired directional chemotactic accuracy, speed and velocity. 
Studies on control neutrophils demonstrated that physiologically-relevant concentrations of 
C-reactive protein (CRP) inhibited baseline reactive oxygen species (ROS) generation, and 
reduced FcγR–stimulated superoxide and F. nucleatum-stimulated luminol/isoluminol 
detectable ROS. However, CRP enhanced F. nucleatum-stimulated neutrophil superoxide 
release. The data demonstrate that chronic periodontitis is characterised by dysregulated 
neutrophil function, notably heightened cytokine and superoxide production and impaired 
chemotaxis.  Furthermore, mildly elevated CRP levels in periodontitis could play a role in 
modifying the neutrophil respiratory burst and provide a link with periodontitis-associated 
systemic disease.  
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1.1 PERIODONTAL DISEASES 
The periodontal tissues form the supporting structures of the human dentition and comprise of 
alveolar bone, root cementum, periodontal ligament, and gingival connective tissues covered 
by crevicular and junctional epithelium. The crevicular epithelium is highly porous with 
gingival crevicular fluid (GCF) continually released into the gingival crevice as a serum 
transudate arising from the surrounding vasculature. In response to intra-oral microbial 
exposure the periodontal tissues are readily infiltrated by polymorphonuclear leukocytes 
(neutrophils; section 1.5) recruited from the periodontal vessels into the periodontal tissues. 
Neutrophils are also present within GCF which becomes a serum exudate during gingival and 
periodontal inflammation.  
 
1.1.1 Chronic periodontitis 
Chronic periodontitis is a common inflammatory condition affecting the periodontal tissues 
resulting in irreversible apical migration of the junctional epithelium, loss of periodontal 
attachment and ultimately tooth loss (Löe et al. 1986). Chronic periodontitis represents a 
pathological progression from gingivitis which, in contrast, is a reversible inflammation in 
response to intra-oral plaque bacteria that is restricted entirely to the gingival soft tissues 
without loss of periodontal connective tissue attachment. Chronic periodontitis is clinically 
and pathologically distinct from other less common periodontal diseases such as aggressive 
and necrotizing ulcerative periodontitis (Milward & Chapple 2003).  
 
The UK Adult Dental Health Survey has highlighted that approximately half of all dentate 
adults have evidence of current periodontal disease, with approximately 66% of adults aged 
>55yrs having evidence of loss of periodontal attachment (White et al. 2012). Periodontal 
disease is the leading cause of tooth loss in the world (Papapanou 1999), with chronic 
periodontitis the most common form representing the vast majority of all periodontal diseases 
(Demmer & Papapanou 2010). It is important to appreciate that chronic periodontitis is a 
chronic, largely asymptomatic condition that may go unnoticed by the patient unless regularly 
screened by a dental professional, and this is likely to be reflected in the high worldwide 
prevalence of this disease and subsequent impact on healthcare costs.  
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1.1.2 Clinical diagnosis of chronic periodontitis 
General Dental Practitioners screen for the presence of periodontal diseases by performing a 
Basic Periodontal Examination (BPE) followed, where appropriate, by a detailed periodontal 
examination. The latter includes measuring periodontal probing pocket depths and recession 
(together measuring clinical attachment loss), tooth mobility, occlusal assessment, the 
presence of bleeding on probing and plaque scoring along with appropriate radiographic 
examination. Once identified, periodontal diseases are then classified in order to reflect the 
differing pathogeneses of these conditions and also to provide an indication as to the most 
appropriate treatment strategy (Armitage 1999). Chronic periodontitis may be defined as the 
presence of at least two non-adjacent sites per quadrant with probing pocket depths >4mm 
along with radiographic bone loss >30% of the root length (non-first molar or incisor sites) in 
accordance with the consensus criteria of the European Federation of Periodontology (Tonetti 
& Claffey 2005). Periodontal health is regarded as being consistent with probing pocket 
depths <4mm (Matuliene et al. 2008), bleeding scores <10% (Lang et al. 1986, 1990) and 
plaque scores <20% (Lang & Tonetti 1996). The presence of gingival recession without 
pocketing represents historical attachment loss that may no longer be active, or tissue loss due 
to traumatic toothbrushing. 
 
1.2 THE PATHOGENESIS OF CHRONIC PERIODONTITIS 
The presence of plaque bacteria is a pre-requisite for gingivitis (Löe et al. 1965, Theilade et 
al. 1966) however gingivitis does not always progress to chronic periodontitis. Approximately 
10% of the population are resistant to the development of periodontitis (Löe et al. 1986). The 
presence of pathogenic plaque bacteria within a susceptible host results in a pathological 
transition from gingivitis to chronic periodontitis, the pathogenesis of which is currently 
poorly understood, but is likely to be caused either directly by periodontal pathogens or 
alternatively as a result of a dysregulated host inflammatory-immune response (Van Dyke 
2008).  
 
1.2.1 The role of bacteria 
Whilst intra-oral bacteria are present naturally, plaque deposits accumulate around the teeth in 
the absence of adequate oral hygiene measures. Supra-gingival plaque is a risk factor for 
dental caries (Mannaa et al. 2013) but also eventually leads to the accumulation of a plaque 
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biofilm sub-gingivally (Kornman 1986). Subgingival plaque bacteria form a biofilm within 
the gingival crevice through the interaction of early and eventually late bacterial colonisers, 
and the salivary molecules of the acquired pellicle surrounding the root dentine (Walket & 
Sedlacek 2007). The subgingival microbial flora is complex and it has been estimated that 
approximately 1,200 species of bacteria have the potential to colonise the periodontium at any 
one time (Paster et al. 2001). However only relatively few periodontal bacteria are directly 
involved in periodontal pathogenesis, and a single causative pathogen has not been identified 
(Socransky et al. 1984). The healthy subgingival microflora consists mainly of facultative 
(both aerobic and anaerobic capabilities) anaerobic Gram positive bacteria, with only 
approximately 5% spirochaetes and motile rods. As the transition from periodontal health to 
gingivitis and chronic periodontitis progresses, a microbial shift occurs with a greater 
proportion of anaerobic, Gram negative spirochaetes and other motile bacteria (Listgarten et 
al. 1978, Marsh 1994). In chronic periodontitis approximately 75% of bacteria are Gram 
negative, of which 90% are strict anaerobes (Marsh 1994). 
 
There are three main theories describing the role of bacteria in the pathogenesis of 
periodontitis. The theory that a limited number of specific bacterial species trigger periodontal 
inflammation is known as the “specific plaque hypothesis” (Loesche 1976). Bacteria have the 
ability to cause disease by directly releasing damaging proteolytic and hydrolytic enzymes 
that may also directly damage the surrounding tissues. Alternatively bacteria may also induce 
a dysregulation of the host response as a result of interaction with surrounding host cells 
(Dale 2002, Milward et al. 2007). Gram-negative anaerobic bacterial pathogens such as 
Fusobacterium nucleatum and Porphyromonas gingivalis are widely regarded as key 
aetiological species (Socransky et al. 1998) and are considered important regulators of the 
host response. This is due to their ability to invade cells and tissues therefore promoting 
bacterial survival, modulating virulence properties along with dysregulation of the 
inflammatory response of the invaded cell (Han et al. 2000, Eick et al. 2006). In addition, F. 
nucleatum coaggregates with other periodontal bacteria via coaggregation receptors, thereby 
acting as a bridge between early and late colonisers (Rickard et al. 2003). In addition, 
anaerobic secondary colonisers, such as P. gingivalis, are unable to survive in the planktonic 
state unless coaggregated to F. nucleatum (Diaz et al. 2002) therefore highlighting the 
importance of F. nucleatum not only with regards to the development of dental plaque, but 
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also in mediating the microbial shift from a non-pathogenic to a pathogenic microflora 
(Kolenbrander et al. 1995; section 1.2.1). Porphyromonas gingivalis is strongly associated 
with periodontal disease pathogenesis (Socransky et al. 1998) and has many different pro-
inflammatory activities. These include the secretion of destructive proteinases (O’Brien-
Simpson et al. 2003), along with effects on cytokine induction, neutrophil chemotaxis and 
contributing to alveolar bone loss by stimulating bone resorption, inducing bone destruction 
and inhibiting bone formation (Lamont & Jenkinson 1998).  
 
The second theory, the “non-specific plaque hypothesis,” proposes that plaque bacteria will 
become pathogenic when a threshold volume is reached, irrespective of its constitution 
(Theilade 1986). This occurs by effectively disrupting host-bacterial homeostasis and 
triggering a host-inflammatory response through non-specific mechanisms such as activation 
by bacterial lipopolysaccharide (LPS; Marsh 2005). Indeed, there is reproducible evidence 
using a 21-day gingivitis model describing the relationship between plaque accumulation and 
gingivitis showing that plaque mass alone does induce gingival inflammation (Löe 1973). 
Whilst the “non-specific plaque hypothesis” is important in the development of gingivitis, it is 
likely that specific bacteria play a larger role in periodontal pathogenesis. This is because, in 
contrast to gingivitis, periodontal disease severity rarely directly correlates clinically with the 
amount of plaque present, along with different thresholds of plaque control required for 
different patients with regards to ultimately achieving periodontal stability. As previously 
discussed, a number of key periodontal pathogens are considered to be important in the 
pathogenesis of chronic periodontitis including P. gingivalis and F. nucleatum (Socransky et 
al. 1998). This is reflected in their widespread selection in relation to published literature and 
current studies investigating the host response in chronic periodontitis. However, as 
previously stated, periodontal pathogens form bacterial complexes in-vivo rather than existing 
in isolation, and therefore a third hypothesis was postulated by Haffajee in 1991, namely the 
“environmental plaque hypothesis” which suggests that the entire subgingival microbial 
environment is involved in periodontal pathogenesis (Haffajee et al. 1991).  
 
1.2.2 The role of the host response 
The two main components of the host response to plaque bacteria are the innate and the 
acquired immune responses. The innate immune system is constantly in function and occurs 
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rapidly, whereas additional time is required for generation of the acquired immune response. 
Both the innate and acquired immune responses have the potential to cause collateral tissue 
damage if not regulated or controlled correctly. Early gingival inflammation largely involves 
the innate system whereas the acquired system also becomes involved in moderate-to-
advanced gingivitis and periodontitis i.e. longer-term, chronic disease (Teng 2003). 
 
The pathogenesis of chronic periodontitis, including the transition from gingivitis to 
periodontitis, involves an imbalanced host-derived inflammatory-immune response, 
coordinated by locally and systemically-derived cytokines (Page 1991, Preshaw et al. 2011, 
Deo & Bhongade 2010). Crevicular epithelial cells and tissue-resident macrophages within 
the periodontal connective tissues are involved in the recognition of plaque bacteria via Toll-
like receptors (TLR) which bind bacterial components such as lipopolysaccharide (LPS), 
lipotechoic acids and/or bacterial DNA. Receptor binding then activates intra-cellular 
signalling pathways (e.g. via transcription factors such as NF-κB) resulting in the secretion of 
a number of key cell signalling molecules into the surrounding tissues, including chemokines 
(e.g. IL-8) and cytokines (e.g. IL-6, IL-1β, TNF-α) that are involved in the recruitment and 
activation of immune cells. Secreted cytokines and chemokines subsequently diffuse from the 
site of production, creating a gradient of concentrations and resulting in the recruitment and 
infiltration of inflammatory cells such as neutrophils from the surrounding vasculature. 
Neutrophils are the most abundant defence cell (section 1.5) and once recruited to the site of 
infection, kill bacteria by either intra- or extra-cellular methods. In addition, macrophages 
scavenge dead cells (both bacterial and host) and also play an important role in bridging the 
gap between innate and acquired immunity by acting as antigen presenting cells leading to the 
development of acquired immuntity. 
 
In periodontal health the junctional epithelium naturally forms an epithelial attachment via 
hemi-desmosomes to the tooth enamel derived from ectoderm embryologically (inner enamel 
epithelium). However once attachment loss occurs, either through periodontitis or recession, 
irreversible apical migration and elongation of the junctional epithelium occurs which then 
migrates onto root cementum, derived from mesenchyme (Pitaru et al. 1994). This situation is 
similar to that of a compound fracture of bone where direct communication exists between the 
external environment and an internalised part of the skeleton, namely the tooth with its 
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investing alveolar bone emerging through an epithelial lining. Migration of the junctional 
epithelium allows subgingival bacteria to be adjacent to the cementum and junctional 
epithelium that was previously associated with attached gingival connective tissue (Nanci & 
Bosshardt 2006). Therefore the junctional epithelium is permeable to GCF carrying host 
defence cells (mainly neutrophils) and various other components of the inflammatory-immune 
response such as complement and antibody. However the downside of this arrangement is that 
bacterial products can then also pass back into the gingival tissues and stimulate both local 
and systemic inflammatory reactions (section 1.3). Subgingival plaque accumulation leads to 
micro-ulceration of the crevicular epithelium accounting for the clinical sign of bleeding on 
probing, as well as further propagating inflammatory-immune responses within the 
surrounding connective tissues and systemic circulation.  
 
Bacteria are essential to the pathogenesis of periodontitis however plaque bacteria alone are 
insufficient to cause periodontal disease. The presence of supragingival plaque deposits is 
inversely associated with the severity of periodontal attachment loss with a relative risk of 0.2 
(Grossi et al. 1994), with the majority of periodontal tissue damage attributed to a 
dysregulated host response (Page et al. 1997). Whilst host responses are designed to be 
protective, the balance between bacterial-host interactions is delicate and under- or over-
activity potentially results in tissue destruction. In health a balance is achieved between the 
oral bacteria and the host response, however such equilibrium may easily be disrupted leading 
to inflammation and tissue damage. Chronic periodontitis is predominantly characterised by a 
neutrophilic inflammatory response which can represent both the first line of defence in the 
innate immune response and part of the effector cell arm of the acquired immune response. A 
“hyper-inflammatory” neutrophil phenotype is considered central to the pathogenesis of 
chronic periodontitis with subgingival plaque resulting in an exaggerated inflammatory-
immune response causing disease. Subsequent failure to remove plaque bacteria via adequate 
oral hygiene and periodontal treatment causes chronicity of the inflammatory lesion. 
Neutrophilic “hyper-inflammation” is also a characteristic of many systemic inflammatory 
diseases associated with chronic periodontitis such as diabetes and cardiovascular disease 
(section 1.3) and may represent mechanisms with which periodontitis contributes to co-
morbidity.  
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1.3 RELATIONSHIP WITH SYSTEMIC DISEASE 
As a result of periodontal inflammation due to plaque accumulation, the crevicular epithelium 
ulcerates (section 1.2.2) and exposes a surface area of exposed gingival connective tissue and 
associated vasculature similar in size to that of the palm of the hand (8-20cm
2
; Hujoel et al. 
2001). As a result, periodontal bacteria and their virulence factors have the potential to enter 
the surrounding tissues and vasculature causing not only local but also systemic acute-phase 
and inflammatory-immune consequences (Loos 2005, Seymour et al. 2007).  
 
The “focal infection theory” was first postulated by Hippocrates (460-370BC) who was first 
to recognise that localised sites of infection, such as the periodontal tissues, may disseminate 
to distant locations which may then result in secondary infections that initiate, sustain or 
worsen systemic disease (Graham 1931, Pallasch & Wahl 2000).  Hippocrates was 
subsequently said to have reported the successful treatment of rheumatoid arthritis by 
extraction of an infected tooth. In addition, Elie Metchnikoff (1845-1916), who discovered 
neutrophil phagocytes, also drew attention to bacteria as potential causes of both septic and 
aseptic inflammatory disease (Metchnikoff 1907). A British surgeon William Hunter (1861-
1937) subsequently identified oral sepsis as a cause of systemic diseases (Hunter 1900, 1901) 
and later claimed that “the worst cases of anaemia, gastritis, colitis, obscure fevers, nervous 
disturbances of all kinds from mental depression to actual lesions of the cord, chronic 
rheumatic infections, kidney diseases are those which owe their origin to or are gravely 
complicated by the oral sepsis produced by these gold traps of sepsis”, referring to the 
presence of dental restorations (Hunter 1923).  Therefore, it has long been recognised that 
periodontal diseases have the potential to influence the systemic health of patients. More 
recent evidence suggests that chronic periodontitis serves as a source of pro-inflammatory 
mediators resulting in an exaggerated systemic inflammatory-immune response which may 
then contribute to the development of systemic disease (Tonetti & Van Dyke 2013). 
 
Chronic periodontitis is associated with many chronic inflammatory diseases including type-2 
diabetes (Chapple & Genco 2013), atherogenic cardiovascular disease (Dietrich et al. 2013), 
rheumatoid arthritis (DePablo et al. 2009), chronic kidney disease (Sharma et al. 2014) and 
chronic obstructive pulmonary disease (Linden & Herzberg 2013). Evidence implicating 
chronic periodontitis in the causal pathway of chronic diseases varies according to the 
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condition, and the European Federation of Periodontology (EFP) and American Academy of 
Periodontology (AAP) recently held a joint workshop compiling a number of comprehensive 
systematic reviews (Tonetti & Kornman 2013). The strongest evidence implicating chronic 
periodontitis in the causal pathway of chronic diseases relate to a bi-directional relationship 
with type-2 diabetes in which patients with periodontitis are 6-times more likely to have poor 
glycaemic control which improves following periodontal treatment (Taylor et al. 2001). 
Periodontal examination and treatment is now included in the consensus report of the joint 
European Federation and American Academy of Periodontology regarding the joint dental 
and medical management of patients diagnosed with type-2 diabetes and typically resulting in 
an approximately 0.4% reduction in HbA1C at 3 months (Chapple & Genco 2013). Meta-
analyses have also demonstrated that patients with chronic periodontitis have a 34% increased 
risk of developing cardiovascular disease (Blaizot et al. 2009) and are 2.9 times more likely to 
suffer from ischaemic stroke (Janket et al. 2003), with periodontal treatment resulting in 
consistent and progressive reductions in systemic inflammation and biomarkers of disease 
risk, including improvements in vascular endothelial function and flow-mediated dilation 
(Tonetti et al. 2007). The impact of chronic periodontitis on systemic health is further 
emphasised and associated with an overall <85% increased risk of premature death resulting 
from all-cause mortality (Garcia et al. 1998).  
 
Systematic reviews and meta-analyses have demonstrated that patients with chronic 
periodontitis have raised levels of inflammatory mediators within the circulation including 
acute phase reactants such as C-reactive protein (CRP), that are lowered following periodontal 
treatment (Paraskevas et al. 2008). Systemic CRP concentrations are widely used medically to 
assess the presence of systemic inflammation and also to determine cardiovascular disease 
risk (Ridker 2003; section 1.7.1). Undiagnosed or untreated periodontal disease is therefore 
likely to increase the systemic inflammatory burden and hence the risk of co-susceptibility 
and co-morbidity. Similarly, both periodontitis and other chronic inflammatory diseases are 
associated with a “hyper-inflammatory” neutrophil phenotype (section 1.2.2) and this is likely 
to further contribute to co-susceptibility, co-morbidity and possibly represent a causal link 
between periodontal and other prevalent systemic inflammatory-immune diseases. The 
consensus view currently is that it is likely that the association between periodontitis and 
systemic disease are linked as a result of a repeated bacteraemia during eating, toothbrushing 
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and daily function, triggering a systemic inflammatory-immune response, with persistent 
chronic entry of oral bacteria into the blood stream arising from the periodontium (Tonetti & 
Kornman 2013).  
 
1.4 RISK FACTORS FOR CHRONIC PERIODONTITIS 
Risk factors increase the probability of a disease developing in a given individual. Risk 
factors for chronic periodontitis may be classified as locally or systemically-derived (Van 
Dyke & Sheilesh 2005) and have the potential to alter the microflora and/or the host response. 
The host’s inflammatory-immune response to bacteria is largely genetically determined, 
however environmental and lifestyle factors play important modifying roles (Tonetti & 
Chapple 2011).  
 
The most important modifiable risk factor is oral hygiene (plaque control), since removal of 
the initiating factor avoids activating the chronic non-resolving inflammation that 
characterizes chronic periodontitis and gingivitis. Local risk factors for periodontitis relate 
directly to plaque accumulation or barriers to biofilm removal, for example the presence of 
calculus, furcation involvement and overhanging or deficient restoration margins. There are 
also many systemic risk factors which impact upon the systemic inflammatory-immune 
response and therefore the risk of chronic periodontitis, and also vice-versa in a bi-directional 
manner (section 1.3; Taylor et al. 2001).  
 
Natural history studies observing the progression of periodontitis including longitudinal 
studies of tea plantation workers in Sri Lanka have demonstrated three subsets of the 
population relative to the development of periodontitis, namely high risk (~10%) and resistant 
(~10%) groups, with the majority (~80%) classified retrospectively as having medium risk of 
developing periodontitis (Löe et al. 1978, 1986). Genetic susceptibility is regarded as 
representing approximately half of chronic periodontitis disease risk and prevalence based on 
twin studies (Michalowicz 1994), with several single gene polymorphisms subsequently 
investigated and the recent use of genome-wide association studies (Vaithilingam et al. 2014).  
 
In contrast to genetic factors, many local and systemic risk factors are modifiable and 
therefore have the potential to minimize disease risk. The most important modifiable risk 
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factor is a patient’s oral hygiene, with full-mouth plaque scores <20% being associated with 
continued periodontal stability (Lang & Tonetti 1996). In addition, smoking is considered a 
significant risk factor for chronic periodontitis (Palmer et al. 2005) with smokers 2-3 times 
more likely to develop periodontitis (Dietrich et al. 2007), and also exhibiting poorer 
responses to treatment (Heasman et al. 2006). Whilst cigarette smoke extract generally 
decreases neutrophil reactive oxygen species (ROS) generation, at higher concentrations 
possibly seen in heavy smokers it also stimulates peripheral blood neutrophil extracellular 
ROS release in a dose-dependent manner (Matthews et al. 2011) which may contribute to a 
“hyper-inflammatory” neutrophil phenotype. Similarly, type-2 diabetes displays a unique bi-
directional relationship with chronic periodontitis (Taylor 2001) and is similarly associated 
with enhanced peripheral blood neutrophil reactive oxygen species (ROS) (Wong et al. 2002), 
cytokine release (Hatanaka et al. 2006), and oxidative stress (Allen et al. 2011). The presence 
of a “hyper-inflammatory” neutrophil phenotype within periodontitis (section 1.3) may result 
in increased neutrophil ROS release leading to oxidative stress (Sies 1986, Halliwell 1990). 
Increased antioxidant intake may therefore help to restore this balance and therefore reduce 
periodontal (and other systemic) disease risk (Chapple 2009). Micronutritional approaches to 
reduce periodontal disease risk by modifying ROS activity have since been highlighted as 
novel therapeutic approaches (Van der Velden et al. 2011). Additional systemic risk factors 
include psychosocial stress that has the ability to not only modify the growth of periodontal 
bacteria (Roberts et al. 2002, 2005) but also impact upon neutrophil responses (Ellard et al. 
2004, 2005). Given the importance of the neutrophil in the host response in periodontitis 
(section 1.2.2), qualitative and quantitative defects in neutrophil numbers (e.g. neutropenia) 
and function (e.g. Papillon-Lefèvre syndrome) increase the risk of very severe forms of 
periodontal disease, along with serious systemic illness, particularly in young children 
(Kanthimathinathan et al. 2013).  
 
1.5 NEUTROPHILS IN HEALTH & DISEASE 
Neutrophils are terminally differentiated leucocytes derived from myeloblasts and produced 
in the bone marrow (Amulic et al. 2012). They account for 50-60% of all leukocytes in 
peripheral blood, with normal mean numbers of ~4.4x10
6
 cells/ml. Neutrophils were 
traditionally regarded as being relatively short-lived however more recent evidence from in-
vivo life expectancy studies have demonstrated neutrophil half-lives as long as 5.4 days 
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(Pillay et al. 2010) and produced in large numbers (1-2x10
11
 cells generated per day; 
Borregaard et al. 2010). They are approximately 9-10µm in diameter and have a characteristic 
multilobed nucleus (Figure 1.1). Neutrophils also possess unique staining characteristics with 
haematoxylin and eosin histological or cytological preparations and stain a neutral pink, 
which allows them to be  distinguished from other types of polymorphonuclear leucocytes 
including basophils and eosinophils (Alberts et al. 2002; Figure 1.2).  
 
 
 
Figure 1.1. Transmission electron micrograph image of a human neutrophil showing 
the characteristic multilobed nucleus and granule-dense cytoplasm (Brinkmann & 
Zychlinsky 2007). 
 
 
Figure 1.2. A neutrophil with characteristic multilobed nucleus is visible alongside 
other immune cells within a light photo micrograph of a blood smear with 
Romanowsky stain (Alberts et al. 2002). 
 
 
The first line of cellular inflammatory-immune defence involves the recruitment of large 
numbers of neutrophils from the systemic circulation to the site of tissue damage or infection. 
Neutrophils kill invading bacteria by phagocytosis, release of intra- and extracellular ROS 
(Chapple & Matthews 2007), neutrophil extracellular traps (NETs; Brinkmann et al. 2004; 
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section 1.5.4.5) as well as hydrolytic and proteolytic enzymes and antimicrobial peptides 
(Borregaard & Cowland 1997). Neutrophils also play an active role in coordinating the 
inflammatory-immune response through the release of cytokines including IL-6, IL-8, IL-1β 
and TNF-α (Cassatella et al. 1997, 1999).  
 
1.5.1 Neutrophil cytokine release 
For a long time, monocytes and lymphocytes were primarily regarded as the predominant 
source of pro-inflammatory cytokines in inflammatory lesions. By contrast, neutrophils were 
initially thought to produce only IL-8 (Bazzoni et al. 1991, Cassatella et al. 1992, 1993, 
Arnold et al. 1994, Wei et al. 1994, Altstaedt et al. 1996), possibly as a result of containing 
relatively few ribosomes and little endoplasmic reticulum. However, neutrophils have since 
been shown to release physiologically-relevant concentrations of important cytokines 
including IL-6, IL-8, IL-1β and TNF-α (Cassatella et al. 1997, 1999, Kasama et al. 2005) and 
play an active role in co-ordinating the inflammatory-immune response, in addition to their 
traditional antimicrobial activity. It is now believed that cytokines within the periodontium 
interact together in a network thereby modulating the inflammatory-immune response and the 
pathogenesis of periodontitis (Preshaw & Taylor 2011). Neutrophils are known to release a 
large number of cytokines (Table 1.1) and chemokines (Table 1.2) in response to a variety of 
conditions, which have a variety of intercalated functions within a network in the 
pathogenesis of chronic periodontitis (Tables 1.1 and 1.2)  
 
1.5.2 Neutrophil recruitment from the systemic circulation 
Epithelial cells of the crevicular epithelium along with resident tissue macrophages and 
neutrophils respond to the presence of bacteria by releasing cytokines and chemokines 
thereby activating the inflammatory-immune response. Cytokines and chemokines, along with 
bacterial products themselves such as fMLP (N-formyl-Met-Leu-Phe) and lipopolysaccharide 
(LPS) subsequently diffuse into the periodontal tissues activating endothelial cells within the 
surrounding vasculature (Chen et al. 2009). TNF-α and IL-1β subsequently upregulate 
endothelial cell adhesion molecules (intracellular adhesion molecules 1 & 2 and vascular cell 
adhesion molecules) that interact with neutrophil integrins (Kettritz et al. 2004, Zhang et al. 
2011). Initial binding between the neutrophils and vascular endothelium is not absolute but 
involves “make and break” contacts which slows the neutrophil and allows it to “roll” across 
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the endothelium (Goetz et al. 1994). Vascular permeability is increased in the presence of 
factors such as complement component C5a and leukotriene B4 (LTB4) (DiStasi & Ley 2009) 
allowing the neutrophil to transmigrate between the endothelial cells (diapedesis; Kvietys & 
Sandig 2001). Neutrophil diapedesis is facilitated by the characteristic lobulated nucleus and 
the actin cytoskeleton thereby enabling flexible movement. Extravasated neutrophils are then 
recruited to sites of tissue injury or infection in response to chemotactic gradients present 
within the periodontal tissues including the chemotaxins CXCL8 (IL-8), fMLP and MIP-1α.  
 
1.5.3 Neutrophil chemotaxis 
Once neutrophils are recruited into the surrounding tissues, chemokines such as CXCL8 (IL-
8) as well as bacterial products such as fMLP, create a chemotactic gradient essentially by 
diffusion away from the site of production. This directs host inflammatory-immune cells, 
including neutrophils, to the site of inflammation via chemotaxis (Kolaczkowska & Kubes 
2013). Neutrophil chemotaxis involves several stages which, to date, are relatively poorly 
understood but initially involve the binding of chemoattractants to specific cell surface 
receptors. Bacterial formylpeptides such as fMLP are one of the major chemotactic stimuli 
(Maney & Walters 2009) and neutrophils typically express approximately 55,000 G-protein-
coupled formylpeptide receptors (FPRs) per cell (Pike & Snyderman 1988, Maney & Walters 
2009) which, when activated, initiate a cascade of enzymatic reactions resulting in cell 
polarisation, orientation and migration towards the source of the chemoattractant (Snyderman 
& Goetzl 1981, Springer 1995, Katanaev 2001, Yagi et al. 2009). Activation of 
phosphoinositide 3-kinase (PI3K) (Hawkins et al. 2006) following signal transduction with 
phosphodinositide-dependent kinase (PDK1) (Yagi et al. 2009) leads to the accumulation of 
phosphatidylinositol (3,4,5)-triphosphate (PIP3) along the leading edge of the migrating 
neutrophil thereby regulating cell orientation (Andrew & Insall 2007, Yagi et al. 2009). This 
is followed by rapid morphological changes from round, relatively smooth cells to elongated 
ruffled cells with the formation of pseudopodia including a frontal protrusion which 
effectively pulls the neutrophil forward in a crawling motion. This is based on the reversible 
assembly of plasma membrane-associated microfilamentous cytoskeletal structures including 
monomeric globular G-actin conversion to polymerised filamentous F-actin (Stossel 1993, 
Champagne et al. 1998). The kinetics of actin polymerisation-depolarisation determines shape 
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changes that occur in the plasma membrane-assocated cytoskeleton to provide the driving 
force for directional cell migration (Champagne et al. 1998). 
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Cytokine Stimuli Reference Functions Reference 
IL-1α HAP Velard et al. 2009 Neutrophil chemotaxis Lee et al. 2011 
      ↑ neutrophil ROS Yagisawa et al. 1995 
IL-1ra LPS Muzio et al. 1994 IL-1 receptor antagonist Ruth et al. 1996 
  Y-IgG / fMLP Cassatella et al. 1997     
  GM-CSF / TNF-α McColl et al. 1992     
IL-1β Unstimulated/GM-CSF Galbraith et al. 1997 Neutrophil chemotaxis Oliveira et al. 2008 
  LPS Jenkins et al. 1994 ↑ hepatic acute-phase protein Gabay et al. 2001 
  Casein Goto et al. 1989 
 
  
IL-3 Ionomycin / PMA Kato et al. 1990 Haemopoietic growth factor Korpelainen et al. 1996 
IL-6 Unstimulated Melani et al. 1993 ↑ hepatic acute-phase protein Heinrich et al. 1990 
  LPS Hatanaka et al. 2006 ↑ osteoclast activity Adebanjo et al. 1998 
    
 
↑ B-cell differentiation Maeda et al. 2010 
    
 
↑ T-cell activation Kishimoto 1989 
    
 
Neutrophil chemotaxis Fielding et al. 2008 
      ↑ ICAM-1 induction Wung et al. 2005 
IL-10 Unstimulated Ocuin et al. 2011 ↓ neutrophil ROS Dang et al. 2006 
  C. albicans Romani et al. 1997 ↓ T-cell proliferation Scott et al. 2006 
      ↓ APC signalling receptors Menezes et al. 2009 
IL-12 C. albicans Romani et al. 1997 ↑ Th1 responses Hsieh et al. 1993 
  LPS Cassatella et al. 1997     
  T. gondii Bliss et al. 2000     
  Herpes simplex virus Kanangat et al. 1996     
TNF-α Unstimulated Galbraith et al. 1997 ↑ ICAM-1 expression Wung et al. 2005 
  LPS Dubravec et al. 1990 ↑ neutrophil ROS Chen et al. 2006 
  Y-IgG Bazzoni et al. 1991 ↑ neutrophil degranulation Brandt et al. 1992 
  fMLP Cassatella et al. 1997     
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TGF-β LPS Grotendorst et al. 1989 Neutrophil chemotaxis Parekh et al. 1994 
    
 
↑ neutrophil phagocytosis & ROS Lagraoui & Gagnon 1997 
      ↑ collagen synthesis and repair Duncan et al. 1999 
GM-CSF Ionomycin 
Kato et al. 1990 
Haemopoietic growth factor Fossati et al. 1998 
  PMA Neutrophil chemotaxis Gomez-Cambronero et al2003 
    
 
↑ neutrophil apoptosis Kobayashi et al. 2005 
    
 
↑ neutrophil degranulation Kaufman et al. 1989 
    
 
↑ neutrophil ROS Matthews et al. 2007 
    
 
↑ ICAM-1 expression Bober et al. 1995 
IFN-α G-CSF Shirafuji et al. 1990 ↑ T-cell proliferation Hervas-Stubbs et al. 2011 
  PMA Denny et al. 2010 ↑ neutrophil ROS Wright et al. 2008 
      ↑ NET release Martinelli et al. 2004 
IFN-γ IL-12 Ethuin et al. 2004 Neutrophil chemotaxis Jeppson et al. 1991 
  TNF-α Yeaman et al. 1998 ↑ neutrophil ROS Wright et al. 2008 
      ↑ NET release Martinelli et al. 2004 
OSM LPS 
Greiner et al. 1999 
Haemopoietic growth factor 
Wallace et al. 1995 
  GM-CSF / PMA Modulate cell differentiation 
HGF Unstimulated 
Wislez et al. 2003 
↑ angiogenesis Grant et al. 1993 
  fMLP / GM-CSF ↑ epithelial cell proliferation Weidner et al. 1993 
  TNF-α     
 
Table 1.1. Known cytokines released by neutrophils in vitro, including recognised stimuli and predominant functions. 
Abbreviations: ↑, increase; IL, interleukin; IL-1ra, interleukin 1 receptor antagonist; PG, prostaglandin; ROS, reactive oxygen species;  Y-
IgG, IgG-opsonised yeast (Saccharomyces cerevisiae); LPS, E-coli lipopolysaccharide; GM-CSF, granulocyte/macrophage colony 
stimulating factor; PMA, phorbol-12-myristate-13-acetate; HAP, hydroxyapatite; OSM, oncostatin M; HGF, hepatocyte growth factor; APC, 
antigen presenting cell; NET, neutrophil extracellular trap. 
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Chemokine Stimuli Reference Function Reference 
IL-8 Unstimulated Fredriksson et al. 2002 ↑ neutrophil chemotaxis Hammond et al. 1995 
(CXCL8) LPS Hatanaka et al. 2006 ↑ neutrophil phagocytosis Baggiolini et al. 1989 
  P. gingivalis 
Restaino et al. 2007 
↑ neutrophil ROS Guichard et al. 2005 
  A. actinomycetemcomitans ↑ NET release Brinkmann et al. 2004 
  Zymosan A     
  TNF-α Hattar et al. 2001     
  IL-1β Ogilvie et al. 1996     
  IL-12 Ethuin et al. 2001     
  fMLP Cassatella et al. 1997     
  GM-CSF Kurt-Jones et al. 2002     
  Y-IgG Cassatella et al. 1997     
  C3a 
Vecchiarelli et al. 1998 
    
  C5a     
  LTB4 McCain et al. 1994     
  HAP Velard et al. 2009     
  C. neoformans Vecchiarelli et al. 1998     
GRO-α LPS 
Gasperini et al. 1995 
↑ neutrophil chemotaxis Geiser et al. 1993 
  TNF-α ↑ neutrophil ROS Oppenheim et al. 1991 
  Y-IgG     
  GM-CSF 
Cassatella et al. 1999 
    
  fMLP     
GRO-β LPS Iida & Grotendorst 1990 ↑ neutrophil chemotaxis / ROS Magazin et al. 1992 
IP-10 IFNγ 
Cassatella et al. 1997 
↑ T-cell chemotaxis Taub et al. 1993 
  IFNγ & LPS     
  IFNγ & TNF-α     
  IFN-α & TNF-α 
Gasperini et al. 1999 
    
  IFN-α & LPS     
  IFN-α & IL-1β     
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MIG IFNγ 
Gasperini et al. 1999 
↑ T-cell chemotaxis Mazanet et al. 2000 
  IFNγ & LPS     
  IFNγ & TNF-α     
I-TAC IFNγ 
Gasperini et al. 1999 
↑ T-cell chemotaxis Cole et al. 1998 
  IFNγ & LPS     
  IFNγ & TNF-α     
MIP-1α HAP Velard et al. 2009 ↑ neutrophil chemotaxis 
Wolpe et al. 1988 
  LPS Kasama et al. 1993 ↑ neutrophil ROS 
  LPS 
Cassatella et al. 1999 
    
  TNF-α     
MIP-1β LPS 
Cassatella et al. 1999 
↑ T-cell chemotaxis Taub et al. 1993 
  TNF-α     
MCP-1 HAP Velard et al. 2009 ↑ monocyte chemotaxis Yoshimura et al. 2007 
  IFNγ 
Yoshimura et al. 2007 
    
  IFNγ & LPS     
CINC-1 Unstimulated Cassatella et al. 1999 ↑ neutrophil chemotaxis Shibata et al. 1995 
CINC-2α Unstimulated Cassatella et al. 1999 ↑ neutrophil chemotaxis Shibata et al. 1995 
 
Table 1.2. Known chemokines released by neutrophils in vitro, including recognised stimuli and predominant functions. 
Abbreviations:  ↑, increase; ROS, reactive oxygen species; IL, interleukin; Y-IgG, IgG-opsonised yeast (Saccharomyces cerevisiae); LPS, 
E-coli lipopolysaccharide; GM-CSF, granulocyte/macrophage colony stimulating factor; GRO-α, growth-related oncogene-α; IP-10, 
interferon-γ-inducible protein-10; MIG, monokine induced IFNγ; I-TAC, IFN-inducible T cell chemoattractant; MIP-1, macrophage 
inflammatory protein 1; MCP-1, monocyte chemoattractant protein-1; CINC-1, cytokine-induced neutrophil chemoattractant 1; HAP, 
hydroxyapatite; NET, neutrophil extracellular trap. 
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1.5.4 Neutrophil antimicrobial response 
Neutrophils have various antimicrobial mechanisms with which to combat invading bacteria. 
These include phagocytosis, intra- and extracellular release of reactive oxygen species (ROS), 
antimicrobial enzymes and granule proteins, along with the release of neutrophil extracellular 
traps (NETs).  
 
1.5.4.1 Phagocytosis 
Bacterial binding by neutrophil cell surface receptors (e.g. the majority of toll-like 
receptors/TLRs, namely TLR1-10 except TLR3; Hayashi et al. 2003) activate phagocytosis 
causing the neutrophil to engulf the microorganism by sending out pseudopodia and then 
internalising it within a phagocytic vacuole (phagosome) bound by the neutrophil cell 
membrane (Lee et al. 2003). Neutrophils may also recognise host-derived molecules such as 
antibody and complement bound to the bacterial surface (e.g. IgG, C3b) through opsonisation 
utilizing Fc and C3b receptors. During phagocytosis, the contents of the neutrophil granules 
(lysosomes) are released and fuse with the phagosome to create a phagolysosome thereby 
creating a highly toxic microenvironment (Nordenfelt & Tapper 2011). Some targets may be 
too large to be fully phagocytosed or they avoid engulfment resulting in “frustrated 
phagocytosis” in which no phagosome is formed, but may then be killed extracellularly either 
with the extracellular release of ROS, granule proteins or NETs. These latter mechanisms 
however are associated with collateral host tissue damage.  
 
1.5.4.2 Neutrophil antimicrobial activity 
Neutrophils display antimicrobial activity by both oxidative (oxygen-dependent) and non-
oxidative (oxygen-independent) methods. Non-oxidative antimicrobial mechanisms involve 
the release of proteases and antimicrobial peptides contained within the azurophilic (primary), 
specific (secondary) and gelatinase (tertiary) neutrophil granules (Faurschou & Borregaard 
2003, Nussbaum & Shapira 2011) which are formed sequentially during granulocyte 
differentiation (Borregaard 1995, 1997, 2010). In contrast, the oxidative killing mechanisms 
employed by neutrophils are the result of the respiratory burst (Babior 1973), with assembly 
of the enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase responsible 
for the production of superoxide and subsequently downstream ROS including hydrogen 
peroxide and hypochlorous acid. Control and modulation of ROS activity is normally 
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achieved by antioxidants that significantly delay or prevent oxidation of substrates (Halliwell 
1995, Chapple et al. 1997). Extracellular antioxidants include ascorbate, α-tocopherol, 
carotenoids, metal binding proteins and compounds with oxidisable thiol groups such as 
glutathione (GSH; Chapple 1996, 2013, Waddington et al. 2000, Brock et al. 2004). The 
importance of ROS to the function of neutrophils is demonstrated in chronic granulomatous 
disease (CGD).  This is a genetic disorder resulting in a dysfunctional NADPH oxidase, and 
therefore failure to generate ROS, with individuals subsequently susceptible to frequent and 
life-threatening bacterial and fungal infections (Dinauer 2005). 
 
1.5.4.3 Production of reactive oxygen species 
Production of neutrophil superoxide involves activation of nicotinamide adenine dinucleotide 
phosphate (NADPH)-oxidase which, together with molecular oxygen, comprises the 
neutrophil “respiratory burst” (Babior 1999, Dahlgren et al. 1999). NADPH-oxidase has a 
complex structure including four cytosolic subunits (p40
phox
, p47
phox
, p67
phox
 and Rac) that 
once phosphorylated enable combination with membrane-bound cytochrome b558 (comprised 
of p22
phox
, gp91
phox
) (Chapple & Matthews 2007).  Once the NADPH-oxidase complex is 
fully assembled at the vacuolar membrane, it generates superoxide anions (O2
-
) by single-
electron reduction of molecular oxygen (Babior 1973, Segal 1989) prior to subsequent 
conversion to downstream ROS such as, hydrogen peroxide and hypochlorous acid (Figure 
1.3). 
 
 
Figure 1.3. NADPH oxidase assembly and activity in human neutrophils (Dahlgren & 
Karlsson 1999). 
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Superoxide is subsequently released into the phagosomal space and also into the extracellular 
environment at a rate of 5-10mmol/l/s (Hampton et al. 1998, Waddington 2000). Superoxide 
is relatively short-lived and dismutates to hydrogen peroxide (H2O2) either spontaneously or 
via the enzyme superoxide dismutase (SOD) (McCord & Fridovich 1969, Battino et al. 1999). 
Hydrogen peroxide is capable of diffusing across cell and nuclear membranes and may be 
released extracellularly.  Alternatively, intracellular hydrogen peroxide is rapidly catabolised 
by catalase or glutathione peroxidase. Although H2O2 alone is microbicidal, its antimicrobial 
potential is further enhanced by its conversion to downstream ROS in the presence of 
peroxidase enzymes such as myeloperoxidase (MPO) which constitutes ~5% of the human 
neutrophil by weight and is responsible for oxidizing halides (Nauseef 1983). Chlorine is 
usually oxidized in the presence of H2O2 because of the relatively high concentration within 
host tissues, resulting in the formation of hypochlorous acid (HOCl) (Nauseef et al. 1983). In 
addition, H2O2 may also undergo a ‘Fenton reaction’ in the presence of Fe
2+
 or Cu
2+
 forming a 
potent hydroxyl radical (
.
OH; Sutton & Winterbourne 1989). This is important given that the 
formation of 
.
OH is site-specific, since uncharged H2O2 diffuses across lipid membranes and 
is subsequently converted to the 
.
OH radical in close proximity to vital cell structures such as 
DNA. Whilst soluble ferrous iron (Fe
2+
) is not normally present in vivo, being bound tightly to 
proteins, it can be produced within cells (e.g. mitochondria or cytosol) by the action of O2
-
 on 
ferric iron (Fe
3+
) within iron storage proteins.  
 
1.5.4.4 Function of reactive oxygen species 
With regards to host defence, including the pathogenesis of chronic periodontitis, arguably 
one of the most important functions of ROS relate to their antimicrobial activity as reviewed 
by Chapple & Matthews (2007). The superoxide radical and H2O2 alone have relatively low 
antimicrobial activity and toxicity in comparison to that observed following oxidase 
activation, and unless concentrations exceed 50µM the cytotoxicity of H2O2 is limited 
(Halliwell et al. 2000). Similarly, HOCl formed from H2O2 (section 1.5.4.3) is directly 
cytotoxic provided that concentrations exceed 20µM (Mainnemare et al. 2004). The 
antimicrobial activity of neutrophil ROS also relates to indirect activation of lysosomal 
proteases. This has been shown to occur with neutrophil activation raising intra-cellular Ca
2+
 
concentrations causing subsequent opening of Ca
2+
-dependent K
+
 channels. Concurrent O2
-
 
release results in membrane depolarisation thereby creating an ionic gradient with activation 
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of antimicrobial lysosomal proteases within a hypertonic K
+
-rich alkaline environment 
(Reeves et al. 2002). HOCl is also an important trigger with regard to subsequent NET release 
which is an additional antimicrobial neutrophil defence strategy (Palmer et al. 2012; section 
1.5.4.5). 
 
In addition to antimicrobial activity, ROS production is vital to a broad range of diverse pro-
inflammatory biological activies with the different subtypes of ROS having different effects 
on both bacterial and host cells (reviewed by Chapple & Matthews 2007). For example, the 
production of O2
-
 from the NADPH oxidase activates host cell NF-κB with subsequent 
transcription of pro-inflammatory cytokines (Ndengele et al. 2005), as well as increasing 
vascular permeability (Haglind et al. 1994) and neutrophil chemotaxis via LTB4 formation 
(Deitch et al. 1990). In addition, O2
-
 has the potential to cause endothelial cell damage (Droy-
Lefaix et al. 1991), lipid peroxidation (Dix & Aikens 1993) and DNA strand breaks (Dix et 
al. 1996). Subsequent formation of H2O2 acts primarily as a second messenger in NF-κB 
activation (Halliwell et al. 2000) and has varying biological functions including increasing 
adhesion molecule expression (Roebuck 1999), inducing apoptosis (Clement et al. 1998) and 
also modulating platelet aggregation (Naseem & Bruckdorfer 1995). In addition, the 
.
OH 
radical and HOCl (section 1.5.4.4) are regarded as the most potent ROS species and known to 
cause cell and tissue damage including lipid peroxidation (Mylonas & Kouretas 1999), 
protein damage (Fu et al. 1995), DNA and RNA damage (Dix et al. 1996) as well as the 
oxidation of important antiproteases such as α1-antitrypsin (Mohsenin & Gee 1989) and 
degradation of extracellular matrix components (Waddington et al 2000). With regard to the 
pathogenesis of chronic periodontitis, O2
-
 and H2O2 have been shown to activate osteoclasts 
(Bax et al. 1992, Hall et al. 1995), promote osteoclast formation (Garrett et al. 1990) and also 
degrade alveolar bone proteoglycans (Moseley et al. 1998). In addition, HOCl has been 
shown to degrade type I collagen from the periodontal ligament via oxidative degradation 
(Petersen et al. 2004), with neutrophil-generated HOCl also being shown to directly cause 
epithelial cell lysis (Altman et al. 1992).   
 
Given the different antimicrobial and biological functions of ROS, their imbalanced release 
leading to oxidative stress is regarded as being responsible (both directly and indirectly) for 
causing collateral host-mediated tissue damage in the pathogenesis of chronic periodontitis as 
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well as other systemic diseases such as rheumatoid arthritis (reviewed by Chapple & 
Matthews 2007; section 1.3). Interestingly, a deficiency in the key antioxidant reduced 
glutathione (GSH) has been shown in GCF in periodontitis patients (Chapple et al. 2002, 
Grant et al. 2010) and also in peripheral blood neutrophils. In the latter situation the redox 
state of the neutrophil (GSH:GSSG ratio) was shown to be reversed leading to cellular stress 
that resulted in relocation of NADPH oxidase to the outer cell membrane (Dias et al. 2013). 
This may explain the excess extracellular ROS release reported by Matthews et al. 2007 
(neutrophil hyperactivity) and associated potential collateral tissue damage.  
 
1.5.4.5 Neutrophil extracellular traps 
As well as the production of ROS, neutrophils also have the ability to release strand-like webs 
of decondensed nuclear chromatin containing granule proteins that function to immobilise and 
potentially kill invading bacteria.  This process, involving the release of neutrophil 
extracellular traps (NETs) is regarded as being as powerful an antimicrobial strategy as that of 
phagocytosis (Brinkmann et al. 2004, Fuchs et al. 2007). Neutrophil extracellular traps 
consist of histones and nuclear DNA wrapped as fibres of approximately 30nm in diameter 
that are decorated with globular antimicrobial proteins (e.g. neutrophil elastase, 
myeloperoxidase) that originate from the neutrophil granules (Brinkmann et al. 2007, Urban 
2009; Figures 1.4, 1.5). 
 
Interestingly, histones are one of the oldest known families of human proteins and it has long 
been established that whilst their primary function is to package DNA as compactly as 
possible they also have the potential to bind DNA to form a nucleosome complex with 
antimicrobial activity. The biological significance of this observation was initially unclear as 
it was not understood where or how histones would encounter microorganisms during an 
infection (Hirsch 1958). However, histones have since been shown to account for ~70% of the 
total protein content of NETs (Urban et al. 2009), the discovery of which now highlights that 
histones are active outside the chromatin milieu and no longer restricted to the nuclear 
environment (Parseghian 2006). 
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Figure 1.4. Scanning electron micrographs of neutrophils with associated fibres from 
extruded neutrophil extracellular traps (Cooper et al. 2013).  
 
 
Figure 1.5. Fluorescence photomicrograph of neutrophil extracellular traps stained 
with the DNA dye Sytox green (Palmer et al. 2012).  
 
Extracellular trap release is not solely confined to neutrophils (Brinkman et al. 2004), and is 
also associated with mast cells (von Kockritz-Blickwede et al. 2009) and eosinophils (Yousefi 
et al. 2008). Extracellular trap release is now considered a fundamental mechanism of the 
innate immune response and has been observed in-vivo in humans (Brinkman et al. 2004; 
Gupta et al. 2005), mice (Beiter et al. 2006; Buchanan et al. 2006; Wartha et al. 2007), 
rabbits (Brinkman et al. 2004), horses (Alghamdi et al. 2005), cows (Lippolis et al. 2006) and 
fish (Palic et al. 2007).  
 
Currently recognised stimuli for NET release include HOCl (Palmer et al. 2012), nitric oxide 
(Keshari et al. 2012), IL-8 (Brinkmann et al. 2004), bacterial toxins (Brinkmann et al. 2004, 
Fuchs et al. 2007, Landoni et al. 2012, Mori et al. 2012, Revelo & Waldron 2012), yeasts 
(Urban et al. 2006), protozoa (Guimaraes-Costa et al. 2009, Behrendt et al. 2010, Abi 
Abdallah et al. 2012), antimicrobial peptides (Kraemer et al. 2011), antibodies (Kessenbrock 
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et al. 2009, Lande et al. 2011, Thomas et al. 2012), platelets (Clark et al. 2007, Massberg et 
al. 2010, Caudrillier et al. 2012, von Bruhl et al. 2012) and statins (Chow et al. 2010).  It has 
also been suggested that activation of multiple receptors is required for optimal stimulation of 
NETs (Fuchs et al. 2007), along with cytokine priming (Yousefi et al. 2009). Release of 
NETs by neutrophils can also be induced by phorbol 12-myristate 13-acetate (PMA), a non-
physiological and direct activator of protein kinase C (PKC) that is independent of membrane 
receptor-ligand interaction and phagocytosis.  Thus, PMA is widely used as a positive-control 
stimulus for NET formation (Fuchs et al. 2007). 
 
1.5.4.6 Formation of neutrophil extracellular traps 
Formation of NETs is dependent upon HOCl production via NADPH oxidase (Fuchs et al. 
2007, Remijsen et al. 2011, Akong-Moore et al. 2012, Palmer et al. 2012) and hyper-
citrullination of histones by peptidylarginine deiminase 4 (PAD4), which converts arginine 
and methylarginine residues of histones to citrulline. Interestingly, a PAD enzyme (PPAD) 
has been shown to be released from the periodontal pathogen P. gingivalis (McGraw et al. 
1999, Bingham & Moni 2013). Citrullination enables decondensation and unfolding of the 
DNA/chromatin complex (Gyorgy et al. 2006, Wang et al. 2009, Li et al. 2010) which then 
expands to the inner margins of the nuclear membrane.  This causes the nucleus to swell and 
lose its lobules and form distinct vesicles (Fuchs et al. 2007, Borregaard et al. 2010). 
Neutrophil granules and nuclear membranes are then lost, allowing the release and mixing of 
decondensed chromatin and granule proteins, particularly neutrophil elastase (Fuchs et al. 
2007). Interestingly, plasma membrane integrity of activated neutrophils is not affected by the 
disruption of internal membranes, allowing the intracellular mixing of NET components, 
before the eventual rupture and loss of the outer membrane integrity and subsequent loss of 
cytoplasm (Fuchs et al. 2007).  Active extrusion of the extracellular trap complex involves the 
actin cytoskeleton and microtubular complex (Brinkmann et al. 2004, Guimaraes-Costa et al. 
2009, Lauth et al. 2009, Neeli et al. 2009, Aulik et al. 2010, Abi Abdallah et al. 2012, Palmer 
et al. 2012). Although NET formation was initially regarded as a terminal event, albeit 
different to necrosis and apoptosis (Brinkmann et al. 2004, Fuchs et al. 2007), NETs 
comprising mitochondrial rather than nuclear DNA have also been shown and released from 
viable neutrophils (Yousefi et al. 2009). 
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1.5.4.7 Function of neutrophil extracellular traps 
Neutrophil extracellular traps have been shown to be effective in killing Gram negative 
(Grinberg et al. 2008) and Gram positive bacteria (Brinkmann et al. 2004), parasites (Abi 
Abdallah et al. 2012) and fungi (Urban et al. 2006). The antimicrobial actions of NETs are 
twofold: firstly, the trapping and immobilising of pathogens preventing tissue and systemic 
spread, and secondly pathogen killing by NET-embedded cathelicidin antimicrobial peptides 
(Cooper et al. 2013). Whilst phagocytosis is the preferred method of bacterial killing by 
neutrophils, NETs can act as a secondary killing approach if required (Fuchs et al. 2007). It is 
also possible that NETs also sequester cytokines and chemokines in the local environment of 
the neutrophil and thereby minimise untoward dissemination of the inflammatory response 
thereby potentially minimising damage to the surrounding host tissues (Bank & Ansorge 
2001).  
 
1.6 NEUTROPHIL FUNCTION IN CHRONIC PERIODONTITIS 
Neutrophils are the predominant cell within the gingival crevice and pocket epithelium 
(Gustafsson & Asman 1996, Nussbaum et al. 2011), constituting ~50% of the leukocytes 
infiltrating the junctional epithelium and ~90% of the leukocytes isolated from GCF 
(Miyasaki et al. 1991). Rather than forming an homogenous bacteria/leukocyte mixture in the 
gingival crevice, neutrophils have been shown to form a “leukocyte wall” interposed between 
the periodontal plaque mass and the junctional and sulcular (or pocket) epithelium (Attstrom 
1971). Immunocytochemical analyses of inflamed periodontal tissues have also confirmed the 
presence of large numbers of recruited neutrophils in diseased tissue in vivo (Hou et al. 2003). 
Neutrophils are considered central to the pathogenesis of chronic periodontitis, with both 
hypo- and hyper-responsive phenotypes having the potential to result in collateral periodontal 
host tissue damage. A hypo-responsive neutrophil will be unable to effectively manage the 
presence of periodontal bacteria. However a hyper-responsive neutrophil could equally result 
in periodontal tissue destruction as a result of collateral host tissue damage through 
inappropriate release of antimicrobial factors such as ROS, NETs and antimicrobial peptides, 
along with the potential to further propagate the chronic inflammatory lesion by the 
inappropriate release of cytokines within the surrounding tissues and systemic circulation. 
Therefore, a delicate balance exists with regards to neutrophil function in chronic 
periodontitis, and excessive ROS release and oxidative stress is considered central to the 
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pathogenesis of chronic periodontitis (reviewed by Chapple & Matthews 2007). Furthermore, 
ROS-induced exaggerated NET release will result in increased extracellular DNA which may 
breach host immunotolerance and result in the generation of autoantibodies, which may also 
play a role in the pathogenesis of chronic periodontitis (Cooper et al. 2013).  
 
1.6.1 Neutrophil cytokine release in chronic periodontitis 
The majority of studies investigating the presence of cytokines in chronic periodontitis have 
been performed on plasma, GCF and tissue biopsy samples and generally show higher levels 
of cytokines in disease compared to health. Greater plasma concentrations of IL-8 (Fredrikson 
et al. 2003, Dias et al. 2011), IL-6 (Loos et al. 2000, Monteiro et al. 2009, Lappin et al. 2011, 
Gani et al. 2012) and IL-1β (Howells 1995, Sadik et al. 2012) have been demonstrated in 
patients with chronic periodontitis. Similarly, increased GCF concentrations of IL-8 (Lagdive 
et al. 2013), IL-6 (Fagundes et al. 2011), IL-1β (Howells 1995, Figueredo et al. 1999) and 
TNF-α (Drugarin et al. 1998, Galmonal et al. 2003, Fagundes et al. 2011) have also been 
reported in chronic periodontitis patients compared to healthy controls. Interestingly, IL-6 and 
IL-1β concentrations in saliva have also been shown to increase in a 21-day experimental 
gingivitis model with levels increasing as plaque accumulated, indicating that cytokine 
concentrations in saliva reflect the degree of gingival inflammation (Zhou et al. 2012). 
Immunohistochemical analyses of inflamed gingival tissue samples, obtained from patients 
with chronic periodontitis, also demonstrate elevated in-vivo IL-8 (Liu et al. 2001), IL-1β 
(Feldner et al. 1994, Lo et al. 1999, Hou et al. 2003) and TNF-α (Liu et al. 2001). 
 
To date, there have only been 4 published studies investigating peripheral blood neutrophil 
cytokine release from patients with chronic periodontitis (Galbraith et al. 1997, Figueredo et 
al. 2000, Fredriksson et al. 2002, Restaino et al. 2007). Such studies may be of importance in 
terms of assessing the relative contribution of neutrophil cytokine release with regards to the 
reported increased cytokine levels observed in chronic periodontitis. Two studies have 
demonstrated that peripheral blood neutrophils from periodontitis patients release similar 
levels of IL-8, IL-1β and TNF-α compared to healthy controls during a 5hr incubation period 
(Galbraith et al. 1997, Fredriksson et al. 2002).  Galbraith et al. cultured isolated neutrophils 
in the presence of GM-CSF for up to 5hrs prior to collection and analysis of the supernatant 
by ELISA. Whilst TNF-α was not detected following 3-5hr culture in the presence of GM-
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CSF, increased IL-1β was identified with increasing time of culture, with IL-1β 
concentrations of up to 86.7pg/10
7
 neutrophils and with no differences between patient and 
control cells (Galbraith et al. 1997). Interestingly, the same study was only able to identify 
TNF-α or IL-1β mRNA in stimulated but not unstimulated conditions at 3hrs (Galbraith et al. 
1997). Fredriksson et al. cultured isolated neutrophils for 5hrs in the presence and absence of 
opsonised S. aureus prior to analysis of the supernatant by ELISA. Similarly no significant 
differences in IL-8 or TNF-α release were observed with median concentrations of <9.8 and 
<36.7pg/ml (IL-8) and <64.4 and <121.8pg/ml (TNF-α) for unstimulated and FcγR-stimulated 
conditions respectively (Fredriksson et al. 2002). By contrast, Restaino et al. demonstrated 
decreased IL-8 release from isolated neutrophils of patients with chronic periodontitis 
compared to healthy controls when cultured for 1hr in the presence and absence of different 
stimuli including LPS, phytohemagglutin (PHA), zymosan A, P. gingivalis and A. 
actinomycetemcomitans (Restaino et al. 2007). Concentrations of ~800ng/ml were reported 
for healthy control neutrophils, with a lack of observable increased release in the presence of 
all stimuli investigated. However stimulation was confirmed for patient neutrophils with 
concentrations of ~100ng/ml and ~200ng/ml for unstimulated and stimulated cells 
respectively (Restaino et al. 2007). In contrast, flow cytometric analyses of fixed, 
permeabilised neutrophils has revealed significantly more IL-1β release in patients with 
chronic periodontitis compared to healthy controls (Figueredo et al. 2000).  
 
Neutrophils are known to biosynthesize cytokines including IL-1β, TNF-α, IL-6 and IL-8 
prior to their release (Lloyd & Oppenheim 1992) with cytokine synthesis induced following 
stimulation (Schindler et al. 1990, Cassatella 1999). Specific mechanisms of neutrophil 
cytokine release are currently poorly understood, and it is therefore important that sufficient 
neutrophil culture times are employed in order to measure suitable cytokine concentrations, 
along with increasing the likelihood of reproducible data. This is highlighted in the 
aforementioned studies whereby a lack of TNF-α release was observed within a 5hr 
incubation period, along with a lack of TNF-α and IL-1β mRNA (Galbraith et al. 1997). A 
lack of IL-8 stimulation above unstimulated conditions was also observed in the presence of 
periodontal pathogens within a 1hr culture period (Restaino et al. 2007). Longer culture times 
taking into consideration neutrophil half-life, will be more likely to reflect maximal cytokine 
release. Escherichia coli LPS represents the most commonly used, and therefore relatively 
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established, stimulus for neutrophil cytokine release (Table 1.1) with only one study having 
employed known periodontal pathogens (Restaino et al. 2007). In addition, none of the 
published papers investigating neutrophil cytokine release in chronic periodontitis specifically 
state post-culture viability testing, and this is important in order to distinguish active cytokine 
release from viable neutrophils in comparison to that released as a product of cell necrosis.  
 
Type-2 diabetes displays a unique bi-directional relationship with chronic periodontitis 
(section 1.3), and peripheral blood neutrophils isolated from diabetes patients have recently 
been shown to release greater amounts of IL-8, IL-1β and TNF-α when cultured for 18hr, in 
the presence and absence of 5µg/ml LPS, than cells isolated from healthy controls (Hatanaka 
et al. 2006). To date there are no similar studies investigating neutrophil cytokine release 
within an 18hr culture period from neutrophils isolated from patients with chronic 
periodontitis compared to matched healthy controls. Given the importance of cytokines in 
modulating and coordinating the inflammatory-immune response including neutrophil 
chemotaxis (Graves et al. 2003), priming for ROS (Gainet et al. 1998, Van Dervort et al. 
1998) and NET release (Brinkmann et al. 2004, Wang et al. 2009), along with osteoclastic 
bone remodelling (Ishimi et al. 1990, Rucci et al. 2008), such differences will provide 
additional information regarding the pathogenesis of chronic periodontitis. 
 
1.6.2 Neutrophil chemotaxis in chronic periodontitis 
The vast majority of studies investigating neutrophil chemotaxis have been conducted with 
juvenile/aggressive periodontitis patients (reviewed by Ryder 2010) rather than chronic 
periodontitis. To date there are only 6 published studies investigating peripheral blood 
neutrophil chemotaxis in chronic periodontitis (Van Dyke et al. 1980, McMullen et al. 1981, 
Altman et al. 1985, Mouynet et al. 1994, Kumar & Prakash 2012, Srinivas et al. 2012) as 
summarised (Table 1.3). These studies effectively measure uni-directional cell movement 
using traditional Boyden chambers and under agarose methods thereby quantifying end points 
of cell movement, recently termed “chemokinesis”, rather than directly observing and 
measuring individual cell movement that is more closely representative of “true chemotaxis” 
(Muinonen-Martin et al. 2010). Studies investigating neutrophil chemokinesis report 
conflicting and inconsistent results. Significantly, increased chemokinesis towards E. coli 
supernatant, fMLP and LPS-activated serum has been reported in patients with chronic 
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periodontitis (Van Dyke et al. 1980, McMullen et al. 1981). No differences in neutrophil 
chemokinesis have also been observed towards LPS-activated serum, fMLP and C5a (Altman 
et al. 1985, Mouynet et al. 1994). In contrast, decreased neutrophil chemokinesis has also 
been reported including in relation to casein (Kumar & Prakash 2012, Srinivas et al. 2012). 
 
A novel direct visualisation chemotaxis chamber has recently been developed by colleagues at 
the University of Glasgow (Muinonen-Martin et al. 2010), that has subsequently been used to 
more accurately measure neutrophil chemotaxis in patients diagnosed with chronic 
obstructive pulmonary disease (COPD; Sapey et al. 2011). Similar experiments have not been 
performed with regards to neutrophil chemotaxis in chronic periodontitis patients, and doing 
so would provide more detailed and accurate information on true neutrophil chemotaxis in the 
pathogenesis of periodontitis.  
 
Reference Method Chemoattractant 
Comparison to 
healthy control 
Van Dyke et al. 1980 Boyden chamber 
LPS-activated serum ↑ 
fMLP ↑ 
E.coli culture 
supernatant ↑ 
McMullen et al. 1981 Boyden chamber 
LPS-activated serum ↑ 
fMLP ↑ 
E.coli culture 
supernatant ↑ 
Altman et al. 1985 Boyden chamber 
LPS-activated serum ↔ 
C5a ↔ 
fMLP ↔ 
Mouynet et al. 1994 Under agarose 
LPS-activated serum ↔ 
fMLP ↔ 
Kumar et al. 2012 Boyden chamber Not stated ↓ 
Srinivas et al. 2012 Under agarose Casein ↓ 
 
Table 1.3. Studies investigating neutrophil chemotaxis in chronic periodontitis, 
including methods, chemoattractant and comparison to healthy controls. 
Abbreviations: ↑, increase; ↔, no difference; ↓, decrease; LPS, lipopolysaccharide; fMLP, 
formyl-methionyl-leucyl-phenylalanine. 
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1.6.3 Neutrophil reactive oxygen species release in chronic periodontitis 
Studies of ROS generation by peripheral blood neutrophils in periodontal disease include a 
variety of patient groups, different pathways of activation and methods of ROS detection (last 
reviewed by Chapple & Matthews 2007). To date, the role of neutrophil-derived ROS in the 
pathogenesis of periodontal disease is not completely understood. 
 
Peripheral blood neutrophils isolated from patients with chronic periodontitis have been 
shown to be hyperactive with regards to baseline extracellular ROS release and also following 
FcγR and TLR stimulation, with and without priming with Porphyromonas gingivalis, 
Fusobacterium nucleatum, Escherichia coli lipopolysaccharide (LPS) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Fredriksson et al. 2003, Matthews et al. 
2007). In addition, total ROS release is higher from neutrophils isolated from patients with 
chronic periodontitis in comparison to healthy controls following stimulation with opsonized 
Staphylococcus aureus, complement-opsonised zymosan and phorbol 12-myristate 13-acetate 
(PMA) (Gustafsson & Asman 1996, Fredriksson et al. 1998, 1999, 2003, Zekonis & Zekonis 
2004, Matthews et al. 2007). In addition, no differences in ROS release from periodontitis 
neutrophils in response to priming with TNF-α, LPS or fMLP has been reported (Gustafsson 
et al. 1997). To date, there has been only one published longitudinal study investigating the 
effect of periodontal treatment on neutrophil ROS responses (Matthews et al. 2007). This 
study demonstrated that successful periodontal therapy reduced the total FcγR-stimulated 
neutrophil hyper-reactivity, but did not alter unstimulated extracellular ROS hyperactivity, 
suggesting that both constitutive and reactive mechanisms underlie elevated neutrophil ROS 
generation in chronic periodontitis (Matthews et al. 2007). As discussed previously, this may 
be due to a constitutive deficiency in GSH synthesis and activation of sphingomyelinase 
generating lipid rafts with NADPH oxidase components embedded within the outer cell 
membrane (Dias et al. 2013).  
 
There have only been 3 published studies investigating peripheral blood neutrophil ROS 
release specific to superoxide using lucigenin-enhanced chemiluminescence in chronic 
periodontitis (Guarnieri et al. 1991, Zekonis et al. 2003, Zilinskas et al. 2011). Baseline 
unstimulated peripheral blood neutrophil superoxide release was reported to be higher from 
cells isolated from patients compared to periodontally healthy controls (Guarnieri et al. 1991, 
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Zekonis et al. 2003, Zilinskas et al. 2011). Greater neutrophil superoxide release is also 
reported following stimulation with opsonized zymosan and E. coli LPS (Zekonis et al. 2003, 
Zilinskas et al. 2011), although no differences between patient and control cells were 
observed following stimulation with PMA (Guarnieri et al. 1991).  
 
To date there have been no published studies investigating superoxide release from peripheral 
blood neutrophils isolated from patients with chronic periodontitis stimulated with 
periodontally-relevant bacteria, along with studying the effect of periodontal treatment. Such 
information is important in order to further characterize the hyperactive and –reactive 
neutrophil phenotype with regards to extracellular ROS release observed in chronic 
periodontitis and therefore for potential for collateral tissue damage.  
 
1.6.4 Neutrophil extracellular trap release in chronic periodontitis 
It has been hypothesized that periodontal disease pathogenesis may be associated with 
dysregulated NET release (Cooper et al. 2013). This is consistent with the fact that patients 
with chronic periodontitis exhibit a hyperactive/-reactive peripheral blood neutrophil 
phenotype in terms of ROS generation and release and that ROS are central to NET formation 
(Fuchs et al. 2007, Palmer et al. 2012). In addition, increased neutrophil ROS production has 
been associated with elevated type-I interferon (IFNα) levels in periodontal disease (Wright et 
al. 2008) that have also been shown to prime for NET release (Martinelli et al. 2004). Whilst 
NETs are antimicrobial they are also thought to function to limit the untoward diffusion of 
degradative agents (e.g. proteases such as elastase) released from neutrophils (Bank & 
Ansorge 2001) and therefore locally contain the inflammatory-immune response. Although 
these functions may be beneficial to the host it has also been hypothesised that excessive NET 
production may be counter-productive (Lee & Grinstein 2004, Clark et al. 2007). For 
example, the presence of extracellular DNA-histones within NETs may act as a target for 
additional endogenous or bacterial-derived PADs with subsequent histone hypercitrullination 
creating autoimmunogenic epitopes thus stimulating the production of anti-citrullinated 
protein antibodies (ACPAs; Parseghian & Luhrs 2006). Importantly, P. gingivalis, regarded 
as one of the most important periodontal pathogens (Socransky et al. 1998), is the only 
bacteria capable of producing a PAD analogous to PAD4 and therefore capable of histone 
citrullination (Rosenstein et al. 2004). Therefore the activity of Porphyromonas gingivalis 
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PAD (PPAD) upon NET histones released into periodontal tissues may trigger a breach of 
immune tolerance via hypercitrullination, potentially adding an autoimmune component to 
periodontitis pathogenesis (Wright et al. 2008). This theory implies that anti-citrullinated 
protein antibodies (ACPA’s) shall be detectable in non-rheumatoid arthritis patients with 
periodontitis, which was recently shown to be the case by our group (dePablo et al. 2013).  
 
There are currently no published studies investigating NET release from peripheral blood 
neutrophils isolated from patients with chronic periodontitis. However in-vivo evidence of 
NETs in purulent exudates from the gingivae of chronic periodontitis patients has been 
reported (Vitkov et al. 2009) and considered comparable to those previously identified in-vivo 
in abscess exudates from group A Streptococcus pyogenes infections in mice (Buchanan et al. 
2006), and also in a mixed bacterial infection of human appendicitis (Brinkmann et al. 2004). 
Transmission electron microscopy of periodontal pocket epithelium also reveals NETs 
associated with periodontal bacteria (Vitkov et al. 2009; Figure 1.6). Similarly, confocal 
image analysis has revealed for the first time the presence of NETs in inflamed but not 
healthy control gingival tissues (Cooper et al. 2013; Figure 1.7). Measurement of peripheral 
blood neutrophil NET release will provide additional novel information regarding this 
recently discovered antimicrobial defence mechanism, as well as providing information on the 
potential role of NETs in the pathogenesis of chronic periodontitis. 
 
 
Figure 1.6. Scanning electron microscopy of a periodontal pocket epithelium biopsy 
indicating the presence of neutrophil extracellular traps and entrapped bacteria (Vitkov 
et al. 2009). 
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Figure 1.7. The first demonstration of neutrophil extracellular trap stuctures within 
gingival connective tissues from a patient with gingivitis (right panel) compared with a 
healthy control (left panel). Confocal images demonstrate the co-localisation of 
myeloperoxidase (in green) with DNA (in red) in gingivitis tissues where neutrophil 
extracellular trap-like structures are evident. In control tissues there are no neutrophil 
extracellular traps visible, simply nuclear DNA (Cooper et al. 2013). 
 
 
1.7 C-REACTIVE PROTEIN 
C-reactive protein (CRP) is a highly conserved protein that was originally discovered in 
Oswald Avery’s laboratory at the Rockefeller Institute during studies of patients with 
Streptococcus pneumoniae infection (Tillet 1930). It is a member of the pentraxin family of 
proteins (Kathariya et al 2013) due to its electon micrographic appearance from the Greek 
penta (five) and ragos (berries) (Pepys & Hirsch 2003). In its native form CRP is composed 
of five identical subunits, each containing 206 amino acid residues, non-covalently linked to 
form a symmetrical disc of approximately 115kDa (Pepys et al. 2003, Eisenhardt et al. 2009). 
More specifically, individual CRP subunit mass has been reported as 23,028Da by 
electrospray mass spectrometry, corresponding to the mass of 23,029Da predicted from the 
known amino acid sequence including the N-terminal pyroglutamic acid (Pepys et al. 2005, 
Oliveira et al. 1979).  
 
In human plasma, CRP exists as a cyclic, disc-shaped pentamer of 115kDa as confirmed by 
electron microscopy, gel chromatography and crystallography (Osmand et al. 1977, Volkanis 
et al. 1978, Shrive et al. 1996, Thompson et al. 1999, Eisenhardt et al. 2009), however 
pentameric CRP can also undergo dissociation and aggregation under certain conditions, 
thereby acquiring distinct functionality (Ji et al. 2007).  
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C-reactive protein is predominantly produced by liver hepatocytes, primarily under 
transcriptional control by IL-6 (Gauldie et al. 1987), although other sites of local extra-hepatic 
CRP synthesis and secretion have also been identified including smooth muscle cells (Calabro 
et al. 2003), endothelial cells (Venugopal et al. 2005, Eisenhardt et al. 2009), neurons, 
atherosclerotic plaques, epithelial cells (Lu & Jin 2010), monocytes and lymphocytes (Jialal et 
al. 2004; Kuta et al. 1986). C-reactive protein has also been detected in all cell layers of 
inflamed and non-inflamed gingival tissue samples using immunohistochemistry, Western 
blotting and gene expression analysis and, as such, human gingivae have been postulated as 
being another site of CRP production (Lu & Jin 2010).  
 
1.7.1 C-reactive protein concentrations in health & disease 
In healthy individuals the median concentration of CRP is ~0.8mg/l, but following an acute-
phase stimulus values may increase significantly to >500mg/l (Pepys & Hirschfield 2003). C-
reactive protein, although non-specific, is regarded as the most sensitive indicator of systemic 
inflammation (Coimbra et al. 2009) and as such is widely used medically as a systemic 
inflammatory marker in the diagnosis of chronic infections and inflammatory conditions 
(Pepys & Hirschfield 2003, Ramamoorthy et al. 2012). C-reactive protein is also widely used 
as a predictor of cardiovascular disease risk with moderate increases being predictive of 
cardiovascular events in otherwise apparently healthy individuals (Ridker et al. 1997), with 
the American Heart Association guidelines for cardiovascular disease risk being 0.1, 1.0 and 
3.0mg/l plasma CRP representing low, medium and high cardiovascular risk respectively 
(Ridker et al. 2002, 2005). Periodontitis is an example of a common disease that results in an 
elevated CRP concentration with plasma CRP significantly raised in patients with chronic 
periodontitis compared to healthy controls with a mean high-sensitivity CRP range of 1-4mg/l 
(Fredriksson et al. 1999, Loos et al. 2000, Paraskevas et al. 2008, Offenbacher et al. 2009, 
D’Aiuto et al. 2010, Allen et al. 2011) thereby falling within the American Heart Association 
medium cardiovascular risk range (Ridker et al. 2002, 2005). A recent systematic review and 
meta-analysis also highlights modest evidence that systemic CRP concentrations are 
subsequently lowered following successful periodontal treatment (Paraskevas et al. 2008).  
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1.7.2 Functions of C-reactive protein 
Systemic CRP concentrations increase rapidly in response to trauma, inflammation and 
infection and similarly decrease rapidly with resolution and therefore the functions of CRP are 
thought to be directly related to the innate immune response (Du Clos et al. 2000). C-reactive 
protein binds in a calcium-dependent manner (Potempa et al. 1981, Du Clos et al. 2000) to 
different ligands including phosphorylcholine which is found in a number of host and 
bacterial cells (Oliveira et al. 1980, Potempa et al. 1981, Du Clos et al. 2000, Agrawal et al. 
2002, Black et al. 2003, Lee et al. 2002) and becomes accessible to CRP only in damaged and 
apoptotic cells. C-reactive protein is therefore important in effectively scavenging cellular 
debris and extracellular matrix components (Pepys et al. 1983, Szalai et al. 1999), nuclear 
antigens such as chromatin and histones (Robey et al. 1984, Du Clos et al. 1988), as well as 
activation of the classical complement pathway through direct interaction with C1q (Taylor & 
van den Berg 2007). There is also evidence that CRP can interact with the Ig receptors FcγRI 
and FcγRII thereby eliciting a response from phagocytic cells including neutrophils (Du Clos 
et al. 2000, Black et al. 2004).  
 
1.7.3 Neutrophil interaction with C-reactive protein 
Neutrophils are regarded as one of the most likely targets of CRP because CRP deposition 
occurs mainly at sites of tissue damage in-vivo within inflammatory sites infiltrated by 
neutrophils (Kushner et al. 1961, 1963, James et al. 1981, Mortensen & Duskiewicz 1977, Du 
Clos et al. 1981, Buchta et al. 1988, Shephard et al. 1990). Binding of CRP to neutrophils has 
been shown to occur via specific CRP receptors related to the neutrophil Fc receptor (Muller 
et al. 1986, Buchta et al. 1987). More specifically, soluble, pentameric CRP has been shown 
to bind rapidly and specifically to all three classes of human FcγR (FcγRI, RII and RIII) in a 
calcium- and magnesium-depended manner (Dobrinich & Spagnuolo 1991, Lu et al. 2008, 
Bottazzi et al. 2010). However, in terms of CRP binding to neutrophils, which normally only 
express low/medium affinity receptors for IgG (FcγRII and FcγRIII), most studies have 
highlighted the role of FcγRIIA (Heuertz et al. 2005). 
 
Soluble, pentameric CRP has been shown to have multiple effects on neutrophils, including 
inhibiting chemotaxis (Wood 1951, Buchta et al. 1987, Kew et al. 1990, Heuertz et al. 1993), 
promoting phagocytosis (Kindmark 1971, Mold et al. 1981, 1982, Holzer et al. 1984, 
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Kilpatrick et al. 1985, Buchta et al. 1987) and reducing the stimulated respiratory burst 
(Buchta et al. 1987, Filep & Foldes-Filep 1989, Dobrinich & Spagnuolo 1991). Low 
concentrations (<5mg/l) of CRP have been suggested to potentiate activation of neutrophil 
superoxide generation following PMA or ConA stimulation, although >10mg/l CRP 
significantly inhibited superoxide generation measured by cytochrome c reduction (Buchta et 
al. 1987). Similarly, purified human CRP at elevated concentrations of >50mg/l inhibited the 
respiratory burst of neutrophils triggered by a variety of stimuli including PMA and fMLP 
(Buchta et al. 1987, 1988, Kew et al. 1990, Dobrinich et al. 1991, Shephard et al. 1992). 
Relatively few studies have investigated physiologically relevant concentrations of CRP, 
although 0.3mg/l CRP has been shown to inhibit neutrophil superoxide generation following 
stimulation with fMLP or PMA (Buchta et al. 1988). C-reactive protein (8mg/l) was also 
found to inhibit neutrophil degranulation and superoxide production, and also stabilized the 
neutrophil membrane against the lytic effect of lysophosphatidylcholine (Filep et al. 1989). In 
contrast, CRP within the concentration range of 10-100mg/l has been reported to have no 
significant effect on hydrogen peroxide generation by stimulated neutrophils (Timoshenko et 
al. 1998). To date there are no published studies investigating physiologically-relevant 
concentrations of CRP on the neutrophil respiratory burst in the presence of periodontally-
relevant bacteria.  
 
1.8 THESIS AIMS & OBJECTIVES 
The pathogenesis of chronic periodontitis remains to be fully elucidated.  However, the 
majority of evidence suggests that a dysregulated neutrophil inflammatory-immune response 
results in collateral host tissue damage within the periodontal tissues (Chapple & Matthews 
2007, Nussbaum & Shapira 2011; section 1.2.2). Therefore, the overall aim of this thesis was 
to contribute to our current understanding of the role of the neutrophil in the pathogenesis of 
chronic periodontitis along with possible associations with systemic disease (such as 
cardiovascular disease) in which raised systemic CRP concentrations are a risk factor. 
 
In order to achieve these aims, the work described in this thesis had the following specific 
objectives: 
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To establish and perform a case-controlled longitudinal intervention study providing 
neutrophils from periodontitis patients, pre- and post-therapy, and from matched 
periodontally healthy controls volunteers 
The first objective was to recruit patients diagnosed with chronic periodontitis along 
with age- and gender-matched periodontally- and systemically-healthy control 
volunteers. Clinical measures were performed to confirm the presence and absence of 
disease for patient and healthy control volunteers respectively. All volunteers provided 
baseline peripheral blood samples for neutrophil isolation and plasma preparation prior 
to patients progressing through conventional quadrant-by-quadrant periodontal 
treatment as clinically indicated. Post-therapy blood samples were collected for all 
patient volunteers and their paired controls.  Clinical measures were performed on all 
patient volunteers post-therapy in order to determine treatment effectiveness and to 
support any observed differences in ex vivo neutrophil function. 
 
To determine neutrophil cytokine release in chronic periodontitis and the effect of non-
surgical periodontal therapy 
IL-6, IL-8, IL-1β and TNF-α release from neutrophils isolated from patients with 
chronic periodontitis pre- and post-therapy and matched healthy controls was 
determined by ELISA analysis of supernatants from 18-hour cell cultures. Given the 
increasing awareness of the ability of neutrophils to secrete cytokines and co-ordinate 
the inflammatory-immune response this will determine whether aberrant cytokine 
release from peripheral blood neutrophils may be involved in the pathogenesis of 
chronic periodontitis.  
 
To determine neutrophil extracellular superoxide release in chronic periodontitis and 
the effect of non-surgical periodontal therapy 
Extracellular O2
-
 release from neutrophils isolated from patients with chronic 
periodontitis pre- and post-therapy and matched healthy controls was determined by 
lucigenin-enhanced chemiluminescence. Although over-production of ROS by 
neutrophils is a well-established feature of chronic periodontitis, investigating the 
specific role of O2
-
 will further elucidate the role of ROS in disease pathogenesis. 
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To determine neutrophil extracellular trap release in chronic periodontitis 
Neutrophil extracellular trap release from patients with chronic periodontitis pre- and 
post-therapy and matched healthy controls was determined using a recently developed 
fluorometric assay. Data from these novel experiments will add to our current 
understanding of the pathogenesis of chronic periodontitis, especially in relation to the 
hyper-responsive neutrophil ROS phenotype, since ROS are essential for NET release.  
 
To determine neutrophil chemotactic accuracy in chronic periodontitis 
Neutrophil directional chemotactic accuracy from patients with chronic periodontitis 
pre- and post-therapy and matched healthy controls was determined, for the first time, 
using a novel direct visualisation chemotaxis chamber. The data obtained will be 
important because enhanced recruitment into, and/or delayed tissue transit times 
through, periodontal tissues by hyper-responsive neutrophils will have the potential to 
increase collateral host tissue damage. 
 
To determine the effect of CRP on the neutrophil respiratory burst 
The final objective of this thesis was to determine the effects of physiologically-
relevant concentrations of CRP on the neutrophil respiratory burst in vitro using 
chemiluminescence methods. This will add to our current understanding of neutrophil 
function in relation to systemic inflammatory markers that are associated with both 
chronic periodontitis and systemic disease. 
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CHAPTER 2 
 
MATERIALS & METHODS 
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2.1  CLINICAL METHODS 
All clinical procedures were performed by M.R.Ling including recruiting all patient and 
control volunteers, collection of clinical measurements, gingival crevicular fluid (GCF) and 
gingival biopsy sampling. Clinical support was provided by J.Crumpler (Research Nurse) 
regarding dental nursing, performing venipuncture for collection of peripheral blood samples 
and organising patient appointments. Additional clinical support was provided by J.Rooney 
(Research Hygienist) who performed periodontal treatment for all patient volunteers.  
 
2.1.1 DETERMINATION OF NEUTROPHIL FUNCTION IN PERIODONTITIS 
PATIENTS PRE- & POST-NON-SURGICAL THERAPY 
This was performed using a longitudinal interventional case-control clinical study including 
patients diagnosed with chronic periodontitis and matched periodontally and systemically 
healthy control volunteers (Figure 2.1). Volunteers progressed through the study with 
sampling visits pre- and post-non-surgical periodontal therapy. Patient volunteers 
subsequently progressed through 4 visits of quadrant-by-quadrant periodontal treatment 
(section 2.1.1.6) on a weekly basis. Patients were then re-assessed 2-months following 
treatment of the 4
th
 quadrant to allow for initial healing consistent with conventional 
periodontal treatment protocols and to reduce the risk of re-infection/disease re-activation 
(Chapple et al. 2007) impacting upon post-treatment measures. The review appointments 
included repeat clinical measures to assess response to treatment along with post-therapy 
sample collection. Healthy control volunteers were recalled and sampled at the same time as 
their matched patient volunteer. The sample size (20 patients and 20 controls; n=40) was 
based upon previous studies of neutrophil responses within the Periodontal Research Group in 
order to obtain a >80% power to detect significant differences between test and control 
volunteer neutrophils at p<0.05 by two-tailed statistical analyses.   
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Figure 2.1. Longitudinal interventional clinical study flow diagram. Note the sampling 
visits for the patient and control volunteers. 
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2.1.1.1 Ethical approval 
Ethical approval for the clinical study was sought using the online Integrated Research 
Application System (IRAS; reference no. 46998) and granted by the West Midlands Research 
Ethics Committee (REC reference no. 10/H1208/48). The study was subsequently adopted 
onto the National Institute of Health Research Network Portfolio (NIHR UKCRN Study ID 
10318) and eligible for additional financial support from the UK NIHR Clinical Research 
Network. The study was also added to ClinicalTrials.gov (Identifier NCT01233765). 
Sponsorship was obtained from the University of Birmingham (Sponsor reference no. RG_10-
077) and NHS Permission was granted by the Birmingham Community Health Care NHS 
Trust on behalf of the Birmingham and the Black Country Comprehensive Local Research 
Network (BBC CLRN) Research Management & Governance (RM&G) Consortium Office 
(NHS R&D reference no. R&D1398; RM&G reference no. BCHCTDent265.1398.P). The 
study was classified as a clinical study and came under the Department of Health Research 
Governance Framework for Health and Social Care.  
 
2.1.1.2 Funding 
Funding for the clinical study was obtained from the Oral and Dental Research Trust (£6,273; 
RCFL14945), the British Society of Periodontology (£4,444; RCRW14944) and the Royal 
College of Surgeons of England (£9,200; RCFX16209). Additional funding was also obtained 
from BBC CLRN (£15,938) to cover the costs of a research nurse and hygienist. 
 
2.1.1.3 Recruitment 
Volunteers enrolled included those diagnosed with chronic periodontitis along with age- and 
gender-matched periodontally and systemically healthy controls. All volunteers were never-
smokers and otherwise systemically healthy as confirmed by a detailed medical history 
questionnaire (appendix I). Chronic periodontitis was defined as the presence of at least two 
non-adjacent sites with probing pocket depths >4mm, along with radiographic bone loss 
>30% of the root length (non-first molar or incisor sites) in accordance with the consensus 
criteria of the European Federation of Periodontology (Tonetti & Claffey 2005). Control 
volunteers had no evidence of attachment loss, no probing pocket depths >4mm and whole-
mouth bleeding scores <10%. Inclusion criteria included the complete absence of systemic 
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disease, pregnancy, special dietary needs, vitamin supplements and no anti-inflammatory or 
antibiotic medication in the previous 3 months. Age and gender-matched periodontally and 
systemically healthy control volunteers were recruited from Staff of the Birmingham Dental 
Hospital and School. Volunteers were initially provided with a study information leaflet 
(appendix II), participation discussed and questions answered prior to providing written 
informed consent. All volunteers were then re-appointed for clinical measures, sample 
collection and periodontal treatment as appropriate. Accrual recruitment data was uploaded on 
a monthly basis onto the UK Clinical Research Network Portal (https://portal.ukcrn.org.uk) as 
a condition of continued support from the BBC CLRN. 
 
2.1.1.4 Clinical measures 
The following clinical measures and samples (section 2.1.1.5) were collected from the patient 
and healthy control volunteers as indicated. Gingival crevicular fluid samples (section 
2.1.1.5b) were collected initially, followed by the gingival index measurements (section 
2.1.1.4a), periodontal probing pocket depths (section 2.1.1.4c), gingival recession (section 
2.1.1.4d), and finally the plaque index measurements due to the additional use of plaque-
disclosing solution (section 2.1.1.4b). Patient and healthy control volunteers were re-
appointed for peripheral blood sampling (section 2.1.1.5a) immediately prior to periodontal 
treatment for the patient volunteers, during which time gingival biopsy samples were 
collected as indicated (section 2.1.1.5c).  
 
a. Gingival index 
The presence of gingival inflammation was measured using the Löe (1967) gingival index 
(GI; Löe 1967). The teeth were dried using a triple air syringe, and a periodontal probe (Hu-
Friedy Manufacturing Co., Chicago, IL) was gently introduced into the gingival crevice at a 
force of ~0.25N at 60
o
 to the long axis of the tooth. 3 buccal/labial and 3 palatal/lingual thirds 
on each tooth (6 sites in total) were analysed according to standard criteria (Table 2.1).  
 
b. Plaque index 
The presence of dental plaque was measured using the Quigley & Hein, Turesky & Lobene 
modified (1982) plaque index (PI; Quigley & Hein 1962, Turesky et al. 1970, Lobene et al. 
1982). Plaque was visualized by gently brushing the surface of the teeth with a cotton bud 
46 
 
soaked in plaque-disclosing solution. A visual assessment of the presence of plaque was 
subsequently undertaken on 3 buccal/labial and 3 palatal/lingual thirds on each tooth (6 sites 
in total) according to standard criteria (Table 2.2). 
 
c. Periodontal probing pocket depths 
Full mouth periodontal probing pocket depths (PPD) were measured using a PCP-UNC-15 
periodontal probe (Hu-Friedy Manufacturing Co., Chicago, IL) with a force of ~0.25N along 
the long axis of each tooth. PPD was measured as the distance between the gingival margin 
and the base of the periodontal pocket/sulcus at a total of 6 sites per tooth, with 3 
measurements on each of the buccal/labial and palatal/lingual surfaces. 
 
d. Gingival recession 
Full mouth gingival recession measures were performed using a PCP-UNC-15 periodontal 
probe (section 2.1.1.4c), and measured as the distance between the cement-enamel junction 
and the gingival margin at a total of 6 sites per tooth, with 3 measurements each on the 
buccal/labial and palatal/lingual surfaces. 
 
e. Clinical attachment loss 
Clinical attachment loss (CAL) was calculated as the sum of the PPD and gingival recession 
measurements in accordance with clinical and histological studies of periodontal attachment 
loss (Haffajee & Socransky 1986).  
 
f. Bleeding on probing 
Bleeding upon periodontal probing was recorded in conjunction with the PPD measurements 
(section 2.1.1.4c) indicating bleeding from the base of the periodontal pocket, as well as 
during probing at 60
o
 to the long axis of the teeth during the measurement of GI (section 
2.1.1.4a), thereby distinguishing from bleeding from the surrounding sulcular/pocket 
epithelium. 
 
 g. Classification of chronic periodontitis 
Chronic periodontitis was classified as localized (<30% sites) or generalized (>30% sites) and 
severity determined, namely mild (1-2mm), moderate (3-4mm) or severe (>4mm) based on 
CAL calculations (Armitage 1999, Milward & Chapple 2003; section 2.1.1.4e).  
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Gingival 
index 
Condition 
Criteria 
Gingival colour Gingival margin Gingival tissue 
0 Health Pale pink or pink 
At or apical to the 
amelo-cemental 
junction 
Firm to palpation 
with a blunt probe 
1 
Mild 
inflammation 
Red or bluish-red 
tinge 
Colourless exudate 
may be present. No 
bleeding on 
periodontal probing 
Little change in 
texture of any 
portion of, but not 
the entire marginal 
or papillary unit 
2 
Mild to 
moderate 
inflammation 
Red or reddish-blue 
glazed appearance 
Enlarged and 
oedematous. No 
bleeding on 
periodontal probing 
Change in texture 
involving the entire 
marginal or 
papillary gingival 
unit 
3 
Moderate to 
severe 
inflammation 
Markedly red or 
bluish-red 
appearance 
Oedema and/or 
hypertrophy, with 
bleeding on 
periodontal probing 
Oedema and/or 
hypertrophy of the 
entire marginal or 
papillary gingival 
unit 
 
Table 2.1. Löe (1967) gingival index criteria. 
 
 
Plaque 
index 
Criteria 
0 Zero plaque 
1 A discontinuous line of plaque at the gingival margin 
2 A continuous line of plaque at the gingival margin up to 1mm in depth 
3 
A continuous line of plaque at the gingival margin >1mm extending up to 1/3
rd
 of 
the tooth surface 
4 
A continuous line of plaque at the gingival margin extending >1/3
rd
 up to 2/3
rd
 of 
the tooth surface 
5 
A continuous line of plaque at the gingival margin extending >2/3
rd
 of the tooth 
surface 
 
Table 2.2. Quigley & Hein, Lobene modification (1982) plaque index criteria. 
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2.1.1.5 Sample collection 
Clinical measurements (section 2.1.1.4), peripheral blood and gingival crevicular fluid (GCF) 
samples were collected for all patient and matched healthy control volunteers both pre- and 
post-periodontal treatment. In addition, patient volunteers progressed through 4 visits of 
quadrant-by-quadrant periodontal treatment (section 2.1.1.6) on a weekly basis which also 
included gingival biopsy harvesting. 
 
 a. Peripheral blood samples 
Peripheral blood was collected from the antecubital fossa into Vacutainers (Greiner, Bio-One 
Ltd., Stonehouse, UK; 6ml) containing lithium heparin (17IU/ml) as an anticoagulant. Blood 
was collected between 09:00 and 10:00am. Preliminary experiments confirmed a typical cell 
retrieval of 1x10
6
 neutrophils per ml of venous blood, and therefore a total of 7 tubes were 
required to have sufficient cells for the enhanced chemiluminescence assay of reactive oxygen 
species (ROS; section 2.2.8), fluorometric neutrophil extracellular trap analysis (section 
2.2.9), directional chemotaxis (section 2.2.10) assays,  as well as neutrophil culture prior to 
determination of cytokine release (section 2.2.6).  One additional tube of blood was collected 
for plasma preparation (section 2.2.1), therefore equating to a total of 8 tubes of blood in total 
(~48ml) per volunteer.  
 
b. Gingival crevicular fluid 
Gingival crevicular fluid (GCF) was collected prior to the clinical measures (section 2.1.1.4) 
using a Periopaper (OraFlow, Plainview, New York, NY, USA) inserted into the mesio-
buccal gingival crevice of 6 teeth (a molar, pre-molar and canine or incisor) within the upper 
left and right sextants. Intra-oral sites were carefully isolated using cotton wool rolls placed 
within the buccal sulcus along with use of a saliva ejector. Air from a triple air syringe was 
gently directed towards the coronal aspect of the tooth to be sampled a total of 5 times from 
the gingivae to the occlusal surface away from the gingival crevice and not into the crevice. A 
Periopaper was removed from the holder using tweezers to grasp the orange section only, and 
the paper portion of the strip was gently inserted into the gingival crevice so that its leading 
edge was parallel to the line of the gingival margin, trying not to bend the strip. The 
Periopaper was left undisturbed for 30s prior to removal and read on a pre-calibrated 
Periotron 8000 (Chapple et al. 1999; OraFlow, Plainview, New York, NY, USA) for 
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calculation of GCF volume.  3 strips from each sextant were immediately placed into 400µl of 
100mM ammonium bicarbonate buffer and stored at -80
o
C, prior to analysis of protein 
citrullination by mass spectrometry (section 2.2.11.3). 
 
c. Gingival biopsy samples 
During periodontal treatment patient volunteers received local anaesthesia prior to 
instrumentation according to standard treatment protocols. During the first two treatment 
visits, whilst anaesthetized, two 2mm diameter gingival biopsy samples were collected 
submarginally from an inflamed and adjacent non-inflamed gingival site, using a 2mm 
diameter biopsy punch (Schuco 33-31-P/25) and sharp dissection with a microsurgical blade, 
immediately prior to root surface debridement of the sampled sextant. Gingival biopsy 
samples were immediately placed into a Universal bottle containing 10% neutral buffered 
formalin (4% formaldehyde v/v) for 18-24hr fixation prior to routine processing to wax at the 
Human Biomaterials Resource Centre, the University of Birmingham. Gingival biopsy 
samples were collected in order to provide tissue for future determination of in vivo NET 
formation by immunohistochemical methods. 
 
2.1.1.6 Periodontal treatment for patient volunteers 
Patient volunteers received tailored oral hygiene instruction and conventional non-surgical 
periodontal therapy. This consisted of scaling and root surface debridement (RSD) of all 
periodontal pockets >4mm performed under local anaesthesia on a quadrant-by-quadrant basis 
within a maximum of 4 weeks.  
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2.1.2 DETERMINATION OF THE EFFECT OF C-REACTIVE PROTEIN ON 
NEUTROPHIL FUNCTION 
Periodontally and systemically healthy volunteers were recruited and each donated a 
peripheral blood sample (section 2.1.1.5a) for isolation of peripheral blood neutrophils prior 
to determination of neutrophil reactive oxygen species (ROS) generation and release in the 
presence of C-reactive protein (CRP; section 2.2.11.8).  
 
2.1.2.1 Ethical approval 
Ethical approval was issued by the University Ethical Review Committee (University of 
Birmingham Ethics Reference ERN_10-0518), and Sponsorship provided by the University of 
Birmingham (Sponsor Reference RG_10-122). The CRP experiments were classified as a 
Supervised Student Clinical Trial, for which M.R.Ling was Chief Investigator, and came 
under the Department of Health Research Governance Framework for Health and Social Care. 
 
2.1.2.2 Volunteer selection 
Volunteers were recruited from staff and students of the Birmingham Dental Hospital and 
School. Inclusion criteria included volunteers to be systemically and periodontal healthy as 
determined by a detailed medical history questionnaire and periodontal examination, no 
pregnancy and no special dietary needs along with a complete absence of vitamin 
supplements and no use of anti-inflammatory or antibiotic medication in the previous 3 
months. All volunteers were non-smokers for >5yrs. Following identification, study 
participation was discussed and questions answered prior to obtaining written informed 
consent. Volunteers were then re-appointed for collection of a peripheral blood sample 
(section 2.1.2.3). 
 
2.1.2.3 Peripheral blood sample 
Peripheral blood was collected from the ante-cubital fossa into Vacutainers (Greiner, Bio-One 
Ltd., Stonehouse, UK; 6ml) containing lithium heparin (17IU/ml) between 9:00 and 10:00hrs. 
According to the anticipated cell retrieval, 3 tubes of blood were required in order to ensure 
an adequate number of cells to undertake all planned enhanced chemiluminescence assay 
experiments (section 2.2.11.8). 
 
51 
 
2.2  LABORATORY METHODS 
All laboratory procedures were performed by M.R.Ling apart from analytical 
ultracentrifugation (section 2.2.11.4), mass spectrometry (section 2.2.11.3) and determination 
of plasma hsCRP concentrations (section 2.2.2). Analysis of neutrophil extracellular trap 
(NET) production (section 2.2.9) and neutrophil chemotaxis (section 2.2.10) were performed 
as part of collaborative projects with P.Harris and H.Roberts respectively who assisted with 
these analyses (see Acknowledgements). 
 
2.2.1  Plasma preparation 
Blood in lithium-heparin Vacutainers
TM
 (Greiner, Bio-One Ltd, Stonehouse, UK; 6ml) was 
centrifuged in sealed buckets at 1,000rcf for 30mins at 4
o
C (IEC Centra 3R). Post-
centrifugation, Vacutainers
TM
 were opened and the separated plasma carefully removed using 
a sterile plastic Pasteur pipette and aliquoted into cryogenic vials (0.5ml/tube) for storage at -
80
o
C.  
 
2.2.2  High-sensitivity C-reactive protein analyses of stored plasma samples 
High-sensitivity CRP (hsCRP) analyses were performed on 0.5ml aliquots of the stored 
plasma samples. This was undertaken by Dr Jonathan Aldis, UK National Protein Reference 
Centre, Immunology Department & Protein Reference Unit, Sheffield Teaching Hospitals 
NHS Foundation Trust. 
 
2.2.3  Isolation of peripheral blood neutrophils 
Peripheral blood neutrophils were isolated from peripheral blood using the following 
reagents, prior to cell counting and confirmation of neutrophil purity and viability. 
  
2.2.3.1 Erythrocyte lysis buffer 
Lysis buffer was prepared by dissolving 8.3g NH4Cl (A9434 Sigma), 1g KHCO3 (P9144 
Sigma), 0.04g Na2 EDTA 2H2O (E5134 Sigma) and 2.5g bovine serum albumin (BSA; 
A4530 Sigma) in 1L of sterile distilled water and stored at 4
o
C until use for a maximum of 2 
weeks. 
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The cell density of granulocytes (1.08-1.09g/ml; Morisaki et al. 1992) is similar to that of 
erythrocytes (1.09-1.10g/ml; Linderkamp et al. 1993). An erythrocyte lysis step was therefore 
required during neutrophil isolation to remove any contaminating erythrocytes due to the 
pseudoperoxidase activity of haemoglobin (Thomas 1985, Widmer et al. 2010) along with 
light absorbing capacity when using chemiluminescence methods (Faber et al. 2003).  
 
2.2.3.2 Phosphate buffered saline (PBS) 
PBS was prepared by dissolving 7.75g NaCl (S9625 Sigma), 0.2g KH2PO4 (P5379 Sigma) 
and 1.5g K2HPO4 (P8281 Sigma) in 1L of sterile distilled water. The solution was autoclaved 
and stored at 4
o
C until use for a maximum of 2 weeks. 
 
2.2.3.3 Percoll density gradients 
Percoll is a silica colloid that is widely used as a density gradient medium to isolate cells from 
peripheral blood with high viability and intact morphology (Dooley et al. 1982). Percoll is 
comprised of a silica sol with a non-dialyzable polyvinylpyrrolidone coating, and a density of 
1.130+0.005g/ml. Percoll was chosen rather than alternative neutrophil separation solutions as 
many of the experiments involved myeloperoxidase (MPO) catalyzed formation of 
hypochlorous acid. Ficoll-Hypaque density gradients were therefore avoided since it is 
possible that I
-
 may leach from the diatrizoate and compete with Cl
-
 for oxidation by the 
MPO-H2O2-halide system (Grisham 1985). In addition, Ficoll isolation techniques are also 
thought to pre-activate neutrophils (Rebecchi et al. 2000). 
 
Neutrophils were isolated using Percoll densities of 1.098g/ml and 1.079g/ml (Bergstrom & 
Asman 1993), prepared using sterile reagents according to the equation: 
 
 
 
Where: 
Vo = volume of Percoll (undiluted) (ml) 
V = volume of the final working solution (ml) 
ρ = desired density of the final solution (g/ml) 
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ρ0 = density of Percoll (undiluted) (g/ml) (exact density specified in the “Certificate of Analysis”) 
ρ10 = density of 1.5M NaCl = 1.058 (g/ml) 
 
The following volumes (ml) were used to prepare Percoll solutions: 
 
 
Percoll Density (g/ml) 
1.079 1.098 
Percoll 19.708 24.823 
dH2O 11.792 6.677 
1.5M NaCl 3.5 3.5 
Total volume (ml) 35 35 
 
To prepare discontinuous density gradients, 8ml of 1.098g/ml Percoll was carefully layered 
underneath 8ml 1.079g/ml Percoll in a sterile 25ml centrifuge tube using a sterile plastic 
Pasteur pipette. Gradients were prepared immediately prior to neutrophil isolation. 
 
2.2.3.4 Neutrophil isolation 
Peripheral blood was carefully layered onto discontinuous Percoll density gradients 
(δ=1.079:1:098) within a sterile 25ml centrifuge tube and then centrifuged (IEC Centra 
CL3R) for 8mins at 150rcf, followed by 10mins at 1,200rcf (Figure 2.2).  
 
 
Figure 2.2. Peripheral blood separation using Percoll density gradient centrifugation. 
The neutrophil layer may be observed immediately above the separated erythrocytes at the 
bottom of the centrifuge tube. 
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Using a sterile plastic Pasteur pipette, the plasma, lymphocyte and monocyte layers at the top 
of the centrifuge tube above the neutrophil and erythrocyte cell layers, were carefully 
removed and discarded. The neutrophil layer, located at the top of the erythrocyte cell layer, 
was then carefully transferred to a 50ml centrifuge tube containing ~20ml erythrocyte lysis 
buffer and the final volume made up to ~50ml with additional erythrocyte lysis buffer. The 
tube was gently inverted to mix, and incubated at room temperature for 5-10mins until the 
erythrocytes had lysed and the cell suspension changed from cloudy to transparent. The lysed 
cell suspension was then centrifuged for 6mins at 500rcf to pellet the neutrophils. The 
supernatant was carefully discarded using a sterile plastic Pasteur pipette and the pellet re-
suspended in an additional 3ml lysis buffer and incubated for 5mins at room temperature prior 
to re-centrifugation (6mins; 500rcf). The supernatant was once again removed and the pellet 
washed in 3ml PBS, and centrifuged once more for 6mins at 500rcf prior to re-suspension in 
4-8ml PBS depending on the size of the cell pellet prior to cell counting (section 2.2.3.5). 
 
2.2.3.5 Neutrophil cell counting 
Neutrophils were counted using a haemocytometer (Sigma Z359629) whose central area was 
1mm
2
, subdivided into 25 (0.04mm
2
) smaller squares surrounded by triple lines, each 
subdivided further into 16 smaller squares as shown (Figure 2.3).  
 
 
 
 
Figure 2.3. Haemocytometer central viewing area (A) & 0.04mm2 squares surrounded 
by triple lines (B) with example cell count (Sigma Z359629 product information sheet).  
 
 
Cells were counted if they were within the triple lines either above or to the left-hand side of 
the 0.04mm
2
 squares, but not the right-hand side or bottom to ensure a uniform cell count 
A B 
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(Figure 2.2). The depth of the haemocytometer was 0.1mm, and therefore the number of cells 
within the PBS suspension was calculated according to the equation: 
 
Cell count x 250 x 1,000 = no. cells in 1ml cell suspension 
9 
Where: 
Cell count = the number of cells counted within a total of nine 0.04mm
2
 squares within the 
diagonal axis of the central 1mm
2
 area of the haemocytometer.  
 
Following counting, the required amount of buffer (PBS, GPBS or RPMI) was added to the 
cell preparation to give a final cell suspension containing the appropriate neutrophil 
concentration required for the different assays. These included 1x10
6
/ml for the neutrophil 
ROS enhanced chemiluminecence assays (section 2.2.8.2) and the NET fluorometric assays 
(section 2.2.9.2); 3.125x10
6
/ml for neutrophil cell culture (section 2.2.6) and 2x10
6
/ml for the 
directional chemotaxis assay (section 2.2.10.1).  
 
2.2.3.6 Confirmation of neutrophil purity and viability 
Isolated cells were >99% polymorphonuclear cells morphologically and devoid of 
erythrocytes and monocytes.  The absence of monocytes in cells prepared using this method 
has also been confirmed previously within our laboratory by gene expression analysis (Wright 
et al. 2008). Giemsa stained cell smears (Barcia 2007) also confirmed the presence of >99% 
neutrophils in the cell preparation. 
 
Neutrophil cell viability was routinely determined by trypan blue dye exclusion (1:1 mix of 
cells with trypan blue; T8154 Sigma) and visualization by light microscopy (Leitz Laborlux). 
Neutrophil viability was expressed as the percentage of cells not permeable to trypan blue.  In 
addition, for some experiments, cell metabolic activity was also analysed using a CellTiter-
Glo
®
 Luminescent Cell Viability Assay Kit (Promega, Southampton, UK) according to the 
manufacturer’s instructions. Briefly 100µl of CellTiter-Glo® Reagent was added to 100µl of 
neutrophil cell suspension in a 96-well plate and incubated for 10mins prior to recording 
luminescence using a microplate reader (Bertold microplate luminometer LB96v). This 
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method is based upon quantifying adenosine triphosphate (ATP) which signals the presence 
of metabolically active cells.  
 
2.2.4  Preparation of bacterial stimuli 
All bacteria were originally obtained commercially and stored in tryptone soya broth 
supplemented with 10% DMSO at -80
o
C in 2ml cryovials.  Initial innoculae were established 
by defrosting the frozen aliquots at room temperature prior to pouring onto tryptone soya agar 
plates and anaerobic incubation for 7 days with plates facing upwards. Bacteria were then 
streak plated onto fresh tryptone soya agar plates and incubated for a further 7 days to observe 
individual colonies indicating a pure culture (Holt 1994). Specific culture conditions for each 
individual bacterial species are described below.  
 
2.2.4.1 Tryptone soya broth 
Tryptone soya broth (CM0129 Oxoid) was prepared according to the manufacturer’s 
instructions, namely 9g tryptone soya broth was dissolved in 300ml distilled water. 10ml of 
the tryptone soya broth was aliquotted into borosilicate glass culture tubes (FB59537 Fisher 
Scientific) with vented plastic caps (TB51373 Fisher Scientific) and autoclaved at 121
o
C for 
15mins prior to storage at 4
o
C.  
 
2.2.4.2 Enriched tryptone soya broth 
Enriched tryptone soya broth, required for the growth of Porphyromonas gingivalis (ATCC 
33277), was prepared by addition of 1mg/ml glucose powder and 0.01ml per ml hemin to the 
standard tryptone soya broth (section 2.2.4.1) prior to autoclaving and 0.3µg/ml vitamin K 
added after autoclaving. 
 
a. Hemin 
50mg hemin (Sigma H-5533) and potassium phosphate 1.74g (Sigma P-5504) were added to 
100ml of distilled water. This solution was boiled until the hemin had dissolved. After cooling 
to room temperature, the solution was stored at 4
o
C covered in aluminium foil for a maximum 
of three weeks. 
 
 
57 
 
b. Vitamin K 
5mg menadione (Sigma M-5625) was dissolved in 1ml of 95% ethanol (Sigma). 99ml 
distilled water was added and the resultant solution filter sterilized (0.2µm; Corning 430944) 
prior to storage at -20
o
C for a maximum of three weeks.  
 
2.2.4.3 Tryptone soya agar 
Tryptone soya agar (CM0131 Oxoid) was prepared by dissolving 40g in 1L distilled water 
according to the manufacturer’s instructions. After autoclaving at 121oC for 15mins the agar 
was cooled to 50
o
C in a water bath before 5% defibrinated horse blood (SR0050B Oxoid) was 
added aseptically. Agar was poured into triple vented Petri dishes (101VR20 Sterilin) and left 
inverted for 24hrs to allow ventilation of excess moisture, prior to storage at 4
o
C. Before use, 
dishes were allowed to equilibrate at room temperature for 1hr. 
 
2.2.4.4 Enriched tryptone soya agar 
The growth of Porphyromonas gingivalis required the use of agar enriched with hemin 
(section 2.2.4.2a), N-acetylmuramic acid (NAM; section 2.2.4.4a) and vitamin K (section 
2.2.4.2b). Ten hemin-NAM-vitamin K (HNK) agar plates were prepared by adding 5.0g 
tryptone soya agar (section 2.2.4.3), 6.5g brain heart infusion (CM225 Oxoid), 2.5g yeast 
extract (Y-1001 Sigma) and 2.5ml hemin (section 2.2.4.2a) to distilled water (final volume = 
250ml). This solution was sterilized by autoclaving at 121
o
C for 15mins and then cooled to 
50
o
C before adding 300µl NAM (section 2.2.4.4.a), 2.5ml vitamin K (section 2.2.4.2b) and 
12.5ml defibrinated horse blood (SR0050B Oxoid) before pouring into 90mm triple vented 
Petri dishes and being allowed to set at room temperature.  
 
a. N-acetylmuramic acid 
100mg of N-acetylmuramic acid (NAM; Sigma A3007) was dissolved in 10ml of distilled 
water and filter sterilized (0.2µm, BC591 Appleton Woods) prior to storage at -20
o
C for a 
maximum of three weeks.   
 
2.2.4.5 Determination of bacterial growth by spectrophotometry 
Post-culture bacterial proliferation was determined by suspending the bacterial cell pellets in 
sterile PBS prior to measuring optical density at 600nm (OD600nm) using a spectrophotometer 
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(Jenway 6300), with samples of non-inoculated media used to correct for media changes not 
due to bacterial growth. Porphyromonas gingivalis (ATCC 33277) and F. nucleatum (ATCC 
10953) OD
1.0
600nm were 1.69x10
9
 and 1.62x10
9
 bacteria/ml respectively as pre-determined by 
the Forsyth Institute, Boston, USA (Roberts et al. 2002).  
 
2.2.4.6 Porphyromonas gingivalis 
Porphyromonas gingivalis is a Gram negative anaerobe that is part of the red complex of 
bacteria considered central to the pathogenesis of chronic periodontitis (Socransky et al. 
1998), and interacts with neutrophil Toll-like receptors (TLR)-2 and -4 (Darveau et al. 2004).  
 
Porphyromonas gingivalis (ATCC 33277) was obtained from the Forsyth Institute, Boston 
and was originally purchased from the American Type Culture Collection (ATCC). 
Porphyromonas gingivalis was grown anaerobically at 37
o
C as previously described (Roberts 
et al. 2002) within an anaerobic chamber (Don Whitley Scientific, Modular Atmosphere 
Controlled System, CAL-3200, Shipley, UK). The atmosphere comprised of 9.97% carbon 
dioxide, 9.92% hydrogen, with nitrogen balance at 37
o
C. Porphyromonas gingivalis cultures 
were maintained on enriched tryptone soya agar and isolated by centrifugation at 700rcf for 
10mins and subsequently washed 3 times in sterile PBS before being heat-treated at 100
o
C for 
10mins prior to dilution in sterile PBS giving a final suspension of 4.12x10
9
 cells/ml (section 
2.2.4.5) which was stored at -30
o
C. 
 
2.2.4.7 Fusobacterium nucleatum 
Fusobacterium nucleatum is a gram-negative anaerobe present at high frequency and number 
in the subgingival plaque biofilm in periodontal lesions and is central to periodontal disease 
pathogenesis as the microflora develops from a non-pathogenic to a pathogenic state 
(Kolenbrander et al. 1995; Socransky et al 1998). F. nucleatum is also a key quorum sensing 
organism present in subgingival plaque (Kolenbrander et al. 1995). Heat-killed F. nucleatum 
activates neutrophils via TLR-2, -4 and -9, but predominantly via TLR-2 (Kikkert et al. 
2007). 
 
Fusobacterium nucleatum (ATCC 10953) was obtained from the Forsyth Institute, Boston 
and originally purchased from the American Type Culture Collection. Fusobacterium 
59 
 
nucleatum was grown anaerobically at 37
o
C
 
as previously described (Roberts et al. 2002) 
within an anaerobic chamber as described for P. gingivalis. F. nucleatum cultures were 
maintained on broth cultures and isolated by centrifugation at 700rcf for 10mins and 
subsequently washed 3 times in sterile PBS before being heat-treated at 80
o
C for 10mins prior 
to dilution in sterile PBS giving a final stock suspension of 8.5x10
9
 cells/ml (section 2.2.4.5) 
which was stored at -30
o
C.  
 
2.2.4.8 Staphylococcus aureus 
Staphylococcus aureus (National Collection of Type Cultures; NCTC 6571, Heatley 1944) 
was obtained from Fisher Scientific and stored at -40
o
C in cryo-preservative on beads (Prolab 
PL160). One bead was retrieved and used to inoculate a mannitol salt agar plate for growth of 
single colonies indicated by a yellow colouration of agar. Following an aerobic overnight 
incubation (5% CO2, 37
o
C), several colonies were used to inoculate 500ml sterile tryptone 
soya broth in a glass flask, using a flame sterilized loop. The inoculated broth was incubated 
overnight (5% CO2, 37
o
C), following which the culture contained stationary phase bacteria 
(approx. 10
9
/ml) as indicated with the broth turning opaque. Bacterial numbers were also 
confirmed using colony counts by streak plating and also measuring optical density before 
and after washing. The culture was divided into 10 separate 50ml centrifuge tubes (Fisher 
Scientific), and bacteria pelleted by centrifugation for 10mins at 700rcf (IEC Centra CL3R). 
The supernatant was discarded into a waste bottle for disposal by autoclaving and the pellets 
were re-suspended in 20ml PBS by vortex mixing. Suspensions in PBS were pooled into 4 
separate 50ml tubes, re-centrifuged, washed again by re-suspension in 20ml PBS, pooled into 
two tubes and then washed a third time by re-suspension in 20ml PBS. All harvesting and 
washing procedures were undertaken in a Biological Safety cabinet (AirOne 1000-GS, 
Safelab Systems Ltd) using aseptic technique.  
  
Following the third re-suspension and washing step, the pellets were then each re-suspended 
in 20ml 3% formaldehyde (P6148 Sigma) for 1 hour at room temperature to fix. The fixative 
was removed by centrifugation and the cells washed a further three times by re-suspension in 
20ml PBS (20ml for each pellet). Finally the pellets were re-suspended in 5ml PBS at a 
concentration of 1x10
11
 bacteria/ml and stored at -80
o
C. 
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a. Opsonisation of Staphylococcus aureus 
Staphylococcus aureus was opsonized with IgG to specifically stimulate neutrophil Fc-
gamma receptors (FcγR). Opsonised S. aureus was prepared as previously described 
(Bergstrom et al. 1993) by the addition of 33µl Vigam liquid (5mg/ml IgG; Bio Products 
Laboratory) per ml of bacteria and incubated overnight at room temperature with constant 
agitation. Finally bacteria were re-suspended in PBS and stored as a 3.75x10
9
 cells/ml 
suspension in 1ml aliquots at -80
o
C prior to use. 
 
2.2.4.9 Escherichia coli O26:B6 lipopolysaccharide 
Lipopolysaccharide is a component of the outer membrane of Gram-negative bacteria and acts 
primarily via TLR-4 ligation (Hoshino et al. 1999). E. coli LPS (Sigma L5543) was supplied 
as a 0.2µm filtered aqueous solution containing 1mg/ml of lipopolysaccharide (LPS) from E. 
coli serotype O26:B6. The LPS used to prepare the solution was phenol-extracted and 
chromatographically purified by gel filtration as confirmed by the product information sheet 
 
Neutrophil responses to LPS are dependent upon binding to membrane CD14 (Nakatomi et al. 
1998) in the presence of plasma or LPS binding protein (Kirkland et al. 1993, Luchi et al. 
1993). Lipopolysaccharide samples were therefore diluted in 20% human plasma (Sigma 
H4522) and PBS using siliconised pipette tips (Cole-Parmer 25711-32, Cole-Parmer 25711-
56) and siliconised microcentrifuge tubes (Sigma T4816), and stored at -20
o
C prior to use.  
 
2.2.5  Preparation of non-bacterial stimuli 
Non-bacterial stimuli included heat-aggregated IgG for neutrophil FcγR stimulation and 
phorbol 12-myristate, 13-acetate (PMA) which bypasses cell surface receptors and directly 
activates protein kinase C (PKC; Johnson et al. 2002). In addition hypochlorous acid (HOCl) 
was included as a recently established stimulus for neutrophil extracellular trap (NET) 
formation (Palmer et al. 2012). 
 
2.2.5.1 Heat-aggregated IgG 
Freeze-dried IgG purified from human serum (Sigma I4506) was re-constituted in 150mM 
NaCl to give a 4.8mg/ml solution as determined by spectrophotometry (E
1%
280 = 14). 
Subsequent dilutions in PBS were heated in a glass tube in a water bath at 63
o
C for 60mins 
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(Zeller et al. 1986) and allowed to cool to room temperature prior to use. Heat-aggregated IgG 
was prepared immediately prior to use. The formation of aggregated IgG was confirmed using 
analytical ultracentrifugation analyses (AUC; section 2.2.11.4).  
 
2.2.5.2 Phorbol 12-myristate, 13-acetate 
Phorbol 12-myristate, 13-acetate (PMA; Sigma P8139) was reconstituted with DMSO to give 
a 1mg/ml (1.62mM) stock solution that was stored at -20
o
C prior to use. Working solutions 
were prepared by diluting this stock solution with PBS. 
 
2.2.5.3 Hypochlorous acid 
Hypochlorous acid (HOCl) was prepared by diluting sodium hypochlorite in sterile water. 
The concentration of hypochlorite ions was estimated by optical density at 292nm of pH 12.0 
solutions using molar absorptivity with a 350M/cm extinction coefficient (Morris 1966). The 
final pH, when used in experiments, was approximately the same as the pKa for HOCl (7.5), 
and it was therefore assumed that 50% existed as HOCl and 50% existed as OCl
-
 (Palmer et 
al. 2012). 
 
 
2.2.6  Neutrophil culture 
Neutrophils were cultured primarily to determine their ability to release cytokines within an 
18 hour culture period.  However, the cell pellets from the cultures were also retained for 
future gene expression analyses. 
 
Freshly isolated neutrophils in PBS were centrifuged at 500rcf for 6mins prior to re-
suspension at a concentration of 3.125x10
6
/ml in RPMI-1640 (Sigma R8758) supplemented 
with 0.3g/l glutamine, 2.32g/l HEPES, 2g/l sodium bicarbonate, 100µg/ml streptomycin and 
100UI/ml penicillin (1% of 10mg/ml streptomycin, 10,000U/ml penicillin; Sigma P4333) and 
10% heat-inactivated FBS. 400µl of cell suspension (1.25x106 neutrophils) was added to each 
well within a 24-well cell culture plate (NUNC 142465, Thermo, Fisher Scientific UK TKT-
190-010Y). Thereafter, 100µl of stimulant diluted in supplemented RPMI (5µg/ml LPS final 
well volume, F. nucleatum and P. gingivalis at MOI 100:1 and opsonized S. aureus at MOI 
300:1) or additional supplemented RPMI was added to each well and the cells incubated for 
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18h at 37
o
C and 5% CO2. Bacterial MOI’s were chosen in relation to previous studies 
investigating neutrophil responses using a similar culture technique (Hatanaka et al. 2006) 
including that of the enhanced chemiluminescent assay to measure neutrophil reactive oxygen 
species release (section 2.2.8.2; Matthews et al. 2007) . Furthermore, an MOI of 100:1 is the 
same as used to study the effects of periodontal bacteria on epithelial cell function and 
comparable to estimates of the maximum number of bacteria associated with epithelial cells 
within periodontal pockets (Dierickx et al. 2002; Milward et al. 2013). 
 
After culture, the neutrophil cell suspensions were carefully collected individually using a 
sterile plastic Pasteur pipette, a sample of which was used to determine post-culture 
neutrophil viability by trypan blue dye exclusion (section 2.2.3.6). Individual cell suspensions 
were then centrifuged in a sterile microtube at 1,800rcf for 10 minutes (Spectra merlin) and 
the supernatant carefully removed, taking care not to disturb the cell pellet, and transferred to 
a separate labeled sterile microtube and initially stored at -80
o
C in 2ml aliquots. 
 
2.2.7  Enzyme-linked immunosorbent assays 
Enzyme-linked immunosorbent assays (ELISAs) were used to assay supernatants from 
cultured neutrophils for the presence of IL-6, IL-8, IL-1β and TNF-α. Commercial ELISA kits 
(R&D Systems, Abingdon, UK) were used for all assays which were performed according to 
the kit manufacturer’s instructions. Preliminary ELISA experiments were performed to 
determine sample dilution and standard ranges within the quoted assay sensitivities. All 
reagents and samples were allowed to equilibrate to room temperature before use, and all 
standards, samples and controls were assayed in duplicate. 
 
2.2.7.1 General ELISA reagents & procedures 
The following reagents and procedures were used for the ELISA assays as stated. 
 
a. Wash buffer and well washing 
ELISA wash buffer was prepared by diluting 20ml wash buffer concentrate (895003; R&D 
Systems) into 480ml distilled water. Although not clear in the kit instructions, R&D Systems 
confirmed that the wash buffer was the same for all four ELISA kits employed. During 
washing stages, each well was aspirated and washed with 400µl wash buffer three times for a 
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total of four washes using a plate autowasher (BioTek ELx50). After the last wash, the plate 
was inverted and blotted against clean paper towels in order to remove any excess wash 
buffer. 
 
b. Assay diluents 
Assay diluents (buffered protein base; R&D Systems) were added to the IL-6 (895117; 
100µl), IL-8 (895117; 100µl) and TNFα (895041; 50µl) ELISA plates immediately prior to 
addition of the standards and samples.  
 
c. Conjugate antibodies 
Following incubation of the standards and samples, and well washing (section 2.2.7.1a), 
200µl of polyclonal antibody conjugated to horseradish peroxidase against IL-6 (890046; 
R&D Systems), IL-1β (890040; R&D Systems), TNF-α (892539; R&D Systems) or 
alternatively 100µl IL-8 conjugate (890465; R&D Systems) was added per well prior to 
covering with a new adhesive strip and incubation for 2h for IL-6, or alternatively 1h for IL-8, 
IL-1β and TNF-α.  
 
d. Substrate and stop solutions 
Colour reagents A (stabilized hydrogen peroxide; 895000; R&D Systems) and B (stabilized 
chromogen; tetramethylbenzidine; 895001; R&D Systems) were mixed together in equal 
volumes within 15mins of use and protected from light. At the end of the ELISA procedure, 
200µl of the substrate mixture was added to each well. Following incubation (20mins for IL-
6, IL-1β and TNF-α and 30mins for IL-8) the reaction was stopped by addition of stop 
solution (2N sulphuric acid; 895032; R&D Systems).  At this point the colour of the solutions 
in the wells changed from blue to yellow.  If the color of the solution in the wells was green 
or the colour change was not uniform then the microplate was gently tapped in order to ensure 
thorough mixing. 
 
e. Determination of optical density 
The optical density (450nm and 570nm) of each well was determined in duplicate as soon as 
possible following addition of the ELISA stop solution (section 2.2.7.1d) using a microplate 
reader (BioTek ELx800) set to 450nm. Additional readings were collected at 570nm which 
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were later subtracted from the readings at 450nm in order to correct for optical imperfections 
in the plate (ELISA product information sheet, R&D Systems). 
 
f. Calculation of ELISA cytokine sample concentrations 
The mean of duplicate readings (OD450nm minus OD570nm) for each standard and sample were 
calculated, and the mean zero standard (blank) optical density subtracted. Individual standard 
curves were then plotted using the mean absorbance for each standard on the x-axis against 
the concentration on the y-axis and a 3
rd
 order polynomial regression trend line added through 
the points on the graph using Microsoft Excel (Microsoft, Washington, USA; Figure 2.4). The 
sample concentrations were calculated from the equation describing the 3
rd
 order polynomial 
regression trend line and then multiplied by the individual dilution factors. Where sample 
ODs were outside the pre-determined standard ranges, repeat analyses were performed at an 
adjusted sample dilution. Outliers were calculated as those >1.5x interquartile range 
(1.5xIQR; Tukey 1977), and tabulated where present.  
 
g. ELISA sensitivities and minimal detectable doses 
Sample recovery and minimal detectable doses were obtained from the respective product 
information sheets supplied from R&D Systems for each of the cytokines investigated, 
namely IL-6 (98%; <0.70pg/ml), IL-8 (98%; ~3.5(1.5-7.5)pg/ml), IL-1β (97%; <1pg/ml) and 
TNF-α (98%; ~1.6(0.5-5.5)pg/ml).  
 
2.2.7.2 Basic ELISA protocol 
Quantikine ELISA kits (R&D Systems, Abingdon, UK) were used for the quantitative 
determination of human IL-6 (S6050; LOT no. 310797), IL-8 (S8000C; LOT no. 309261), IL-
1β (SLB50; LOT no. 311937) and TNF-α (STA00C; LOT no. 310802) within the culture 
supernatants. 
 
Individual sample dilutions and standard ranges were pre-determined using additional 
samples prior to analysis of the main study samples as outlined in Table 2.3, with standards 
prepared by serial dilution in the respective calibrator diluent for IL-6 (RD5T; 895175), IL-8 
(RD5P; 895151), IL-1β (RD5-5; 895485) and TNF-α (RD6-35; 895360).  
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IL-6, IL-8, IL-1β and TNF-α ELISAs were performed according to the relevant product 
instructions as summarized in Table 2.4.  
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Figure 2.4. Typical standard curves for IL-6 (A), IL-8 (B), IL-1β (C) and TNF-α (D). 
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Cytokine 
Sample 
dilution 
Standard ranges (pg/ml) 
IL-6 1:3 0 3.12 6.25 12.5 25 50 100 300 
IL-8 1:40 0 10 20 40 80 160 640 2,000 
IL-1β Neat 0 1 2 3.9 15.6 31.2 62.5 125 
TNF-α Neat 0 3.9 7.8 15.6 31.2 62.5 125 250 
 
Table 2.3. Sample dilutions and standard ranges used in the IL-6, IL-8, IL-1β and TNF-α 
ELISAs (R&D Systems, Abingdon, UK).  
 
 
 Cytokine 
Reagent IL-6 IL-8 IL-1β TNF-α 
Assay diluent 100µl 100µl None 50µl 
Standard/sample 100µl 50µl 200µl 200µl 
Incubation at room temperature 2h 2h 2h 2h 
Plate washing (section 2.2.7.1a) 
Conjugate 200µl 100µl 200µl 200µl 
Incubation at room temperature 2h 1h 1h 1h 
Plate washing (section 2.2.7.1a) 
200µl substrate solution (section 2.2.7.1d) 
Incubation at room temperature 
(protected from light) 
20mins 30mins 20mins 20mins 
50µl stop solution (section 2.2.7.1d) 
 
Table 2.4. Overview of IL-6, IL-8, IL-1β and TNF-α ELISA procedures according to the 
individual kit instructions (R&D Systems, Abingdon, UK).  
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2.2.8  Chemiluminescence methods for detection of neutrophil derived ROS 
There are different techniques that may be used to measure cellular release of ROS, largely 
involving photometry, fluorometry and luminometry (reviewed by Dahlgren & Karlsson 
1999). These include peroxidase-dependent (luminol and isoluminol) and lucigenin-amplified 
chemiluminescence, advantages of which include high sensitivity and the ability to follow the 
kinetics of the response. In addition, luminol, isoluminol and lucigenin-enhanced 
chemiluminescence techniques are well established within our laboratory, with data directly 
comparable to published values (Matthews et al. 2007, 2011, 2012, Wright et al. 2008, 2011, 
Dias et al. 2011, Palmer et al. 2012, Chapple et al. 2013, Ling et al. 2014).  
 
Chemiluminescent substrates are excited by oxygen radicals and emit light when returning to 
the ground state (Allen & Loose 1976). Luminol and isoluminol amplified 
chemiluminescence requires the presence of a peroxidase, such as myeloperoxidase (MPO) 
originating from azurophilic neutrophil granules. Luminol is able to cross the cell membrane 
predominantly detecting the intracellular MPO-catalyzed formation of hypochlorous acid 
derived from hydrogen peroxide (Dahlgren et al. 1983, Lundqvist et al. 1994). Isoluminol 
differs from luminol in only one respect, namely the position of the amino group in the 
phthalate ring of the molecule.   This difference makes it more hydrophilic and membrane-
impermeable, whilst not affecting the light generating reaction (Dahlgren & Karlsson 1999). 
Thus isoluminol measures extracellular reactive oxygen species in the presence of peroxidase, 
if present. In practice, in the laboratory, horse radish peroxidase (HRP) is added to the assay 
mixture in order to compensate for a relative lack of secreted neutrophil extracellular MPO 
(Lundqvist 1995, 1996).  The isoluminol assay therefore predominantly detects extracellular 
HRP-catalyzed formation of hypochlorous acid (HOCl) derived from extracellular hydrogen 
peroxide (H2O2). In contrast, lucigenin is a larger molecule (511Da) than luminol or 
isoluminol (177Da) and amplifies the chemiluminescent response by an MPO-independent 
mechanism directly related to the presence of superoxide (O2
-
; Williams et al. 1981, 
Hasegawa 1997). Lucigenin is also impermeable to cells and therefore measures specifically 
extracellular O2
-
 release (Dahlgren et al. 1985).  
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2.2.8.1 Buffers, chemiluminescent reagents and multiwell plates/strips 
All reagents for the enhanced chemiluminescence assays were added to the multiwell plates 
following plate washing and immediately prior to the addition of cells and subsequent plate-
reading. All reagents were equilibrated to room temperature prior to use, with all 
chemiluminescent substrate tubes and multiwell plates covered with tin foil and out of natural 
and artificial light where possible in order to prevent reagent degradation as stated in the 
relevant product information sheets.  
 
a. Blocking buffer 
10g bovine serum albumin (BSA; A4503 Sigma) was dissolved in 1L PBS to give 1% BSA in 
PBS. The solution was aliquoted into working volumes of ~20ml and stored at -20
o
C for a 
maximum of four weeks. 
 
b. Glucose-supplemented PBS 
Previous studies have demonstrated that both glucose and cations are required for optimal 
superoxide production by neutrophils (Tan et al. 1998). Whilst glucose alone can transiently 
activate neutrophils, its presence at 1mM has been shown to have no effect on neutrophil 
metabolism and oxidant release (Kummer et al. 2007). 
 
Glucose-supplemented PBS (GPBS) was produced by adding 1.8g glucose (1mM), 0.15g 
CaCl2 (1.5mM; 10070 BDH) and 1.5ml MgCl2 (1M; 22093 BDH) to 1L of PBS. Each reagent 
was added and mixed completely prior to the addition of the next reagent in order to ensure 
thorough dissolution of all added reagents.  Supplemented PBS was stored at 4
o
C for a 
maximum of 4 weeks. 
 
c. Luminol & isoluminol 
30mM stock solutions of luminol (3-Aminophthalhydrazide, 5-Amino-2,3-dihydro-1,4-
phthalazinedione; A8511 Sigma) and isoluminol (6-Amino-2,3-dihydro-1,4-phthalazinedione; 
A8264 Sigma) were prepared by dissolving 0.5g luminol/isoluminol in 94.05ml 0.1M NaOH.  
These stock solutions were tin foil-wrapped and stored at 4
o
C for a maximum of one week. 
The 3mM working solutions were prepared by diluting 1ml stock luminol or isoluminol with 
9ml PBS, pH checked and adjusted where necessary to pH 7.3. The final well concentrations 
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for use in the ROS assays were 0.45mmol/l for luminol and 0.9mmol/l for isoluminol 
respectively (Bergstrom & Asman 1993, Matthews et al. 2007). 
 
d. Horseradish peroxidase 
A 1,000U/ml stock solution of horseradish peroxidase (Sigma P8415) in PBS was prepared 
and stored at -20
o
C. The working solution (100U/ml) was prepared by diluting the stock 1:10 
with PBS, with 15µl added to a 200µl final well volume resulting in 1.5U/well in the ROS 
assays. 
 
e. Lucigenin 
A 1mg/ml stock solution of lucigenin (N.N’-Dimethyl-9,9’biacridium dinitrate; Sigma 
M8010) in PBS was prepared and stored at 4
o
C for a maximum of 1 week. A 0.33mg/ml 
working solution was prepared by diluting the stock 1:3 with PBS, with 30µl added to the 
200µl ROS assay wells resulting in a 0.05mg/ml final well concentration (Blair et al. 1988).  
 
f. Multiwell plates/strips 
96-well white plates (Microlite2; 7567 Thermo Scientific, Dynex) were used for all enhanced 
chemiluminescence assays. Plates were blocked (PBS BSA 1%, overnight at 4
o
C) and washed 
with PBS using an automated plate washer (BioTek ELx50) immediately prior to addition of 
reagents and cells.  
 
2.2.8.2 Enhanced chemiluminescence assay 
30µl GPBS was added to pre-blocked white 96-well plates (2.2.8.1f). To detect predominantly 
intracellular hypochlorous acid (HOCl) generation, 30µl luminol (3mmol/l; pH 7.3; section 
2.2.8.1c) was added. Alternatively, either 60µl isoluminol (3mmol/l; pH 7.3; section 2.2.8.1c) 
and 1.5U horseradish peroxidase diluted in PBS (HRP; Sigma P8415; 15µl; section 2.2.8.1d) 
were added to detect predominantly extracellular HOCl, or, to specifically detect extracellular 
superoxide release, 30µl lucigenin (0.33mg/ml; section 2.2.8.1e) was added. Following the 
addition of reagents, 100µl of neutrophil suspension (1x10
6
 cells/ml in GPBS; 1x10
5
 cells) 
was added and the plate immediately transferred to the plate reader and light output recorded 
for 1s per well in relative light units (Berthold microplate luminometer LB96v Berthold 
Technologies UK Ltd) at 37
o
C. Baseline light output was recorded for 30mins before addition 
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of stimulating agent or vehicle control (25µl), giving a total volume of 200µl per well.  Light 
output was then recorded for a further 120 minutes (Figure 2.5). 
 
 
Figure 2.5. Schematic representation of the neutrophil respiratory burst using 
enhanced chemiluminescent techniques. Please note baseline readings prior to the 
addition of a stimulus after 30mins resulting in increased light output representative of the 
stimulated respiratory burst.  
 
All analyses were controlled within the same plate, since day-to-day variation in luminol 
chemiluminescence is thought to be 17.4+8.8% (Bergstrom & Asman 1993). All samples 
were analysed in quadruplicate, with paired patient and control cells isolated and analysed at 
the same time. Peak height was used for assessment of chemiluminescence kinetics, as this is 
considered a reliable parameter (Allen 1986) and corresponds with the area under the curve 
(Allen 1986, Hasegawa 1997). 
 
2.2.9  Determination of neutrophil extracellular trap (NET) production 
Given that DNA is a major structural component of NETs (Brinkmann et al 2004), the 
fluorescent DNA stain Sytox Green (Invitrogen S7020) was used to visualize and quantify 
NET release from peripheral blood neutrophils (Palmer et al. 2012).  
 
2.2.9.1 NET visualization using Sytox Green 
Neutrophils (1x10
5
; suspended in 300µl RPMI) were seeded onto 1% PBS BSA (overnight, 
4
o
C; 2.2.8.1a) coated 24-well plates (Microlite2; 7567 Thermo Scientific, Dynex) and allowed 
Addition 
of 
stimulus 
Stimulated 
respiratory 
burst 
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to settle for 30 minutes in a 5% CO2 atmosphere at 37
o
C. The neutrophils were then 
stimulated with 100µl PMA (25nM final concentration) or HOCl (0.75mM final 
concentration) for 3h at 37
o
C, 5% CO2. Following incubation, 25µl of 10µM Sytox Green 
(1:500; Invitrogen S7020; 1µM final concentration) was added. NETs were subsequently 
visualized at room temperature using a fluorescent microscope (Nikon Eclipse TE300, 
Kingston upon Thames, UK) with fluorescent filter excitation 450-490nm and emission 
520nm (BrightLine® GFP-3035B, Semrock) at x20 magnification. Images were obtained 
using a digital camera (Nikon D5000). 
 
2.2.9.2 Fluorometric assay 
Fluorometric assays of NET release were performed using black 96-well microplates (3915 
Corning) that had been pre-blocked with 200µl syringe-filtered 1% PBS BSA overnight at 
4
o
C. 75µl media (RPMI Sigma R7509 without phenol red, supplemented with 0.5% L-
glutamine), were added per well along with 1x10
5
 neutrophils in 100µl RPMI (1x10
6
/ml). 
After a 30 minute baseline incubation period (37
o
C, 5% CO2), selected wells were stimulated 
with 25µl of PMA (Sigma P8139; final well concentration 25nM; Brinkmann et al 2004) or 
HOCl (final well concentration 0.75mM; Palmer et al. 2012) and incubated for 3h at 37
o
C, 
5% CO2. Following incubation, 15µl of 14.3U/ml micrococcal nuclease (MNase; LS004797; 
Worthington Biochemical Corporation LS004797; final well concentration 1U/ml) was added 
per well and incubated at room temperature for 10 minutes prior to plate centrifugation 
(Hettich Universal 320R, 10mins at 1,800rcf) in order to pellet the cells and debris.  
Following centrifugation, 150µl of the supernatant was transferred to a separate sterile black 
96-well plate (3915 Corning, Appleton Woods), taking care not to disturb the cell pellet. 
Extracellular NET-DNA, free within the supernatant, was quantified fluorometrically by 
adding 15µl of 10µM Sytox Green (Invitrogen S7020; final well concentration 0.9mM). The 
fluorescence from each well was recorded ten times at 37
o
C in arbitrary fluorescence units 
(AFU) using a fluorometer (Twinkle LB970, Berthold Technologies, Harpenden, UK) with an 
excitation wavelength of 485nm and an emission wavelength of 525nm. 
   
2.2.10  Determination of neutrophil directional chemotaxis (chemotactic accuracy) 
The majority of studies investigating neutrophil chemotaxis measure end points of cell 
movement using trans-well methods such as Boyden chambers. These methods essentially 
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gain indirect quantitative data by counting cells that have migrated into the chemoattractant 
well within a fixed time, and whilst these methods are useful they effectively only measure 
unidirectional movement of cells, more representative of chemokinesis, which is the random 
migration of cells observed in a homogenous solution of an extracellular signal (Wells 2000). 
In contrast, direct visualization chambers allow individual cell migration to be observed using 
time-lapse microscopy more representative of chemotaxis. A novel direct visualization 
chemotaxis (“Insall”) chamber has recently been developed by colleagues at the University of 
Glasgow (Muinonen-Martin et al. 2010) and has subsequently been used to measure 
neutrophil chemotaxis in patients diagnosed with chronic obstructive pulmonary disease 
(COPD; Sapey et al. 2011).  Similar experiments have not yet been performed with regards to 
neutrophil chemotaxis in chronic periodontitis patients. 
 
2.2.10.1 Directional chemotaxis assay 
In order to inhibit non-specific adhesion, dry, acid-washed coverslips (22mm
2
, #1.5, 0.16-
0.18mm; 0.2M HCl, 15 min followed by distilled water; 15 min) were coated in 400µl 7.5% 
serum albumin fraction whilst placed on filter paper.  Excess serum albumin solution was 
removed and 400µl of a 2x10
6
/ml neutrophil cell suspension in RPMI supplemented with 1% 
BSA (Sigma A4812) were then placed on the coverslip and incubated for 30 minutes at room 
temperature. At the end of the incubation period, the Insall chemotaxis chamber (Muinonen-
Martin et al. 2010; Figure 2.6) was washed three times with 400µl RPMI and a droplet of 
RPMI immediately placed on the chamber surface. The coverslip was then gently inverted 
and carefully lowered onto the chemotaxis chamber/RPMI droplet, resting one edge of the 
coverslip before gently lowering to ensure the central chamber remained bubble free and that 
the pipette loading bays remained exposed. Excess RPMI surrounding the coverslip and 
within the chemoattractant well was then carefully removed using filter paper and taking care 
not to displace the cover slip. 80µl IL-8 (10nM; R&D Systems, Abingdon, Oxfordshire, UK), 
formyl-methionyl-leucyl-phenylalanine (fMLP; 100nM; Sigma-Aldrich, Dorset, UK) or 
RPMI control was then injected into the chemoattractant well using a microloading tip. 
Chemoattractant concentrations were determined in agreement with pilot data collected whilst 
validating the experimental aspects of this assay within our laboratory and in accordance with 
the initial publication outlining this technique with patients diagnosed with chronic 
obstructive pulmonary disease (Sapey et al. 2011). The chemotaxis chamber was then viewed 
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using a Zeiss Primovert microscope (Carl Zeiss Ltd, Herts, UK) at x40 magnification, and 
images captured using a Q Imaging Retiga 2000R camera. All chemotaxis experiments were 
performed within a measured temperature range of 18.2-23.2
o
C in an air-conditioned 
laboratory.  
    
Figure 2.6. Directional chemotaxis (Insall) chamber (Muinonen-Martin et al. 2010). 
Please note the positions of the wells in relation to the chamber along with the position of the 
micropipette tip with which to introduce the chemoattractant (A). A detailed view of the wells 
displaying the outline of the inverted coverslip in relation to the chemoattractant wells, along 
with the viewing area highlighted in red (B).  
 
2.2.10.2 Time-lapse videomicroscopy image analysis 
Images were generated every 30 seconds for 20 minutes resulting in 40 image stacks per 
experiment. Images were processed using Q proimaging software (Q Imaging Canada). 
Fifteen cells were chosen at random as those considered representative of the whole image 
area from the first image frame (Sapey et al. 2011). Chosen cells were subsequently tracked 
through the 40 image stacks using java software Image J 1.45SR software (Wayne Rasband; 
National Institutes of Health, Bethesda, Maryland, USA) with a manual tracking plug-in 
(MtrackJ) to determine XY coordinates of individual cells. The numerical data generated was 
then exported into Microsoft Excel (Microsoft, Washington, USA) prior to determination of 
chemotactic index, cell velocity and speed using pre-determined criteria and equations 
(Section 2.2.10.3; Sapey et al. 2011) and spider diagrams. The circular statistics (CircStat) 
toolbox from MATLAB (MathWorks Inc, Massachusetts, USA) was used to produce the 
angular histograms (rose plots) and resultant vector plots. The CircStat toolbox provided 
statistics for directional data including calculation of the mean resultant vector length using 
pre-determined equations, the length and orientation of which indicates the direction and 
magnitude of the mean cell migration (Figure 2.7; Berens 2009). The original spider diagram, 
A B 
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angular histogram and rose plots obtained using this novel technique are shown as an example 
(Figure 2.8; Muinonen-Martin et al. 2010).  
 
 
 
Figure 2.7. Example illustrations of the calculation of mean resultant vector lengths 
(Berens 2009). Three equally separated migratory cells (A) yield a resultant vector length of 
zero since the points are uniformly spaced around the circle. Three migratory cells at 120, 
180 and 240o (B) will result in a mean resultant vector length of 2/3 (0.67) towards 180o. 
Three migratory cells at 150, 180 and 210o (C) will yield a mean resultant vector length of 5/6 
(0.83) towards 180o.  
 
 
 
Figure 2.8. Example spider diagrams (A), angular histograms (rose plots) (B) and 
resultant vector plots (C) representative of the migration of 43 MV3 human melanoma 
cells over 12 hours as published to initially describe the improved chamber for direct 
visualisation of chemotaxis (Muinonen-Martin et al. 2010). In these experiments the 
chemoattractant (foetal bovine serum) was to the right of the images. The spider diagram (A) 
represents individual cell migration calibrated to the zero starting point with the angular 
histogram (B) representing cell migration predominantly towards the source of the 
chemoattractant. The small circles on the circumference of the resultant vector plot (C) 
representative of the end-points of each individual cell movement, with the central red line 
displaying the mean resultant vector length highlighting the direction and magnitude of the 
mean cell migration bounded by the 95% confidence intervals. 
 
 
 
A B C 
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2.2.10.3 Calculation of chemotactic index, speed and velocity of neutrophil migration 
Chemotactic index, speed and velocity of neutrophil migration were calculated as previously reported 
(Sapey et al. 2011). Chemotactic index (a measure of the accuracy of neutrophil directional 
orientation) was calculated from the individual frame-by-frame cosines of the angles between the 
cell’s migratory direction and the orientation of the chemoattractant gradient. Neutrophil speed of 
movement was calculated by measuring the distance travelled between frames and representative of 
random movement in any direction (chemokinesis). Velocity was also calculated as neutrophil speed 
of migration in a consistent direction towards the chemoattractant. 
 
2.2.11  C-reactive protein 
C-reactive protein (CRP) from human plasma (2mg/ml) was obtained commercially (Sigma 
C4063) and supplied as a solution in 20mM Tris, pH 7.8-8.2, containing 280mM sodium 
chloride, 5mM calcium chloride and 0.1% sodium azide as a preservative. Prior to examining 
the effects of CRP on neutrophil ROS production, removal of sodium azide was required as 
this is known to inhibit MPO, HRP and catalase activity (Ortiz de Montellano et al. 1988, 
Van Uffelen et al. 1998) that are directly involved in both neutrophil ROS generation as well 
as the ex vivo ROS assay methodology.  
 
2.2.11.1Determination of the antioxidant capacity of CRP 
The luminol-based enhanced chemiluminescence antioxidant assay measures the antioxidant 
capacity of biological fluids (Brock et al. 2004, Chapple et al. 2007). Reactive oxygen species 
are generated that subsequently oxidise luminol and emitting a flash of light. By incorporating 
an enhancer species (p-iodophenol) a prolonged glow of light results from radical re-cycling, 
which is inhibited by antioxidant scavengers when added to the reaction (Chapple et al. 
1997). HRP was used to initiate the reaction and the resulting light was measured using a tube 
luminometer (BioOrbit 1250 luminometer, Labtech International, UK) and a PICO data 
logger 200/12 analogue digital converter and accompanying software (Pico Technology Ltd). 
The antioxidant assay was calibrated on the day of sample analysis using a water-soluble 
vitamin-E analogue (6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid; Trolox). 
Standard curves were constructed using a series of Trolox standards (20, 40, 60 and 80µM in 
PBS containing 50mg/L BSA) run in triplicate immediately before and upon completion of 
the assays of CRP samples. 100µl of signal reagent (from a pre-equilibrated stock solution; 
Amerlite
TM
, Johnson & Johnson Clinical Diagnostic Ltd; Amersham UK) were added to a 
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clean glass Rohern tube, along with 1ml running buffer (PBS containing 50mg/L BSA) and 
the solutions mixed 3 times using manual pipette aspiration. The HRP working solution 
(1:200 in PBS-BSA; The Binding Site AP311) was subsequently mixed by gently flicking the 
base of the tube 5 times, manually-aspirated a further 5 times to ensure a good re-mix, and 3-
8µl of this working solution added to the signal/buffer mix and further aspirated 5 times, and 
vortex-mixed briefly (1-2s only). The tube and contents were then loaded immediately into 
the luminometer and light output measured in real-time until equilibration between 7-9.9V 
was achieved and began to decrease (typically ~3 minutes). At this stage the Pico software 
was paused, the tube removed from the luminometer and 20µl of either the Trolox standard, 
CRP sample (0.2 & 4µg/ml final concentrations) or alternatively azide-free Tris buffer were 
added. The solutions were mixed thoroughly once again by manual pipette aspiration 5-times 
and flicking the base of the tube 5-times, and the tube returned immediately to the 
luminometer and light output recording resumed. A typical recovery curve for the inhibition 
and restoration of light output by the Trolox standards is shown in Figure 2.9. The recovery 
time to 10% of the chemiluminescent signal (T10%) was plotted for each Trolox standard and 
linearity determined as shown in Figure 2.10.  
 
The ability of azide-free CRP (0.2 & 4µg/ml final concentrations) to reduce luminol 
chemiluminescence generated by horse radish peroxidase/H2O2 was subsequently determined 
and compared with vehicle control (azide-free Tris buffer). The data was analysed as the 
percentage reduction in light output as follows. 
 
(Light output after addition CRP – light output after addition of buffer) x 100 
Light output prior to addition 
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Figure 2.9. Typical recovery curve for four Trolox standards (20, 40, 60 and 80µM/L) in 
chemiluminescence assay for antioxidant capacity. Recovery time to 10% 
chemiluminescent signal equates to T10%. 
 
 
Figure 2.10. Typical standard curve  for Trolox as the recovery time to 10% 
chemiluminescent signal (T10% + standard deviation). Data representative of triplicate 
readings at 3 time points throughout the day (n=9). 
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2.2.11.2 Removal of sodium azide from CRP 
In order to remove the sodium azide preservative from the CRP, 0.5ml CRP was diluted 1:1 
with azide-free Tris buffer (total volume = 1ml; final concentration = 1mg/ml) and dialysed 
against 1L of sodium azide-free buffer (20mM Tris, pH 7.8, containing 280mM sodium 
chloride, 5mM calcium chloride; TBS), as was a corresponding blank control (Tris buffer 
containing 1mg/ml sodium azide diluted 1:1 in buffer minus sodium azide). Dialysis was 
performed using Spectra/Por
®
Float-A-Lyser
®
 G2 (1ml, MWCO 3.5-5kDa, Sigma Z726060) 
over 3 days with three 1L buffer changes per day (nine 1L buffer changes in total) whilst 
stirring at 4
o
C.  
 
Dialysis was performed aseptically using sterile technique in order to minimize the risk of 
contamination due to the removal of the sample preservative. In addition, any contaminating 
bacteria and most enzymes within the dialysis buffer that could affect CRP would be larger 
than 5kDa and be unable to pass through the dialysis membrane.  In addition, having a large 
buffer dialysis volume also lowered the concentration that any contaminating products could 
attain between buffer changes. Both dialysed CRP and dialysed buffer blank were filter-
sterilised post-dialysis (4mm diam. regenerated cellulose membrane, pore size 0.2µm; Sigma 
CLS431212) and stored at 2-8
o
C for a maximum of 2 weeks prior to use. 
 
This dialysis procedure was thought to be rigorous enough to lower the azide concentration 
within the CRP sample to levels that would be effectively zero.  With 9 changes of buffer (1L 
volumes) over three days, assuming that dialysis was only 30% effective at each buffer 
change, the calculated residual concentration of sodium azide within the CRP sample would 
be 7.621x10
-20
 µg/ml. 
 
CRP concentrations were determined using spectrophotometry pre- and post-dialysis. 
Concentrations were determined from optical density measurements at 280nm (Jenway 6300) 
using the extinction coefficient for CRP (E
0.1%
280 = 1.75; Nelson 1991, Clapp 2005). 
 
2.2.11.3  Liquid chromatography-tandem mass spectrometry 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed in order to 
detect the presence of protein contaminants within the commercial CRP sample. Apart from 
80 
 
initial preparation of azide-free CRP, all procedures were performed by Dr Andy Creese at the 
School of Biosciences, University of Birmingham.  Briefly, after reduction and alkylation of 
disulphide bonds using dithiothreitol and iodoacetamide, neat CRP samples were digested 
overnight with trypsin Gold (500ng, Promega, USA) at 37
o
C and the resultant peptides 
prepared for analysis as previously described (Grant et al. 2010). Peptides were loaded onto a 
150mm Acclaim PepMap100 C18 column (LC Packings, Sunnyvale, CA) in mobile phase A 
(0.1% formic acid. JT Baker, Holland, Sigma Aldrich) and separated over a linear gradient 
from 3.2% to 44% mobile phase B (acetonitrile + 0.1% formic acid. JT Baker, Sigma) with a 
flow rate of 350nl/min. The column was then washed with 90% mobile phase B before re-
equilibrating at 3.2% mobile phase B. The column oven was heated to 35
o
C. The LC system 
was coupled to an Advion Triversa Nanomate (Advion, Ithaca, NY) which infused the 
peptides with a spray voltage of 1.7kV. 
 
The mass spectrometer performed a full FT-MS scan (m/z 380-1,600) and subsequent 
collision induced dissociation (CID) MS/MS scans of the five most abundant ions above a 
threshold of 1,000. Survey scans were acquired in the Orbitrap with a resolution of 60,000 at 
m/z 400. Precursor ions were subjected to CID in the linear ion trap. The width of the 
precursor isolation window was 2 m/z and only multiply charged precursor ions were 
subjected to CID. CID was performed with helium gas at a normalized collision energy of 
35% (target 5x10
4
, maximum fill time 100ms). CID activation was performed for 10ms. A 
dynamic exclusion repeat count was set to 1 with a duration of 30s. Data acquisition was 
controlled by Xcalibur 2.1 (Thermo Fisher Scientific). Purity of CRP was assessed by 
comparing the intensity of the peptide precursor ions identified from CRP to the peptides 
which were identified from contaminants. 
 
2.2.11.4 Analytical ultracentrifugation 
Analytical ultracentrifugation was performed in order to assess the molecular structure of 
commercial CRP both pre- and post-dialysis, along with confirming aggregation of IgG as 
indicated. Apart from preparation of the protein samples, all procedures were performed by 
Professor Tim Dafforn at the School of Biosciences, University of Birmingham. A Beckman 
XL-I analytical ultracentrifuge using an 8-piece An-60 Ti cell rotor in a Beckman-Optima 
XL-I (Beckman Coulter, ProteomeLab XL-1, Protein Characterisation System) was used for 
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the analytical ultracentrifugation (AUC) analyses. Protein samples (CRP, IgG and heat 
aggregated IgG; 450µl) were loaded into 2-sector cells for sedimentation velocity experiments 
and centrifuged at 32,256rcf for 8hrs at 20°C. The absorbance of the sample was measured at 
a wavelength of 220nm throughout the cell. A total of 100 measurements were taken 
throughout each 8hr run. Sedimentation velocity data was analysed using direct boundary 
Lamm fits from the continuous c(s) distribution model implemented within SEDFIT (version 
11.0) (Schuck 2000). SEDFIT resulted in size- distribution analyses c(s) that assume that all 
macromolecular species have the same frictional ratio, f/fo. 
 
2.2.11.5 Direct effect of Tris buffer on chemiluminescence 
Assays were performed without neutrophils in pre-blocked (PBS 1% BSA, overnight at 4
o
C) 
white microwells (Microlite2, Dynex, East Grinstead, W.Sussex, UK). After washing the 
plate in PBS, GPBS was added to each well (100μl) followed by luminol (30μl), isoluminol 
(60μl), lucigenin (30µl) or PBS control (30μl). The plate was then placed into the microplate 
reader (Bertold microplate luminometer LB96v) at 37
o
C.
 
Light output was monitored for each 
well before (2s), during and after (10s; 12s in total) automatic injection of freshly prepared 
Tris diluted in distilled water (Sigma 93377, pH 7.8-8.2, 0.25-25mM; 40μl). All analyses 
were performed in quadruplicate and peak light emission in relative light units (RLU) 
determined. 
 
2.2.11.6 Effect of Tris buffer on H2O2-induced chemiluminescence 
Assays were performed without neutrophils in pre-blocked (PBS 1% BSA, overnight at 4
o
C)
 
white microwells (Microlite2, Dynex, East Grinstead, W.Sussex, UK). After washing the 
plate in PBS, GPBS was added to each well (110μl) followed by luminol (30μl), isoluminol 
(60μl) with horseradish peroxidase (HRP, 7.8x10-4U; 10μl, Sigma, Gillingham, Kent, UK) or 
lucigenin (30µl) along with various concentrations of Tris diluted in distilled water Sigma 
93377, pH 7.8-8.2, 0.25-25mM; 20μl). The plate was then placed into the microplate reader 
(Bertold microplate luminometer LB96v) at 37
o
C.
 
Light output was monitored for each well 
before (2s), during and after (10s; 12s in total) automatic injection of freshly prepared H2O2 
solution (30μl, 3%). All analyses were performed in sextuplicate (6 wells for each substrate) 
and peak light emission in relative light units (RLU) determined. 
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2.2.11.7  Effect of CRP and sodium azide on neutrophil viability 
The viability of neutrophils treated with commercial CRP solutions in 20mM Tris, pH 7.8-
8.2, containing 280mM sodium chloride, 5mM calcium chloride and 0.1% sodium azide 
buffer (1-6μg/ml; 37oC) following a 60 minute incubation period was assessed by trypan blue 
dye exclusion along with cell metabolic activity analysed separately using CellTiter-Glo
®
 
Luminescent Cell Viability Assay Kit (Promega, Southhampton, UK) with a microplate 
reader (Bertold microplate luminometer LB96v) (section 2.2.3.6). 
 
2.2.11.8  Neutrophil ROS generation and release in the presence of CRP 
Enhanced chemiluminescence assays were performed as previously described (section 2.2.8). 
In brief, 100µl of neutrophil suspension (1x10
6
 cells/ml in GPBS; 1x10
5
 cells) were placed in 
pre-blocked (PBS BSA 1%, overnight at 4
o
C) white microwells (Microlite 2; Thermo 
Scientific, Dynex) along with GPBS (20µl), luminol (3mmol/l; pH 7.3; 30µl) or lucigenin 
(0.33mg/ml; 30µl) and PBS (15µl), or alternatively isoluminol (3mmol/l; 60µl) with 1.5U 
HRP in PBS (Sigma P8415; 15µl; total volume 75µl). The plate was then carefully and 
immediately transferred to a microplate reader (37
o
C, Berthold microplate luminometer; 
LB96v) and baseline light output was recorded for 1s per well in relative light units (RLU) for 
30mins.  
 
Following the initial 30mins baseline measurements, dialysed CRP (10µl) was added (final 
concentrations: 0, 1, 3 and 10µg/ml in dialysed Tris buffer) and light output recorded in RLU 
for a further 30 minutes. Following the 30 minute incubation with CRP, neutrophils were 
subsequently stimulated with either F. nucleatum (ATCC 10953; MOI 100:1; 25µl: section 
2.2.4.7), opsonized S. aureus (NCTC 6571; MOI 300:1; 25µl; section 2.2.4.8), heat-
aggregated IgG (25µl; 600µg/ml final well concentration; Sigma I4506; section 2.2.5.1) or 
PBS (25µl) and light output monitored for an additional 120 minutes. All analyses were 
performed in triplicate, with peak light emission determined in RLU for the equilibrium phase 
(“unstimulated”, baseline radical generation), after addition of CRP and after stimulation. 
 
2.2.12  Statistical analyses 
Data for all experiments was manipulated in Microsoft Excel, and evaluated using Minitab 
(version 15.1.0.0; Minitab Ltd, Coventry, UK) or GraphPad Instat (version 3.10; GraphPad 
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Software Inc, California, USA). Distributions of all datasets were initially assessed using the 
Kolmogorov-Smirnov test in order to determine Gaussian distributions, along with effective 
pairing determined by calculation of the correlation coefficient. The most appropriate 
statistical test was then applied as outlined (Table 2.5). 
 
 Paired datasets Unpaired datasets 
Single Multiple Single Multiple 
Parametric Paired T test ANOVA with 
post Tukey test 
Unpaired T test ANOVA with 
post Tukey test 
Non-
parametric 
Wilcoxon Friedman with 
post Dunn’s test 
Mann-Whitney Kruskal-Wallis 
with post 
Dunn’s test 
 
Table 2.5. Overview of statistical analyses performed depending on the data 
distribution, pairing and the number of comparisons. 
 
Unpaired statistical testing comparing patients with chronic periodontitis and controls were 
deemed the most appropriate analyses given the limitations of patient/control pairing which 
did not take into consideration certain parameters such as volunteer body mass index (BMI). 
However paired statistical testing using the Wilcoxon rank sum test was required for the 
superoxide release data (Chapter 5). Detection of ROS by chemiluminescence methods can 
show considerable day-to-day variation making the inclusion of a paired, age and gender 
matched control, whose neutrophils are analysed simultaneously with those from the patient, 
important if consistent and comparable results are to be obtained (Yaffe et al. 1999). Data 
derived from such experiments are thus normally analysed using the Wilcoxon (one-tailed) 
test to determine the presence of neutrophil hyper-reactivity (Fredriksson et al. 1998, 2003, 
Matthews et al. 2007, Wright et al. 2008).  
 
In addition, image capture and analyses for the chemotaxis assay were performed as 
previously described (section 2.2.10.2) with chemotactic index, cell velocity and speed 
calculated in Microsoft Excel using pre-determined equations. MATLAB (MathWorks Inc, 
Massachusetts, USA) was used to produce the various chemotaxis plots (Sapey et al. 2011). A 
level of P<0.05 was used for assigning statistical significance for all experiments. 
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CHAPTER 3 
 RESULTS & DISCUSSION 
 
Case-control longitudinal intervention study: 
Clinical measures & plasma hsCRP levels 
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3.1 INTRODUCTION   
Patients diagnosed with chronic periodontitis, together with periodontally and systemically 
healthy control volunteers, were recruited. Baseline clinical measures of periodontal disease 
were measured for patients and healthy control volunteers to confirm the presence and 
absence of disease. Additional collection of clinical measures for the patient volunteers was 
performed post-periodontal treatment to determine treatment effectiveness and to support the 
observed differences in ex vivo neutrophil function.  
 
3.2 VOLUNTEER RECRUITMENT TO LONGITUDINAL CLINICAL STUDY 
Patient volunteers (n=20) for the longitudinal case-control interventional study were recruited 
from those referred to the Periodontal Department of Birmingham Dental Hospital by their 
General Dental Practitioner (section 2.1.1.3). Once a volunteer diagnosed with chronic 
periodontitis was recruited, a corresponding age- and gender-matched periodontally and 
systemically healthy control volunteer was recruited from Staff of Birmingham Dental 
Hospital and School.  
 
Unfortunately patient volunteer no. 13 decided that she no longer wished to undergo 
periodontal treatment during the course of root surface debridement and following collection 
of baseline samples. Therefore, this patient was discontinued from the study and discharged 
back to her General Dental Practitioner for additional treatment and follow-up as appropriate. 
All other volunteers (38 in total; 19 pairs) progressed through the clinical study uneventfully. 
 
3.2.1 Age and gender of recruited clinical study volunteers 
Gender distribution comprised of 12 male and 8 female volunteer pairs. Initially patient and 
control volunteers were matched to within <5yrs, but because of the limited numbers of 
periodontally-healthy controls available this was not possible for 6 of the patient and control 
pairs with the largest difference being 9yrs for volunteer pair no. 19. Overall mean patient 
volunteer age to the nearest year at the time of sampling (46+8yrs; range 37-61yrs) was not 
significantly different to that of the healthy control group (46+8yrs; range 32-62yrs; Mann-
Whitney test P=0.98; Table 3.1).  
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Volunteer 
no. 
Gender 
Age (yrs) 
Patient Control 
1 Male 42 43 
2 Male 45 41 
3 Male 40 44 
4 Female 56 62 
5 Male 42 41 
6 Male 46 47 
7 Female 47 50 
8 Male 39 32 
9 Male 38 38 
10 Female 38 42 
11 Male 59 55 
12 Male 37 45 
13 Female 48 42 
14 Female 61 59 
15 Male 51 58 
16 Female 42 39 
17 Female 37 35 
18 Female 52 52 
19 Male 57 48 
20 Male 48 48 
  Mean 46 46 
  St Dev 8 8 
  Min 37 32 
  Max 61 62 
 
Table 3.1. Age (to the nearest year at time of sampling) and gender of patient and control 
volunteers recruited to the longitudinal interventional study. 
 
 
3.3 CLINICAL MEASURES OF PERIODONTAL DISEASE 
Periodontal probing pocket depths (PPD) and gingival recession were measured and clinical 
attachment loss calculated (section 2.1.1.4e). Periodontal pocketing >4mm was derived from 
the raw PPD data, with >2 non-adjacent sites of pocketing >4mm indicative of the presence of 
periodontal disease in accordance with European Federation of Periodontology guidelines 
(section 2.1.1.3). As part of the detailed periodontal assessment, the percentage of full-mouth 
periodontal sulcus/pocket depths demonstrating bleeding on probing (BOP) was calculated 
(section 2.1.1.4f) and full-mouth gingival (section 2.1.1.4a) and plaque (section 2.1.1.4b) 
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indices performed. Following the collection of clinical measures, all volunteers were re-
appointed for peripheral blood sampling including the preparation of plasma samples for 
high-sensitivity CRP (hsCRP) analyses (sections 2.1.1.5a and 2.2.2).  
 
3.3.1 Clinical attachment loss 
Baseline clinical attachment loss (CAL) for individual patient volunteers was measured. Mean 
CAL and percentage sites with 1-2, 3-4 and >4mm CAL, relating to mild, moderate and 
severe disease accordingly, along with disease classification are shown in Table 3.2 and 
Figure 3.1. The majority of patient volunteers presented with generalised moderate and 
localised severe chronic periodontitis (n=12; 60%), along with generalised mild and localised 
severe (n=3; 15%) and generalised severe (n=5; 25%) chronic periodontitis.  
 
 
 
 
Figure 3.1. Severity and extent of baseline clinical attachment loss for patient 
volunteers (n=20). Histogram shows mean percentage sites CAL+SD.  
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
1-2 3-4 >4
%
 s
it
e
s 
Clinical attachment loss (mm) 
88 
 
Patient 
volunteer 
no. 
Clinical attachment loss 
Classification of chronic periodontitis Mean + 
SD (mm) 
% sites  
1-2mm 
% sites  
3-4mm 
% sites  
>4mm 
1 4.4+3.2 39.1 21.8 39.1 Generalised severe 
2 2.4+1.9 66.7 26.3 7.0 Generalised moderate, localised severe 
3 3.7+2.1 36.5 35.3 28.2 Generalised moderate, localised severe 
4 3.5+1.8 35.9 41.0 23.1 Generalised moderate, localised severe 
5 2.8+1.6 59.0 24.4 16.6 Generalised moderate, localised severe 
6 3.7+2.1 37.0 31.2 31.8 Generalised severe 
7 3.4+2.4 55.6 21.6 22.8 Generalised moderate, localised severe 
8 2.4+0.9 67.9 28.6 3.5 Generalised moderate, localised severe 
9 3.4+1.6 36.9 45.8 16.3 Generalised moderate, localised severe 
10 2.8+1.3 44.4 48.3 7.2 Generalised moderate, localised severe 
11 2.2+1.8 85.7 5.4 8.9 Generalised mild, localised severe 
12 2.9+2.6 66.1 13.3 20.6 Generalised moderate, localised severe 
13 6.0+2.7 5.8 33.3 60.8 Generalised severe 
14 3.3+2.0 46.4 34.5 19.0 Generalised moderate, localised severe 
15 3.9+1.6 20.1 50.3 29.6 Generalised moderate, localised severe 
16 3.2+2.2 55.7 25.9 18.4 Generalised moderate, localised severe 
17 5.9+3.3 25.6 11.9 62.5 Generalised severe 
18 2.2+1.5 78.0 16.7 5.3 Generalised mild, localised severe 
19 4.1+2.5 33.3 33.3 33.3 Generalised severe 
20 1.9+1.4 79.0 15.6 5.4 Generalised mild, localised severe 
Mean 3.4 48.7 28.2 23.0 
  SD 1.1 21.1 12.4 16.8 
 
Table 3.2. Clinical attachment loss and classification of chronic periodontitis for patient 
volunteers at baseline (n=20). 
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3.3.2   Periodontal probing pocket depths 
Probing pocket depths for individual patient volunteers pre- and post-treatment and matched 
healthy controls were measured. Mean PPD and the number of sites >4mm per volunteer is 
shown (Table 3.3). Whilst the raw PPD data conformed to a normal distribution, this was not 
confirmed for the number of sites >4mm. 
 
The mean PPD differed between patient volunteers pre- and post-treatment and healthy 
controls (P<0.0001; Figure 3.2A). As expected, baseline PPD in patients (3.0+0.8mm) was 
significantly greater than periodontally healthy controls (1.5+0.4mm; P<0.001). At the 2-
month post-treatment review, the mean PPD in patients (2.1+0.5mm) was significantly 
reduced from their paired baseline, pre-treatment levels (3.0+0.8mm; P<0.001), although they 
remained significantly greater than those detected in the healthy control volunteers (P<0.01).  
 
Similarly, the number of sites with a PPD >4mm differed between healthy controls and 
patients pre- and post-treatment (P<0.0001; Figure 3.2B). As expected, the baseline median 
number of sites with a PPD >4mm in patients (27; range 5-91) was significantly greater than 
periodontally healthy controls (0; range 0-4; P<0.001). At the 2-month post-treatment review, 
the median number of PPD >4mm in patients (7; range 0-52) was significantly reduced from 
their paired baseline, pre-therapy levels (27; range 5-91; P<0.05) although they remained 
significantly greater than those detected in the healthy control volunteers (P<0.01).   
 
One patient displayed an uncharacteristically large number of PPD >4mm of 91 and 52 sites 
pre- and post-treatment (volunteer no. 17; Table 3.3). This patient subsequently underwent an 
additional course of periodontal treatment with adjunctive antimicrobials. Omission of the 
PPD data for volunteer no. 17 did not alter any of the probing pocket depth statistical 
comparisons. 
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Volunteer 
no. 
Probing pocket depths 
Patient pre-treatment Patient post-treatment Healthy control 
Mean + 
SD 
(mm) 
Range 
(mm) 
No. 
sites 
>4mm 
Mean + 
SD 
(mm) 
Range 
(mm) 
No. 
sites 
>4mm 
Mean + 
SD 
(mm) 
Range 
(mm) 
No. 
sites 
>4mm 
1 3.5+2.8 1-12 45 2.7+1.4 1-9 24 2.1+0.9 1-5 1 
2 2.2+1.5 1-12 7 2.2+0.9 1-7 8 2.1+0.9 1-5 1 
3 3.4+2.0 1-9 36 2.7+1.3 1-7 15 1.8+0.7 1-4 0 
4 3.4+1.7 1-9 33 1.6+0.7 0-4 0 2.0+0.8 1-5 3 
5 2.6+1.5 1-7 22 2.0+0.8 0-5 2 1.2+0.4 1-2 0 
6 3.4+2.1 1-8 45 2.5+1.0 1-7 7 1.5+0.6 1-3 0 
7 2.9+1.9 1-12 28 2.2+1.4 1-10 9 1.7+0.6 1-4 0 
8 2.3+0.9 1-7 5 1.4+0.8 0-5 1 2.2+0.9 1-5 4 
9 3.4+1.6 1-8 29 2.4+1.1 1-6 7 1.3+0.5 1-3 0 
10 2.6+1.2 1-7 10 1.8+0.9 1-4 0 1.4+0.6 1-3 0 
11 2.1+1.8 1-9 14 1.5+1.1 0-9 2 1.1+0.4 1-3 0 
12 2.8+2.4 0-12 35 2.5+2.1 1-10 23 1.1+0.4 1-3 0 
13 5.0+2.6 1-13 54 Treatment discontinued 1.1+0.3 1-2 0 
14 2.9+1.7 0-8 25 1.8+1.2 0-6 5 1.8+0.9 1-5 1 
15 2.8+1.4 1-7 23 2.4+1.5 1-8 16 1.3+0.5 1-3 0 
16 3.2+2.2 1-9 32 2.0+1.3 0-9 9 1.1+0.3 1-3 0 
17 4.8+2.7 1-12 91 3.5+2.2 1-10 52 1.4+0.5 1-3 0 
18 2.1+1.5 0-11 8 1.5+0.9 0-7 1 1.7+0.7 1-4 0 
19 2.8+1.6 1-9 13 2.2+1.3 1-9 8 1.6+0.6 1-3 0 
20 1.5+1.0 1-7 5 1.5+0.8 1-7 1 1.3+0.6 1-4 0 
Mean 3.0 
  
2.1 
  
1.5 
  
SD 0.8 
  
0.5 
  
0.4 
  
Max 
  
91 
  
52 
  
4 
Q3 
  
36 
  
15 
  
1 
Median 
  
27 
  
7 
  
0 
Q1 
  
11 
  
1 
  
0 
Min 
  
5 
  
0 
  
0 
 
Table 3.3. Probing pocket depths for patients (n=20 pre-treatment; n=19 post-
treatment) and periodontally and systemically healthy control volunteers (n=20).  Data 
presented as probing pocket depths (mean + SD & range) and the number of sites >4mm.  
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Figure 3.2. Probing pocket depths (A) and number of sites >4mm (B) in patients and 
matched periodontally and systemically healthy control volunteers (n=19). Histogram 
(A) shows mean PPD+SD, & P-values (Tukey-Kramer multiple comparisons test). Box and 
whisker plot (B) shows median, interquartile range, maximum and minimum values & P-
values (Dunn’s multiple comparisons test). 
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3.3.3 Bleeding on periodontal probing 
Bleeding on probing was recorded and the percentage of sites displaying BOP calculated for 
each individual volunteer during the sampling visits (Table 3.4; Figure 3.3). As expected, the 
baseline median percentage of sites displaying BOP in patients (43; range 16-87) was 
significantly greater than periodontally healthy controls (2; range 0-39; P<0.001) consistent 
with the presence of periodontal inflammation. At the 2-month post-treatment review, the 
median percentage of sites with BOP in patients (14; range 3-35) was significantly reduced 
from their paired baseline pre-therapy levels (43; range 16-87; P<0.001; Figure 3.3). Post-
therapy BOP levels were not significantly different from healthy controls, despite patients 
continuing to have a greater median percentage of sites that displayed BOP (P>0.05).  
 
3.3.4 Gingival indices 
Individual and full-mouth cumulative gingival indices (GI) are shown in Table 3.5. Median 
and cumulative GI differed between pre- and post-treatment patient volunteers and healthy 
controls (P<0.0001). Baseline median and cumulative GI values in patients were significantly 
greater than periodontally healthy controls (P<0.001) as expected and consistent with the 
presence of periodontal inflammation. At the 2-month post-treatment review, the GI values in 
patients were significantly reduced from their paired baseline pre-therapy levels (P<0.01) to 
levels comparable to healthy controls (P>0.05; Figure 3.4).  
 
3.3.5 Plaque indices 
Individual and full-mouth cumulative plaque indices (PI) are shown in Table 3.6. Median and 
cumulative PI differed between patient volunteers pre- and post-treatment and healthy 
controls (P<0.0001). Baseline median and cumulative PI values were significantly greater 
than periodontally healthy controls (P<0.001). At the 2-month post-treatment review, the PI 
values in patients were significantly reduced from the paired baseline pre-therapy levels 
(P<0.001) to levels comparable to healthy controls (P>0.05; Figure 3.5).  
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Volunteer 
no. 
Bleeding on probing (% sites) 
Patient Healthy 
control Pre-treatment Post-treatment 
1 37 23 39 
2 16 14 17 
3 87 33 0 
4 51 8 0 
5 26 5 0 
6 47 12 0 
7 44 11 16 
8 42 18 20 
9 72 15 0 
10 63 13 1 
11 21 10 0 
12 53 22 0 
13 41 Discontinued 0 
14 70 14 20 
15 23 20 2 
16 21 5 0 
17 63 35 9 
18 33 5 16 
19 43 14 17 
20 17 3 8 
Max 87 35 39 
Q3 61 20 17 
Median 43 14 2 
Q1 24 8 0 
Min 16 3 0 
 
Table 3.4. Percentage sites displaying bleeding upon periodontal probing for patients 
(n=20 pre-treatment; n=19 post-treatment) and periodontally and systemically healthy 
control volunteers (n=20). Data presented as percentage sites with bleeding on periodontal 
probing. 
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Figure 3.3. Percentage of sites demonstrating bleeding on periodontal probing in 
patients and matched periodontally and systemically healthy control volunteers 
(n=19). Box and whisker plots showing median, interquartile range, maximum and minimum 
values & P-values (Dunn’s multiple comparisons test). 
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Volunteer 
no. 
Gingival index 
Patient 
Healthy control 
Pre-treatment Post-treatment 
Individual Cumulative Individual Cumulative Individual Cumulative 
1 1 (1-2) 195 1 (0-1) 111 1 (0-1) 136 
2 1 (1-2) 187 1 (0-1) 137 1 (0-1) 141 
3 3 (2-3) 426 1 (1-2) 216 1 (0-1) 103 
4 3 (2-3) 405 1 (1-1) 169 1 (1-2) 190 
5 2 (2-2) 322 1 (0-1) 94 0 (0-1) 77 
6 2 (2-2) 350 1 (0-1) 149 1 (0-1) 136 
7 2 (1-2) 310 1 (1-2) 216 1 (1-1) 185 
8 2 (1-2) 316 1 (1-2) 235 0 (0-1) 87 
9 2 (1-2) 296 1 (1-1) 126 0 (0-1) 43 
10 1 (1-2) 292 1 (0-1) 112 0 (0-0) 26 
11 1 (1-1) 203 1 (0-1) 122 0 (0-1) 36 
12 2 (1-3) 338 1 (0-1) 125 0 (0-0) 23 
13 2 (2-3) 274 Discontinued 0 (0-1) 43 
14 2 (1-4) 338 1 (0-1) 106 1 (0-1) 140 
15 2 (2-2) 358 0 (0-1) 105 1 (0-1) 108 
16 1 (1-2) 274 0 (0-1) 83 0 (0-1) 49 
17 2 (2-2) 390 1 (0-1) 147 0 (0-1) 81 
18 2 (1-2) 266 0 (0-1) 37 1 (0-1) 108 
19 2 (2-2) 269 1 (1-1) 145 1 (1-1) 178 
20 1 (1-2) 250 0 (0-1) 72 1 (1-1) 177 
Max 3 426 1 235 1 190 
Q3 2 347 1 149 1 141 
Median 2 303 1 125 1 106 
Q1 1 267 1 105 0 45 
Min 1 187 0 37 0 23 
Friedman test 
P<0.0001             
P<0.0001             
Dunn's test 
P<0.01             
P<0.001             
NS             
P<0.001             
P<0.001             
NS             
Table 3.5. Gingival indices for patient (n=20 pre-treatment; n=19 post-treatment) and 
periodontally and systemically healthy control volunteers (n=20). Data presented as individual 
median gingival index and interquartile range along with full-mouth cumulative values. P-values 
calculated (n=19) using Friedman test followed by Dunn’s multiple comparisons test (Groups 
compared in table =        ). 
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Figure 3.4. Cumulative gingival index in patients and matched periodontally and 
systemically healthy control volunteers (n=19). Box and whisker plots showing median, 
interquartile range, maximum and minimum values & P-values (Dunn’s multiple comparisons 
test). 
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Volunteer 
no. 
Plaque index 
Patient 
Healthy control 
Pre-treatment Post-treatment 
Individual Cumulative Individual Cumulative Individual Cumulative 
1 1 (1-2) 210 1 (1-2) 185 1 (1-1) 168 
2 1 (1-1) 137 1 (1-2) 197 1 (0-1) 125 
3 3 (2-3) 429 2 (1-2) 244 1 (1-1) 182 
4 2 (2-3) 382 1 (1-1) 150 2 (1-2) 249 
5 2 (2-3) 367 1 (0-1) 141 1 (1-2) 186 
6 2 (2-2) 311 1 (1-2) 212 1 (1-2) 253 
7 2 (1-3) 351 1 (1-2) 218 1 (1-2) 212 
8 2 (1-2) 314 2 (1-2) 265 1 (0-1) 145 
9 2 (1-2) 256 1 (1-1) 150 0 (0-1) 60 
10 1 (1-2) 228 1 (0-1) 100 1 (1-1) 157 
11 1 (1-2) 250 0 (0-1) 73 1 (1-1) 119 
12 2 (1-2) 267 1 (0-1) 117 0 (0-1) 61 
13 3 (3-4) 345 Discontinued 1 (0-1) 124 
14 2 (2-3) 339 1 (1-2) 135 1 (1-2) 156 
15 2 (2-3) 353 1 (1-1) 116 1 (0-1) 128 
16 2 (1-2) 272 0 (0-1) 51 1 (0-1) 125 
17 2 (1-3) 324 1 (0-1) 106 1 (0-1) 143 
18 2 (1-3) 279 0 (0-1) 57 1 (1-1) 150 
19 2 (2-3) 271 1 (1-2) 147 1 (1-1) 175 
20 2 (2-3) 366 1 (0-1) 122 1 (1-2) 162 
Max 3 429 2 265 2 253 
Q3 2 353 1 197 1 180 
Median 2 313 1 141 1 153 
Q1 2 259 1 106 1 125 
Min 1 137 0 51 0 60 
Friedman test 
P<0.0001             
P<0.0001             
Dunn's test 
P<0.01             
P<0.001             
NS             
P<0.001             
P<0.001             
NS             
Table 3.6. Plaque indices for patients (n=20 pre-treatment; n=19 post-treatment) and 
periodontally and systemically healthy control volunteers (n=20). Data presented as median 
gingival index and interquartile range along with full-mouth cumulative values. * P-values calculated 
(n=19) using Friedman test (P<0.0001) followed by Dunn’s multiple comparisons test (Groups 
compared in table =        ). 
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Figure 3.5. Cumulative plaque index in patients and matched periodontally and 
systemically healthy control volunteers (n=19). Box and whisker plots showing median, 
interquartile range, maximum and minimum values & P-values (Dunn’s multiple comparisons 
test). 
 
 
3.4 Plasma high-sensitivity C-reactive protein concentrations pre- and post-
periodontal treatment 
Plasma hsCRP concentrations are shown in Table 3.7. Median hsCRP concentrations in 
patients did not significantly differ from those detected in periodontally healthy controls 
either at baseline or at the 2 month review (Figure 3.6).  However, individual variations in 
plasma hsCRP concentrations were observed between the baseline and review sampling visits 
(Table 3.7). Notably, patient volunteer no. 4 presented with a high baseline hsCRP 
concentration (20.80mg/ml) that was reduced markedly at the post-periodontal treatment 
review (2.69mg/ml). Similarly control volunteer no. 17 had a high review hsCRP 
concentration (16.10mg/ml) despite a much lower concentration (0.79mg/ml) at the baseline 
sampling visit.  
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Volunteer 
no. 
hsCRP (mg/l) 
Baseline Review 
Patient Control Patient Control 
1 6.82 0.79 3.16 0.91 
2 2.69 0.73 0.74 0.65 
3 2.95 2.72 3.56 1.39 
4 20.80 0.41 2.69 2.02 
5 0.56 9.58 0.28 0.32 
6 0.60 1.89 0.99 0.98 
7 Insufficient sample* 5.21 0.42 
8 5.13 0.53 5.10 0.79 
9 3.18 4.42 2.01 3.18 
10 1.27 0.95 1.02 0.57 
11 0.16 0.18 0.81 0.35 
12 0.77 9.12 0.65 0.23 
13 5.87 5.41 Discontinued 
14 0.45 4.20 0.79 4.62 
15 0.92 1.18 1.36 1.09 
16 1.44 0.16 0.89 0.16 
17 2.15 0.79 1.80 16.10 
18 0.98 3.05 0.74 4.30 
19 3.43 0.76 1.97 2.15 
20 2.23 0.48 6.37 0.49 
Max 20.80 9.58 6.37 16.10 
Q3 3.43 4.20 3.16 2.15 
Median 2.15 0.95 1.36 0.91 
Q1 0.77 0.53 0.79 0.42 
Min 0.16 0.16 0.28 0.26 
 
Table 3.7. Plasma hsCRP concentrations (mg/l) for patients and periodontally and 
systemically healthy control volunteers at baseline and review (n=19). * Due to difficult 
venous access, limited blood was collected from patient and control volunteer no. 7 and 
therefore pre-treatment hsCRP levels could not be determined.  
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Figure 3.6. Baseline and review plasma hsCRP concentrations for patients and 
matched periodontally and systemically healthy control volunteers (n=19). Box and 
whisker plots showing median, interquartile range and maximum and minimum values. P-
values calculated using Mann-Whitney test. 
 
 
3.5 DISCUSSION 
The majority of patient volunteers recruited to the clinical study were categorised with 
generalised moderate, localised severe chronic periodontitis (Armitage 1999, Milward & 
Chapple 2003). All patients had clinical measures of chronic periodontitis consistent with the 
national Adult Dental Health Survey and previously published literature (Goodson et al. 1982, 
Fuller et al. 2011, Chapple et al. 2012, Steele et al. 2012, White et al. 2012). All healthy 
control volunteers had clinical measures consistent with periodontal health.  
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individual reductions in all clinical measures associated with clinical periodontitis. However, 
overall treatment responses varied between patient volunteers. A variety of factors might 
explain this variation in treatment response, including the individual host response and 
susceptibility and compliance with prescribed oral hygiene advice (Axelsson & Lindhe 1981, 
Lang & Tonneti 1996). Several patients achieved stable periodontal treatment outcomes (Sanz 
et al. 2012, Dentino et al. 2013) and therefore required no additional corrective periodontal 
therapy other than periodontal maintenance to reduce the risk of disease recurrence 
(Chambrone et al. 2010). However a number of patient volunteers continued to display 
clinical measures consistent with continuing chronic periodontitis at review, all of which were 
reduced in comparison to individual baseline values. For example, patient volunteer no. 17 
required additional periodontal treatment because of the persistence of periodontal pocketing.  
This was despite a marked reduction in periodontal inflammation and plaque deposits 
confirming patient compliance with prescribed oral hygiene advice. Along with individual 
host susceptibility and compliance with plaque control, variations in treatment response may 
also be a reflection of the relative disease severity and extent at initial presentation.  If chronic 
periodontitis is severe with abundant supra- and subgingival plaque and calculus deposits, as 
was the case with patient volunteer no. 17, additional courses of root surface debridement 
(Badersten et al. 1984), use of local (Matesanz-Perez et al. 2013) or systemic antimicrobials 
(Zandbergen et al. 2013) or alternatively, periodontal surgery (Graziani et al. 2012) may be 
required to achieve periodontal stability. Histological studies have confirmed that periodontal 
disease stabilisation occurs through a combination of attachment gain with the formation of a 
long junctional epithelium, along with post-treatment gingival recession due to the resolution 
of gingival inflammation and subsequent collagen cross-linking with tightening of the 
gingival cuff (Lindhe et al. 1982, Nyman et al. 1982). Reductions in BOP and GI result from 
the resolution of inflammation and the repair of sulcular/pocket epithelium ulceration, 
whereas a reduction in PI results from improved mechanical plaque removal by the patient 
following compliance with individually tailored oral hygiene instruction. 
 
Median plasma hsCRP concentration for the patient volunteers (2.15mg/l) was within the 
reported range of 1-4mg/l for patients with periodontitis (Fredriksson et al. 1999, Loos et al. 
2000, Offenbacher et al. 2009, D’Auito et al. 2010, Allen et al. 2011). The median plasma 
hsCRP concentration of periodontally-healthy control volunteers was lower than that detected 
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for patients pre-treatment, however there was no significant difference when the groups were 
compared. Furthermore, median plasma hsCRP concentrations in patients were non-
significantly reduced by periodontal treatment to levels similar to those of control volunteers. 
This study may be relatively underpowered with regard to detecting changes in systemic CRP 
concentration with previously large meta-analyses (Paraskevas et al. 2008) required to 
identify relatively subtle, but statistically significant, differences in systemic CRP observed as 
a result of chronic periodontitis. Therefore, although the differences were not statistically 
significant, the trend in plasma hsCRP concentration between patients and controls presented 
in this thesis is consistent with current literature.  
 
Patient and control volunteers had median plasma hsCRP concentrations of 2.15 and 0.95mg/l 
respectively, thereby falling within the average and low risk categories respectively for the 
development of cardiovascular disease according to the American Heart Association 
guidelines (Ridker et al. 2002, 2005; section 1.7.1). With regards to periodontitis and co-
morbidity, systemic CRP concentrations have been measured in patients with chronic 
periodontitis and co-diagnosed with cardiovascular disease (CVD) with CRP concentrations 
decreasing following stabilisation of periodontal disease (Hussain Bokhari et al. 2009, El Fadl 
et al. 2011, Bokhari et al. 2012, Koppolu et al. 2013, Zhou et al. 2013), suggesting that 
periodontitis is a potential modifiable risk factor for CVD. In addition, systemic CRP 
concentrations have also been measured in patients co-diagnosed with type-2 diabetes, with 
serum and GCF CRP concentrations similarly decreasing following periodontal treatment 
(Sun et al. 2010, 2011, Pradeep et al. 2013). Reductions in systemic CRP have also been 
observed in patients diagnosed with type-1 diabetes following periodontal treatment, albeit 
non-significantly, in agreement with the data presented in this thesis (Correa et al. 2010, 
Kardesler et al. 2010, Llambes et al. 2012). Systemic CRP concentrations have also been 
measured in patients with chronic periodontitis co-diagnosed with chronic renal disease and 
receiving haemodialysis treatment, with CRP levels significantly reducing following 
periodontal treatment (Kadiroglu et al. 2006, Siribamrungwong & Puangpanngam 2012, 
Yazdi et al. 2013). However CRP concentrations did not relate to the severity of periodontitis, 
possibly due to the large superimposed inflammatory burden as a result of the renal disease, 
thereby masking the effect of the periodontal disease (Yazdi et al. 2013). In addition, systemic 
CRP concentrations have been measured in patients with chronic periodontitis co-diagnosed 
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with rheumatoid arthritis (Pinho Mde et al. 2009), obesity (Al-Zahrani & Alghamdi 2012) and 
metabolic syndrome (Acharya et al. 2010, Lopez et al. 2012) with CRP concentrations 
significantly decreasing following periodontal treatment for patients with metabolic syndrome 
but not for rheumatoid arthritis. 
 
Whilst no significant differences in patient and control plasma CRP concentrations are 
reported in this thesis, systemic CRP concentrations are considered important in investigating 
co-morbidity links between periodontal and systemic health. The effect of CRP on the host 
inflammatory-immune response remains to be elucidated, including neutrophil responses such 
as neutrophil respiratory burst activity. Systemic reactive oxygen metabolites positively 
associate with plasma CRP concentrations in chronic periodontitis (D’Aiuto et al. 2010) 
suggesting a link between CRP and systemic oxidative stress in the pathogenesis of chronic 
periodontitis. Therefore, part of this thesis (Chapter 8) has specifically examined the effects of 
CRP on neutrophil respiratory burst activity along with its antioxidant potential in relation to 
the host response and the pathogenesis of both chronic periodontitis and the systemic 
inflammatory burden. 
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CHAPTER 4 
 RESULTS & DISCUSSION 
 
Case-control longitudinal intervention study: 
Neutrophil cytokine release in chronic periodontitis 
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4.1 INTRODUCTION 
Cytokine release from peripheral blood neutrophils isolated from patients with chronic 
periodontitis pre- and post-treatment was determined and compared to matched healthy 
controls in order to investigate whether aberrant neutrophil cytokine release is a plausible 
mechanism in the pathogenesis of chronic periodontitis. Peripheral blood samples were 
collected from the study volunteers at baseline and review (following non-surgical periodontal 
treatment of patients) and, after isolation, neutrophils were cultured for 18 hours as previously 
described (sections 2.2.3 and 2.2.6). Culture supernatants were harvested and the 
concentrations of IL-6, IL-8, IL-1β and TNF-α were determined by ELISA.  
 
4.2 NEUTROPHIL VIABILITY FOLLOWING CULTURE 
There were no significant differences in neutrophil viability following 18 hours of culture 
between patient (mean 97.7%; range 94.1-100%) and control volunteers (mean 97.5%; range 
93.5-100%; P=0.7983). However, comparing all treatments, there was a significant difference 
in mean neutrophil viability following 18 hours of culture in the presence of additional RPMI 
(98.6%), E. coli LPS (98.4%), F. nucleatum (99.2%), P. gingivalis (99.2%) and opsonised S. 
aureus (95.4%) (P<0.0001).  This difference was due to neutrophil viability in the presence of 
opsonised S. aureus being significantly lower than that in cultures containing additional 
RPMI or other stimuli (P<0.05).  
 
4.3 UNSTIMULATED NEUTROPHIL CYTOKINE RELEASE 
Neutrophils were cultured in the presence of additional RPMI (vehicle control) to determine 
cytokine release from essentially unstimulated cells (section 2.2.6; Figure 4.1). At baseline, 
there were significant differences in the amounts of each cytokine released by neutrophils 
(P<0.0001) after 18 hours culture, with a clear pattern of release (IL-8>IL-6>IL-1=TNF). 
There was considerable individual variation in cytokine release by both patient and control 
cells.  This was particularly evident for IL-8 release by patients’ cells and IL-1 release by 
both patient and control cells (Figure 4.1A). Overall, median levels of baseline IL-6, IL-8, IL-
1β and TNF-α release from patient neutrophils were higher than those from controls, although 
this was not statistically significant when comparing data for individual cytokines (P<0.3335) 
or data for all cytokines combined (P=0.1658). 
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At review, and as seen at baseline, patient and control neutrophils consistently released 
amounts of cytokines in the order IL-8>IL-6>IL-1=TNF (Table 4.1). Overall, there was 
greater variation in cytokine release from patient neutrophils at review compared to control 
cells.  This was particularly noticeable for IL-8 due to very high amounts being released from 
cells derived from 2 donors (Figure 4.1B). As seen at baseline, median levels of cytokine 
release at review were greater from patient compared to control neutrophils, however this 
difference was only statistically significant for IL-6 (median 36 & 16pg/ml; P=0.0331), with 
no significant difference for all cytokines combined (P=0.1586). 
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Figure 4.1. Unstimulated cytokine release (pg/ml, IL-1β & TNF-α; pg/mlx10-1, IL-6; 
pg/mlx10-2, IL-8) by neutrophils (A) baseline, pre-treatment (n=17) and (B) review, post-
treatment (n=17) after 18 hours culture in the absence of stimulation (RPMI control). 
Box and whisker plots showing median, interquartile range, maximum and minimum. Values 
for outliers (calculated as >1.5xIQR) are tabulated. (A) control volunteer no. 5 gave 
consistently high values in the absence of stimulation and are highlighted in blue; (B) patient 
volunteer no. 6 gave consistently high values in the absence of stimulation and are 
highlighted in red. P-values are calculated using two-tailed Mann-Whitney tests.
0
10
20
30
40
Patient Control Patient Control Patient Control Patient Control
IL-6 IL-8 IL-1β TNF-α 
C
o
n
c
e
n
tr
a
ti
o
n
 
0
10
20
30
40
Patient Control Patient Control Patient Control Patient Control
IL-6 IL-8 IL-1β TNF-α 
C
o
n
c
e
n
tr
a
ti
o
n
 
 
218 
826 
387 
387 
2818 
21389 
4855 37 
69 
664 
50 
115 
174 
209 
27 
228 
 
504 
638 
160 7658 
12668 
4032 28 
66 
102 
28 
58 
36 
157 
32 
37 
 
B 
P=0.0331 
A 
108 
 
4.4 STIMULATED NEUTROPHIL CYTOKINE RELEASE 
Neutrophils generally released significantly greater amounts of IL-6, IL-8, IL-1β and TNF-α 
in the presence of E. coli LPS, F. nucleatum, opsonised S. aureus and P. gingivalis compared 
with RPMI control, demonstrating a positive cytokine response to the stimuli employed 
(P<0.05; Table 4.2; Figures 4.2-4.4). However, F. nucleatum did not stimulate significant IL-
6 release from patient or control neutrophils, despite median levels being higher than the 
RPMI control (Figure 4.3). When considering the combined cytokine levels for all stimuli 
tested, stimulated patient and control neutrophils showed a similar cytokine release profile to 
that found for unstimulated cells (i.e. IL-8>IL-6> TNF-=IL-1), with amounts released 
differing significantly between cytokines (P<0.0001; Table 4.3). As seen in unstimulated 
cultures, cytokine levels varied greatly between cells from different individuals.  Overall, 
there was greater variation in cytokine release from patient compared with control neutrophils 
for all stimulated conditions. 
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Cytokine Stimulus 
Change in cytokine concentration compared with RPMI 
control 
Baseline Review 
Patient Control Patient Control 
 
 
IL-6 
(n=17) 
 
 
 
E. coli LPS           ↑ ***           ↑ ***           ↑ ***           ↑ *** 
F. nucleatum           ↔           ↔           ↔           ↔ 
ops S. aureus           ↑ **           ↑ ***           ↑ ***           ↑ *** 
P. gingivalis           ↑ ***           ↑ ***           ↑ ***           ↑ ** 
 
 
 
IL-8 
(n=18) 
 
 
 
E. coli LPS           ↑ **           ↑ ***           ↑ ***           ↑ *** 
F. nucleatum           ↑ ***           ↑ ***           ↑ ***           ↑ *** 
ops S. aureus           ↑ ***           ↑ ***           ↑ ***           ↑ *** 
P. gingivalis           ↑ ***           ↑ ***           ↑ ***           ↑ *** 
 
 
IL-1β 
(n=19) 
 
 
 
E. coli LPS           ↑ ***           ↑ ***           ↑ ***           ↑ *** 
F. nucleatum           ↑ *           ↑ ***           ↑ *           ↑ ** 
ops S. aureus           ↑ ***           ↑ ***           ↑ ***           ↑ *** 
P. gingivalis           ↑ **           ↑ *           ↑ **           ↑ * 
 
 
 
TNF-α 
(n=19) 
 
 
 
E. coli LPS           ↑ ***           ↑ ***           ↑ ***           ↑ *** 
F. nucleatum           ↑ ***           ↑ ***           ↑ ***           ↑ *** 
ops S. aureus           ↑ ***           ↑ ***           ↑ ***           ↑ *** 
P. gingivalis           ↑ *           ↑ *           ↑ **           ↑ * 
 
Table 4.1. Summary of the difference in cytokine release by neutrophils after 18 hours 
culture in the presence of E. coli LPS (5µg/ml), F. nucleatum (MOI 100:1), IgG-
opsonised S. aureus (MOI 300:1) and P. gingivalis (MOI 100:1) compared to RPMI 
control. ↑ signifies increase and ↔ signifies no change. P-values calculated using Dunn’s 
multiple comparisons test; * P<0.05, ** P<0.01, *** P<0.001. 
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Cytokine 
Patient Control Comparison between cytokines 
Baseline Review Baseline Review 
Kruskal- 
Wallis 
Dunn's test 
IL-8 
20,707+17,560 
(15,846) 
24,105+22,516 
(17,467) 
10,554+10,188 
(7,271) 
10,625+9,578 
(8,117) 
P<0.0001 
IL-8 v IL-6  
 
P<0.001 
    
IL-6 
1,066+2,332 
(379) 
860+1,465 
(356) 
456+805 
(183) 
334+327 
(232) IL-6 v TNF 
 
P<0.001 
  
TNF-α 
520+1,387 
(97) 
287+395 
(158) 
120+165 
(67) 
169+535 
(81) 
  TNF v IL-1 
 
ns IL-1β 
243+557 
(69) 
129+185 
(73) 
107+224 
(34) 
53+52 
(33) 
    
Comparisons between patients & controls 
Mann- 
Whitney 
IL-8 
*  *  P<0.0001 
 *  * P<0.0001 
IL-6 
*  *  P=0.001 
 *  * P=0.0104 
TNF-α 
*  *  P=0.0127 
 *  * P=0.0027 
IL-1β 
*  *  P=0.0029 
 *  * P=0.0014 
 
Table 4.2. Summary of the differences in stimulated IL-8, IL-6, TNF-α and IL-1β release (pg/ml) from patient and control 
neutrophils at baseline and review in the presence of E. coli LPS (5µg/ml), F. nucleatum (MOI 100:1), IgG-opsonised S. aureus 
(MOI 300:1) and P. gingivalis (MOI 100:1). Data presented as mean+SD (median) pg/ml for all stimuli combined. P-values calculated 
using Kruskal-Wallis test followed by Dunn’s multiple comparison’s test (differences between cytokine levels for patient and control cells 
including baseline and review visits; ns: not significant.  P-values apply to all four cytokine comparisons), and Mann-Whitney test 
(differences between patients & controls comparing highlighted/starred groups). 
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4.4.1 Neutrophil IL-8 release 
Baseline IL-8 release from patient and control neutrophils is shown in Figure 4.2A. Overall, 
patient neutrophils released significantly greater amounts of IL-8 compared to controls when 
comparing the combined data for all stimuli (Table 4.3; P<0.0001). When examining data for 
individual stimuli, patient neutrophils released significantly more IL-8 compared to controls 
following FcγR (median 19,538 & 7,271pg/ml; P=0.0002) and F. nucleatum stimulation only 
(median 11,575 & 8,189pg/ml; P=0.0328; Figure 4.2A).  
 
Release of IL-8 from patient and control neutrophils at review is shown in Figure 4.2B. In 
agreement with the baseline data, patient neutrophils released significantly greater amounts of 
IL-8 than controls when comparing the combined data for all stimuli (Table 4.3; P<0.0001). 
In terms of the effect of individual stimuli, patient neutrophils released significantly more IL-
8 compared to controls following FcγR (median 23,540 & 8,171pg/ml; P<0.0001), P. 
gingivalis (median 23,727 & 5,796pg/ml; P=0.0094) and E. coli LPS stimulation (median 
9,211 & 4,686pg/ml; P=0.0154) but not after stimulation with F. nucleatum (Figure 4.2B).  
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Figure 4.2. Stimulated IL-8 production by neutrophils (A) baseline, pre-treatment 
(n=18) and (B) review, post-treatment (n=18) after 18 hours culture in the absence 
(RPMI control) or presence of E. coli LPS (5µg/ml), F. nucleatum (MOI 100:1), IgG-
opsonised S. aureus (MOI 300:1) and P. gingivalis (MOI 100:1). Box and whisker plots 
showing median, interquartile range, maximum and minimum. Values for outliers (calculated 
as >1.5xIQR) are tabulated as follows. (A) patient volunteer no. 13 gave consistently extreme 
IL-8 levels and are shown in red; (B) patient volunteer no. 6 gave consistently extreme IL-8 
levels and are shown in red. P-values calculated using two-tailed Mann-Whitney tests.  
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4.4.2 Neutrophil IL-6 release 
Baseline IL-6 release from patient and control neutrophils is shown in Figure 4.3A. Patient 
neutrophils released greater amounts of IL-6 compared to controls that was significant when 
comparing the combined IL-6 concentrations (Table 4.3; P=0.001). Similarly, patient 
neutrophils released more IL-6 compared to controls in the presence of F. nucleatum (median 
150 & 74pg/ml; P=0.0275) and following stimulation with E. coli LPS (median 658 & 
333pg/ml; P=0.0528). Release of IL-6 from patient and control neutrophils at review is shown 
in Figure 4.3B. In agreement with the baseline data, patient neutrophils released more IL-6 
than controls at review, which was significant when comparing the combined IL-6 
concentrations (Table 4.3; P=0.0104). In addition, patient neutrophils released significantly 
more IL-6 compared to controls following FcγR stimulation at review (median 443 & 
225pg/ml; P=0.0228) but not after stimulation with E.coli LPS or F. nucleatum.  
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Figure 4.3. Stimulated IL-6 production by neutrophils (A) baseline, pre-treatment 
(n=17) and (B) review, post-treatment (n=17) after 18 hours culture in the absence 
(RPMI control) or presence of E. coli LPS (5µg/ml), F. nucleatum (MOI 100:1), IgG-
opsonised S. aureus (MOI 300:1) and P. gingivalis (MOI 100:1). Box and whisker plots 
showing median, interquartile range, maximum and minimum. Values for outliers (calculated 
as >1.5xIQR) are tabulated as follows. (A) control volunteer no.’s 10 & 12 gave consistently 
high IL-6 levels and are shown in blue. Extreme values in red were obtained from neutrophil 
cultures from patient volunteer no. 13; (B) patient volunteer no. 6 gave consistently high IL-6 
levels and are shown in red. P-values calculated using two-tailed Mann-Whitney tests.  
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4.4.3 Neutrophil IL-1β release 
Baseline IL-1β release from patient and control neutrophils is shown in Figure 4.4A. 
Neutrophils from periodontitis patients released significantly greater amounts of IL-1β 
compared to controls when comparing the combined IL-1β concentrations (Table 4.3; 
P=0.0029). Patient neutrophils similarly released more IL-1β compared to controls following 
stimulation with P. gingivalis (median 38 & 18pg/ml; P=0.0319) and also FcγR stimulation 
(median 91 & 35pg/ml; P=0.068). Review IL-1β release from patient and control neutrophils 
is shown in Figure 4.4B. In agreement with the baseline data, patient neutrophils released 
greater amounts of IL-1β than controls at review, which was significant when comparing the 
combined IL-1β concentrations (Table 4.3; P<0.0014). Patient neutrophils continued to 
release significantly more IL-1β compared to control cells following FcγR (median 101 & 
41pg/ml; P<0.0072) and P. gingivalis stimulation (median 37 & 18pg/ml; P=0.0355).  
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Figure 4.4. Stimulated IL-1β production by neutrophils (A) baseline, pre-treatment 
(n=19) and (B) review, post-treatment (n=19) after 18 hours culture in the absence 
(RPMI control) or presence of E. coli LPS (5µg/ml), F. nucleatum (MOI 100:1), IgG-
opsonised S. aureus (MOI 300:1) and P. gingivalis (MOI 100:1). Box and whisker plots 
showing median, interquartile range, maximum and minimum. Values for outliers (calculated 
as >1.5xIQR) are tabulated as follows. (A) control volunteer no. 10 gave consistently high IL-
1β levels and are shown in blue.  Extreme values in red were obtained from neutrophil 
cultures from patient volunteer no.’s 6 & 13; (B) patient volunteer no. 6 gave consistently 
extreme IL-1β levels and are shown in red. P-values calculated using two-tailed Mann-
Whitney tests.  
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4.4.4 Neutrophil TNF-α release 
Baseline TNF-α release from patient and control neutrophils is shown in Figure 4.5A. 
Periodontitis patient neutrophils released significantly more TNF-α compared to controls 
when comparing the combined TNF-α concentrations (Table 4.3; P=0.0127). Patient 
neutrophils released more TNF-α compared to controls following FcγR (median 225 & 
98pg/ml; P=0.0162) and also F. nucleatum stimulation (median 96 & 70pg/ml; P=0.0505). 
Review TNF-α release from patient and control neutrophils is shown in Figure 4.5B. In 
agreement with the baseline data, periodontitis neutrophils released greater amounts of TNF-α 
than controls at review which was significant when comparing the combined TNF-α 
concentrations (Table 4.3; P<0.0027). Patient neutrophils continued to release significantly 
more TNF-α compared to control cells following FcγR stimulation (median 465 & 159pg/ml; 
P=0.0086) but not following TLR stimulation with F. nucleatum. 
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Figure 4.5. Stimulated TNF-α production by neutrophils (A) baseline, pre-treatment 
(n=19) and (B) review, post-treatment (n=19) after 18 hours culture in the absence 
(RPMI control) or presence of E. coli LPS (5µg/ml), F. nucleatum (MOI 100:1), IgG-
opsonised S. aureus (MOI 300:1) and P. gingivalis (MOI 100:1). Box and whisker plots 
showing median, interquartile range, maximum and minimum. Values for outliers (calculated 
as >1.5xIQR) are tabulated as follows. (A) control volunteer no.’s 5 & 10 gave consistently 
high TNF-α levels and are shown in blue Extreme values in red were obtained from 
neutrophil cultures from patient volunteer no.’s 6 & 13; (B) patient volunteer no. 6 gave 
consistently extreme TNF-α levels and are shown in red. P-values calculated using two-tailed 
Mann-Whitney tests.  
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4.5 SUMMARY OF DIFFERENCES IN CYTOKINE RELEASE BY PATIENT & 
CONTROL NEUTROPHILS 
A summary of the differences in baseline and review IL-6, IL-8, IL-1β and TNF-α release 
between patient and control neutrophils in the presence and absence of individual stimuli is 
shown in Table 4.4. Cytokine release from control cells was always similar to, or less than, 
that released from patient cells.  There were no differences in unstimulated cytokine release 
by patient and control neutrophils except for the greater release of IL-6 by patient cells at 
review. By contrast, at baseline and review, various cytokines were produced in higher 
amounts by patient neutrophils after stimulation. Patient neutrophils released greater amounts 
of IL-6, IL-8 and TNF-α than controls in the presence of F. nucleatum at baseline (P<0.05), 
with no significant differences at review. Increased FcγR stimulated neutrophil cytokine 
release was only significant for IL-8 and TNF-α at baseline, however FcγR stimulated hyper-
reactivity was a consistent feature of periodontitis neutrophils for all cytokines at review 
(P<0.0228). In addition, P. gingivalis stimulated IL-1β hyper-reactivity was a consistent 
feature of periodontitis neutrophils at baseline and review (P<0.0355). 
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Cytokine Stimulus 
Difference in cytokine 
release between patient & 
control cells 
Baseline Review 
IL-6 (n=17) 
RPMI control ↔ ↑ (P=0.0331) 
E. coli LPS ↑ (P=0.0582) ↔ 
F. nucleatum ↑ (P=0.0275) ↔ 
ops S. aureus ↔ ↑ (P=0.0228) 
P. gingivalis ↔ ↔ 
IL-8 (n=18) 
RPMI control ↔ ↔ 
E. coli LPS ↔ ↑ (P=0.0154) 
F. nucleatum ↑ (P=0.0328) ↔ 
ops S. aureus ↑ (P=0.0002) ↑ (P<0.0001) 
P. gingivalis ↔ ↑ (P=0.0094) 
IL-1β (n=19) 
RPMI control ↔ ↔ 
E. coli LPS ↔ ↔ 
F. nucleatum ↔ ↔ 
ops S. aureus ↔ ↑ (P=0.0072) 
P. gingivalis ↑ (P=0.0319) ↑ (P=0.0355) 
TNF-α 
(n=19) 
RPMI control ↔ ↔ 
E. coli LPS ↔ ↔ 
F. nucleatum ↑ (P=0.0505) ↔ 
ops S. aureus ↑ (P=0.0162) ↑ (P=0.0086) 
P. gingivalis ↔ ↔ 
 
Table 4.3. Summary of the difference in cytokine release between patient and control 
neutrophils at baseline and review after 18 hours culture in the absence (RPMI control) 
or presence of E. coli LPS (5µg/ml), F. nucleatum (MOI 100:1), IgG-opsonised S. aureus 
(MOI 300:1) and P. gingivalis (MOI 100:1). ↑ signifies patient>control and ↔ signifies no 
difference. P-values calculated using two-tailed Mann-Whitney tests.  
 
 
4.6 CHANGE IN REVIEW COMPARED WITH BASELINE CYTOKINE 
RELEASE BY PATIENT & CONTROL NEUTROPHILS 
The changes in neutrophil IL-6, IL-8, IL-1β and TNF-α release between baseline and review 
sampling visits are summarised in Table 4.5. Control neutrophils released less IL-6 at review 
compared to baseline in the absence of stimulation (RPMI control; P=0.029), which may 
partly explain the greater IL-6 release from patient compared to control neutrophils found at 
review (P=0.0331; Figure 4.3; Table 4.4). The remaining changes in cytokine release from 
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neutrophils between sampling visits did not influence any of the other differences detected in 
cytokine release from patient and control neutrophils (Figures 4.2, 4.4, 4.5; Table 4.4).  
 
Cytokine Stimulus 
Changes in cytokine release  
between baseline and review  
Patient Control 
IL-6 
(n=17) 
RPMI control ↔ ↓ (P = 0.029) 
E. coli LPS ↔ ↔ 
F. nucleatum ↔ ↔ 
ops S. aureus ↔ ↔ 
P. gingivalis ↔ ↔ 
IL-8 
(n=18) 
RPMI control ↑ (P = 0.0448) ↔ 
E. coli LPS ↔ ↔ 
F. nucleatum ↔ ↔ 
ops S. aureus ↔ ↔ 
P. gingivalis ↔ ↔ 
IL-1β 
(n=19) 
RPMI control ↔ ↔ 
E. coli LPS ↔ ↔ 
F. nucleatum ↔ ↓ (P = 0.029) 
ops S. aureus ↔ ↔ 
P. gingivalis ↔ ↔ 
 
TNF-α 
(n=19) 
 
 
RPMI control ↔ ↔ 
E. coli LPS ↔ ↔ 
F. nucleatum ↔ ↔ 
ops S. aureus ↓ (P = 0.0079) ↔ 
P. gingivalis ↑ (P = 0.0174) ↔ 
 
Table 4.4. Summary of the changes in cytokine release between baseline and review  
for patient and control neutrophils after 18 hours culture in the absence (RPMI control) 
or presence of E. coli LPS (5µg/ml), F. nucleatum (MOI 100:1), IgG-opsonised S. aureus 
(MOI 300:1) and P. gingivalis (MOI 100:1). ↑ review > baseline, ↓ review < baseline & ↔ no 
change. P-values calculated using two-tailed Wilcoxon signed-rank test. 
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4.7 DISCUSSION 
The cytokine data presented in this chapter demonstrates, for the first time, that peripheral 
blood neutrophils from untreated patients with chronic periodontitis exhibit hyper-reactive IL-
6, IL-8, IL-1β and TNF-α release compared with healthy controls. The current work is also 
the first longitudinal intervention study analysing the impact of therapeutic reductions in 
periodontal infection and inflammation on the ability of peripheral blood neutrophils to 
generate cytokines in the presence and absence of periodontally relevant bacteria. This study 
reports F. nucleatum stimulated hyper-reactivity with regards to IL-6, IL-8 and TNF-α release 
when comparing patient and control volunteers at baseline that was not detected at review. 
The data also demonstrate FcγR-stimulated IL-6, IL-8, IL-1β and TNF-α and P. gingivalis-
stimulated IL-1β hyper-reactivity when comparing patient and control volunteers at baseline 
that was maintained at review. Together, these data are consistent with current literature 
highlighting a dysregulated neutrophil phenotype in untreated chronic periodontitis, and this 
is biologically significant given that cytokines regulate many different aspects of the 
inflammatory-immune response, including neutrophil ROS and NET release as well as 
chemotactic potential.  
 
Monocytes and lymphocytes were originally thought to be the predominant source of pro-
inflammatory cytokines in inflammatory lesions. However, the data presented in this thesis 
confirms that neutrophils are similarly able to release IL-8, IL-6, IL-1β and TNF-α and are 
consistent with current literature (Cassatella et al. 1997, 1999). This study also confirms 
previous studies showing that neutrophils release significantly greater amounts of IL-8 and 
IL-6 compared to IL-1β and TNF-α (Altstaedt et al. 1996, Retini et al. 1996). This finding 
may relate to the ability of IL-1β and TNF-α to act synergistically to induce expression of IL-
8 and IL-6 (Kent et al. 1998, Hattar et al. 2006). Given the relatively high levels of IL-8 
production detected in this thesis, it is not surprising that neutrophils were initially thought to 
produce only IL-8 (Bazzoni et al. 1991, Cassatella et al. 1992, 1993, Arnold et al. 1994, Wei 
et al. 1994, Altstaedt et al. 1996). Significantly, given the large amounts of IL-8 released, it is 
relevant that IL-8 is not only an important chemo-attractant (Hammond et al. 1995), but also 
has the ability to prime neutrophils for ROS release (Gainet et al. 1998, Van Dervort et al. 
1998, Guichard C et al. 2005, Dias et al. 2011, Fredriksson 2012) and NET release (Brinkman 
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et al. 2004).  Therefore, neutrophil-derived IL-8 is likely to play a major role in regulating key 
inflammatory-immune responses generally and in periodontitis in particular. 
 
Although mean and median levels of unstimulated cytokine release were highest for patient 
cells, the difference, compared to control cell levels, was not significant for either the 
combined or individual cytokine data, except for IL-6 at review. This latter result appeared to 
be the result of a decrease in control neutrophil IL-6 release at review compared to baseline, 
despite no known intervention between the sampling visits.  While further studies on larger 
numbers are required to determine whether the greater release of cytokines by patient cells is 
statistically significant, it is interesting to speculate that even small differences may be 
biologically important in the pathogenesis of chronic periodontitis, given the large numbers of 
systemic and locally recruited neutrophils within the periodontium.  
 
To date, there are only 4 published studies investigating peripheral blood neutrophil cytokine 
release in chronic periodontitis (Galbraith et al. 1997, Figueredo et al. 2000, Fredriksson et al. 
2002, Restaino et al. 2007). Whilst Figueredo et al. has previously reported greater 
unstimulated neutrophil IL-1β release from patient compared to control neutrophils, the study 
used flow cytometric analyses of fixed and permeabilised neutrophils which, as such, cannot 
measure active IL-1β release (Figueredo et al. 2000). The data presented in this chapter are in 
agreement with those of Galbraith et al. in that there were no significant differences in IL-1β 
release from patient and control neutrophils in the absence of stimulation (Galbraith et al. 
1997). However, this study detected TNF-α production by both unstimulated and stimulated 
neutrophils whereas Galbraith and co-workers failed to detect TNF-α in the presence or 
absence of priming with GM-CSF, possibly relating to a shorter 5 hour neutrophil cell culture 
time (Galbraith et al. 1997). The lack of significant difference in unstimulated IL-8 release 
from patient and control neutrophils in this chapter also contrasts with a study suggesting 
lower IL-8 release from periodontitis neutrophils (Restaino et al. 2007). This discrepancy in 
the data is likely to result from differences in neutrophil isolation method used, with 
inadvertent cell activation of neutrophils occurring in the study of Restaino and co-workers 
(2007). 
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There is a relative lack of published studies investigating peripheral blood neutrophil cytokine 
release in human disease. The data presented in this chapter are in agreement with studies 
demonstrating no difference in unstimulated IL-8 release from neutrophils isolated from 
patients diagnosed with obstructive sleep apnea (Guasti et al. 2011) or chronic obstructive 
pulmonary disease (Blidberg et al. 2012) compared to those from healthy controls. By 
contrast, greater unstimulated IL-8, IL-1β and TNF-α release has been reported for 
neutrophils from patients with type-2 diabetes compared to those from healthy control 
volunteers using a study design similar to that used in the current work (Hatanaka et al. 2006). 
However, the cytokine levels detected were much larger than those in this chapter which may 
be representative of the increased inflammatory burden associated with type-2 diabetes 
compared to chronic periodontitis.  
 
All stimuli resulted in significantly increased neutrophil release of all cytokines except for F. 
nucleatum, which failed to significantly stimulate IL-6 release. Whilst F. nucleatum 
stimulated neutrophils have been shown to release IL-8, IL-1β, TNF-α (Yoshimura et al. 
1997, Sheikhi et al. 2000), both of these studies did not investigate neutrophil IL-6 release. In 
addition, there are no known published studies investigating neutrophil IL-6 release in the 
presence of the periodontal pathogen F. nucleatum, despite published literature demonstrating 
F. nucleatum stimulated IL-6 release from monocytes and gingival fibroblasts (Rossano et al. 
1993).  The data in this thesis therefore provides important and unexpected novel data in that 
F. nucleatum does not significantly stimulate neutrophil IL-6 release. 
 
Although cytokine hyperactivity (increased cytokine release in the absence of stimulation)   
was not detected, greater stimulated IL-8, IL-6, IL-1β and TNF-α release from patient 
compared to control neutrophils was a consistent feature when comparing data for all stimuli  
combined, suggesting that patient cells were hyper-reactive in terms of cytokine production. 
Neutrophil cytokine hyper-reactivity in the absence of hyperactivity contrasts with the 
peripheral blood neutrophil ROS hyperactivity and hyper-reactivity characteristic of untreated 
chronic periodontitis (reviewed by Chapple & Matthews 2007; section 5.3). 
 
In terms of responses to individual stimuli, patient neutrophils released greater amounts of IL-
6, IL-8 and TNF-α in the presence of F. nucleatum, greater FcγR-stimulated IL-8 and TNF-α, 
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and greater P. gingivalis-stimulated IL-1β compared to controls. The FcγR-stimulated IL-8 
and TNF-α hyper-reactivity presented in this thesis contrasts with the lack of significant 
differences previously reported for periodontitis and control neutrophils (Fredriksson et al. 
2002). However Fredriksson et al. utilised a 5 hour culture time and detected only low levels 
of IL-8 (range 16-64pg/ml) and TNF-α (range 13-248pg/ml) compared to those presented in 
this chapter (ranges 1,640-68,050pg/ml and 54-8,326pg/ml for IL-8 and TNF-α respectively) 
using an 18 hour culture period. The kinetics of neutrophil cytokine generation have been 
described and have shown that the majority of stimulated neutrophil IL-1β, IL-8, IL-6, TNF-α 
release occurs at 16-18 hours (Cassatella et al. 1993, Hattar et al. 2006, Retini et al. 1996), 
with neutrophil IL-8, IL-1β and TNF-α release gradually decreasing after 16 hours (Hattar et 
al. 2006). The lack of significant difference in E. coli LPS and P. gingivalis stimulated IL-8 
release from patient and control neutrophils presented in this chapter contrasts with a study 
reporting lower E. coli LPS and P. gingivalis stimulated IL-8 release from periodontitis 
neutrophils (Restaino et al. 2007). However the discrepancies in both unstimulated and 
stimulated IL-8 release with Restaino et al. may be related to differences in neutrophil 
isolation method including the potential for inadvertent cell activation. This is because 
extremely high amounts of IL-8 (~800ng/ml) were detected from control neutrophils along 
with a lack of observable stimulation. Taken together this suggests cell activation during 
isolation therefore causing heightened IL-8 release compared to relatively inactivated 
neutrophils isolated from periodontitis patients (Restaino et al. 2007). 
 
With regards to in-vitro methodology, it is also important to confirm neutrophil viability 
following culture in order to distinguish between active cytokine release rather than passive or 
low-level release due to cell necrosis or apoptosis. Such details are not included in the 
published neutrophil cytokine studies in chronic periodontitis. Whilst this was confirmed in 
this study, with neutrophil viability confirmed following 18 hour culture, there was a small 
but statistically significant decrease in neutrophil viability in the presence of IgG-opsonised S. 
aureus compared with the other culture conditions, although this did not appear to affect the 
amount of IL-8, IL-6, IL-1β or TNF-α released compared to the other stimuli. The small but 
significant reduction in neutrophil viability in the presence of IgG-opsonised S. aureus  may 
be the result of increased phagocytosis due to bacterial opsonisation, as well as the 
multiplicity of infection (MOI) used compared to the other, non-opsonised, bacterial stimuli, 
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namely MOI 300:1 compared with an MOI of 100:1 when including unopsonised periodontal 
pathogens.  The MOI’s were chosen as indicated (section 2.2.12) namely in agreement with 
similar studies investigating neutrophil responses to unopsonised and opsonised bacteria to 
elicit measurable neutrophil responses whilst maintaining neutrophil viability. In addition, 
opsonised S. aureus neutrophil stimulation may additionally result from lipoteichoic acid 
(LTA) binding via the outer cell membrane of Gram-positive bacteria (Hatter et al. 2006). It is 
therefore also possible that neutrophil viability in the presence of IgG-opsonised S. aureus is 
negatively influenced by multiple receptor binding following bacterial opsonisation. 
Furthermore, opsonised S. aureus stimulation leads to increased NETosis (personal 
communication P.White August 2014), which may also negatively influence neutrophil 
viability. 
 
The effect of periodontal treatment on neutrophil cytokine release was also determined. The 
data presented in this thesis was unable to demonstrate that periodontal treatment significantly 
reduced neutrophil cytokine release when comparing baseline and review visits for the patient 
volunteers. Therefore, neutrophil cytokine hyper-reactivity observed at baseline which was no 
longer present at review cannot reliably be attributed solely to the effect of periodontal 
treatment itself. The only exception was the significantly reduced neutrophil FcγR-stimulated 
TNFα release for the patient volunteers between baseline and review visits. Interestingly, F. 
nucleatum-stimulated IL-6, IL-8 and TNF-α hyper-reactivity of patient neutrophils at baseline 
was not observed at review following periodontal treatment. However, as previously 
discussed, careful data interpretation is required given that patient neutrophil cytokine release 
did not significantly reduce following therapy for these parameters. However, it is interesting 
to speculate that the non-significant differences between patient and control volunteers at 
review may be biologically significant and could potentially suggest a benefit of periodontal 
treatment regarding systemic host inflammatory-immune responses. In contrast, consistently 
heightened FcγR-stimulated cytokine release from patient compared to control neutrophils 
was observed both at baseline and review, despite the aforementioned significant reduction in 
neutrophil FcγR-stimulated TNFα release for the patient volunteers in between the sampling 
visits. Whilst this may suggest that FcγR neutrophil cytokine hyper-reactivity is a constitutive 
feature in chronic periodontitis, it contrasts with data from our research group that have 
shown that FcγR-stimulated ROS hyper-reactivity is corrected following treatment (Matthews 
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et al. 2007). Greater P. gingivalis-stimulated IL-1β release from patient compared to control 
neutrophils was similarly a consistent finding at both baseline and post-treatment review. 
Porphyromonas gingivalis is strongly associated with chronic periodontitis pathogenesis 
(Socransky et al. 1998), and P. gingivalis LPS is structurally distinct from other sources of 
LPS (Ogawa 1993) and induces cytokine production via different signalling mechanisms 
(Diya et al. 2008). Porphyromonas gingivalis LPS is heterogenous, with some P. gingivalis 
LPS molecules binding to TLR-2 and others to TLR-4 and, possibly, also receptor antagonists 
(Hajishengallis et al. 2002, Darveau et al. 2004). Furthermore, recent evidence reveals the 
complexity of IL-1β secretion with two signals required, the first being a TLR-induced 
transcription of pro-IL-1β, for example binding of LPS to TLR-4, and the second being an 
additional signal (e.g. extracellular ATP) which results in assembly of an inflammasome, 
activation of caspase-I prior to the secretion of mature IL-1β (Latz 2010). Taken together, a 
constitutive defect in TLR receptor or downstream signalling relating to IL-1β may explain 
the persistent hyper-reactive P. gingivalis stimulated IL-1β release from patient compared to 
control neutrophils presented in this chapter.  
 
Dysregulated neutrophil cytokine release, namely cytokine hyper-reactivity to periodontal 
pathogens and FcR activation, will have a number of different consequences on the 
inflammatory-immune response in relation to the pathogenesis of chronic periodontitis as 
summarised in Figure 4.6. Greater neutrophil IL-8, IL-6 and TNF-α release will result in 
neutrophil priming for greater ROS release (Guichard et al. 2005, Chen et al. 2006) which 
will be further modified by CRP (Chapter 8) following IL-6 and IL-1β activation of the acute-
phase response (Heinrich et al. 1990, Gabay et al. 2001). Whilst a reduction in neutrophil 
ROS release will result in impaired antimicrobial capability resulting in delayed bacterial 
clearance from the gingival crevice, greater extracellular ROS release may cause collateral 
host tissue damage as a result of osteoclast activation causing bone resorption (Lee et al. 
2005) in addition to degradation of type I collagen of the periodontal ligament (Henrotin et al. 
2003). Neutrophil ROS and IL-8 release will also result in NET formation (Brinkmann et al. 
2004, Palmer et al. 2012) which, if excessive, may result in the generation of autoantibodies 
(de Pablo et al. 2014) along with impairing the inflammatory-immune response by 
sequestering local cytokine dissemination (Bank & Ansorge 2001). Neutrophil IL-8, IL-6, IL-
1β and TNF-α release will also trigger neutrophil antimicrobial enzyme and granule protein 
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release with the potential to cause destruction of adjacent periodontal connective tissue (Lacy 
2006). In addition, there are a number of indirect effects of dysregulated neutrophil cytokine 
release that will impact on the pathogenesis of chronic periodontitis. For example, neutrophil 
IL-8 release is likely to affect concurrent neutrophil chemotaxis and recruitment within the 
periodontal tissues (Hammond et al. 1995; Chapter 6). Furthermore, any adaptive immune 
response will be heightened by IL-8, IL-6 and TNF-α resulting in T-cell differentiation 
(Kishimoto et al. 1989, Ben-Sasson et al. 2009) and B-lymphocyte activation which is also 
directly influenced by IL-6 (Maeda et al. 2010). The generation of antibodies and bacterial 
opsonisation will result in FcγR-stimulated neutrophil activation thereby further exacerbating 
the inflammatory-immune response in relation to the persistent FcγR-stimulated IL-8, IL-6, 
IL-1β and TNF-α release presented in this chapter and FcγR-stimulated neutrophil ROS 
hyper-reactivity in chronic periodontitis (Matthews et al. 2007).  
 
Overall the neutrophil cytokine release data presented as part of this thesis demonstrate that 
neutrophils from untreated periodontitis patients are hyper-reactive with regards to IL-8, IL-6, 
IL-1β and TNF-α release compared to cells from healthy control individuals. Furthermore 
consistent FcγR-stimulated IL-6, IL-8, IL-1β and TNF-α and P. gingivalis stimulated IL-1β 
neutrophil hyper-reactivity appears to be a constitutive and consistent feature of the 
pathogenesis of chronic periodontitis. Despite therapy having no detectable effect on 
neutrophil cytokine production in response to F. nucleatum, the apparent loss of F. 
nucleatum-stimulated IL-6, IL-8 and TNF-α hyper-reactivity of patient neutrophils at review 
could potentially highlight a systemic benefit of periodontal therapy that might reduce the risk 
of co-morbidity associated with a dysregulated systemic inflammatory-immune response. 
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Figure 4.6. Overview of neutrophil cytokine release in the pathogenesis of chronic periodontitis. Abbreviations: LPS, 
lipopolysaccharide; TLR, toll-like receptor; CR, complement receptor; IL, interleukin; C, complement; TNF, tumour necrosis factor; CRP, 
C-reactive protein; FcγR, Fcγ-receptor; ROS, reactive oxygen species; NET, neutrophil extracellular trap; PDL, periodontal ligament. 
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CHAPTER 5 
 RESULTS & DISCUSSION 
 
Case-control longitudinal intervention study: 
Neutrophil superoxide release in chronic periodontitis 
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5.1 INTRODUCTION 
 Lucigenin-detectable superoxide (O2
-
) release from peripheral blood neutrophils isolated 
from patients with chronic periodontitis pre- and post-treatment was determined and 
compared to that of cells from healthy controls. The aim was to increase our understanding of 
the specific contribution of O2
-
 to the hyper-responsive neutrophil phenotype associated with 
periodontal bacteria (P. gingivalis & F. nucleatum) and any changes related to successful 
periodontal therapy. Phorbol 12-myristate 13-acetate (PMA) and PBS (vehicle control) were 
also included as positive and negative controls respectively. Previous studies have shown 
increased FcγR and E. coli LPS-stimulated lucigenin-detectable O2
-
 release in chronic 
periodontitis but none have reported responses to un-opsonised putative periodontal 
pathogens (Zekonis et al. 2003, Zilinskas et al. 2011).  
 
5.2 UNSTIMULATED NEUTROPHIL SUPEROXIDE RELEASE 
Baseline O2
- 
release from patient and control neutrophils is shown in Figure 5.1(A, C). Pre-
therapy O2
- 
release from patient neutrophils (median 2,152RLU; range 181-7,746RLU) was 
significantly greater than controls (median 846RLU; range 309-3,634RLU; P=0.011). 
However, at the 2-month post-therapy review, there was no significant difference in O2
- 
release between patient (median 2,505RLU; range 692-6,300RLU) and control neutrophils 
(median 2,130RLU; range 834-5,547RLU; P=0.3124; Figures 5.1B, D).  
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Figure 5.1. Unstimulated neutrophil extracellular superoxide release at baseline (A, C; 
n=20) and review (B, D; n=19) measured by lucigenin-enhanced chemiluminescence 
(relative light units; RLU). Box and whisker plots (A, B) showing median, interquartile 
range, maximum and minimum values. Line charts (C, D) showing paired patient and control 
neutrophils. P-values calculated using two-tailed Wilcoxon matched pairs test.  
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5.3  STIMULATED NEUTROPHIL SUPEROXIDE RELEASE 
The overall changes in neutrophil O2
- 
release in the presence of P. gingivalis, F. nucleatum 
and PMA compared with PBS control at baseline and 2-month review are shown in Table 5.1. 
As expected, neutrophils released significantly greater amounts of extracellular O2
- 
after 
stimulation with P. gingivalis, F. nucleatum and PMA compared to PBS vehicle control 
(P<0.05). The amount of neutrophil O2
-
 release differed significantly between stimuli 
(P=0.0001). Whilst there were no significant differences between P. gingivalis and F. 
nucleatum stimulated O2
-
 release, PMA released approximately 3-6 times more O2
- 
compared 
to bacterial stimuli (P<0.001; Tables 5.2).  
 
 
Stimulus 
Change in lucigenin-enhanced  chemiluminescence compared 
with PBS control 
Baseline Review 
Patient Control Patient Control 
Friedman 
P=0.0001 
Friedman 
P=0.0001 
Friedman 
P=0.0001 
Friedman 
P=0.0001 
P. gingivalis   ↑*   ↑*       ↑***   ↑* 
F. nucleatum       ↑***       ↑***       ↑***       ↑*** 
PMA       ↑***       ↑***       ↑***       ↑*** 
 
Table 5.1. Confirmation of stimulation of superoxide release detected by lucigenin-
enhanced chemiluminescence by patient and control neutrophils (n=20 baseline; n=19 
review) in the presence of P. gingivalis (MOI 100:1), F. nucleatum (MOI 100:1), and 
PMA (5nM). ↑ increase or ↔ no change in chemiluminescence compared to PBS control. P-
values calculated using Friedman test followed by Dunn’s multiple comparisons test for 
comparisons with PBS control:   * P<0.05, ** P<0.01, *** P<0.001. The RLU data upon which 
these changes are based are shown in Tables 5.2 & 5.3.  
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BASELINE  
Patient Control 
PBS Pg Fn PMA PBS Pg Fn PMA 
Median 2,669 4,028 5,603 15,026 1,077 2,024 4,049 14,224 
Max 7,333 11,009 10,572 24,328 4,633 5,230 7,142 21,241 
Min 234 500 1,707 6,850 286 494 1,599 2,189 
Friedman test Within patient & control groups 
P=0.0001         
Dunn’s test Within patient & control groups 
ns         
P<0.001         
P<0.001         
Wilcoxon test Between patient and control groups 
ns 
        
P=0.0266 
        
P=0.0064 
        
ns 
        
 
2-MONTH 
REVIEW 
Patient Control 
PBS Pg Fn PMA PBS Pg Fn PMA 
Median 2,103 4,492 6,138 14,712 2,468 5,054 6,242 14,321 
Max 6,228 11,336 8,348 18,937 4,965 9,840 8,462 22,235 
Min 568 1,362 2,371 9,826 888 1,629 4,527 9,413 
Friedman test Within patient & control groups 
P<0.0001         
Dunn’s test Within patient & control groups 
ns         
P<0.001         
P<0.001/P<0.01         
Wilcoxon test Between patient and control groups 
ns 
        
ns 
        
ns 
        
ns 
        
 
Table 5.2. Baseline and review superoxide release from patient and control 
neutrophils (n=19) in the absence (PBS control) and following stimulation with P. 
gingivalis (MOI 100:1), F. nucleatum (MOI 100:1) and PMA (5nM). Data presented as 
median relative light units, maximum and minimum values.   Differences between stimuli, 
within test groups, performed by Friedman test followed by Dunn’s multiple comparisons test.   
Differences between patient and controls for each stimulus calculated using 2-tailed 
Wilcoxon matched pairs test (groups compared in table = , ns = not significant).  
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Baseline stimulated O2
-
 release from patient and control neutrophils is shown graphically in 
Figure 5.2. Overall, patient neutrophils released significantly more O2
- 
compared to controls 
when comparing the combined data for all stimuli (P=0.0002). Analysis of the data for 
individual stimuli demonstrated that patient neutrophils released significantly more O2
- 
compared with healthy controls following stimulation with P. gingivalis (P=0.0266) and F. 
nucleatum (P=0.0064) but not PMA. In response to addition of PBS (vehicle control), median 
levels of O2
-
 release were higher from patient neutrophils compared with those from control 
cells but the difference did not  reach statistical significance (P=0.0637). However, these data 
are consistent with the greater O2
-
 release by patient cells at baseline when measured without 
addition of anything other than the chemiluminescence assay reagents (i.e. unstimulated cells; 
P=0.011; Figure 5.1). This failure to detect a statistically significant difference in O2
-
 
production between patient and control cells is likely due to the addition of PBS resulting in a 
small increase in neutrophil O2
-
 release compared to the baseline unstimulated data for both 
patient (median increase from 2,152 to 2,669RLU) and control neutrophils (median increase 
from 846 to 1,077RLU) thereby reducing the differences in unstimulated O2
-
 release 
following addition of PBS. 
 
At the 2-month post-treatment review, there were no significant differences in stimulated 
extracellular O2
- 
release between patients and control neutrophils when comparing data for all 
stimuli (P=0.8295). In addition, there were no significant differences in neutrophil 
extracellular O2
- 
release between patients and controls when analysing data for the individual 
stimuli (Table 5.2 & Figure 5.3).  
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Figure 5.2. Baseline stimulated neutrophil extracellular superoxide release by patient 
and control neutrophils measured by lucigenin enhanced chemiluminescence (relative 
light units; RLU) (n=20) in the absence (PBS control), or presence of P. gingivalis (MOI 
100:1), F. nucleatum (MOI 100:1) and PMA (5nM). Box and whisker plot (A) showing 
median, interquartile range, maximum and minimum values. Line chart (B) showing paired 
patient and control neutrophils. P-values calculated using two-tailed Wilcoxon matched pairs 
test.  
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Figure 5.3. Review stimulated neutrophil extracellular superoxide release by patient 
and control neutrophils measured by lucigenin enhanced chemiluminescence (relative 
light units; RLU) (n=19) in the absence (PBS control), or presence of P. gingivalis (MOI 
100:1), F. nucleatum (MOI 100:1) and PMA (5nM). Box and whisker plot (A) showing 
median, interquartile range, maximum and minimum values. Line chart (B) showing paired 
patient and control neutrophils. There were no significant differences between patient and 
control volunteers using two-tailed Wilcoxon matched pairs test.  
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5.4 EFFECT OF PERIODONTAL THERAPY ON NEUTROPHIL SUPEROXIDE 
RELEASE 
An overall summary of the differences in neutrophil superoxide release between patients and 
controls at baseline and review is shown in Table 5.3.  Paired data analysis of the lucigenin 
chemiluminescence results show that, 2 months post therapy, the greater release of O2
-
 by 
patient cells compared to those from controls seen at baseline is no longer present.  The 
change in patient O2
-
 release, as a percentage of control, demonstrates a significant reduction 
at review compared to baseline for PBS treated cells (vehicle control), P. gingivalis and F. 
nucleatum stimulated cells (Figure 5.4).  Interestingly, the O2
-
 response of patients’ cells to 
PMA, a receptor-independent protein kinase C activator, was similar to that of control cells at 
baseline and review. 
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Condition 
Differences in neutrophil 
superoxide release between 
patient and control volunteers 
Baseline Review 
Unstimulated ↑ (P=0.011) ↔ 
Stimulated 
PBS  ↔ (P=0.0637) ↔ 
P. gingivalis ↑ (P=0.0266) ↔ 
F. nucleatum ↑ (P=0.0064) ↔ 
PMA ↔ ↔ 
 
Table 5.3. Summary of the differences in neutrophil superoxide release between 
patients and controls at baseline and review without stimulation and in the presence 
of additional PBS (“unstimulated” vehicle control),  P. gingivalis (MOI 100:1), F. 
nucleatum (MOI 100:1) and PMA (5nM). ↑ signifies patient>control and ↔ signifies no 
difference. P-values calculated using two-tailed Wilcoxon matched pairs test 
 
 
 
 
 
 
Figure 5.4. Effect of periodontal treatment on unstimulated and stimulated superoxide 
release by patient neutrophils (n=19) measured by lucigenin-enhanced 
chemiluminescence (relative light units; RLU) without stimulation and in the presence 
of additional PBS (“unstimulated” vehicle control),  P. gingivalis (MOI 100:1), F. 
nucleatum (MOI 100:1) and PMA (5nM). Data presented as patient RLU as a percentage of 
paired control RLU. Box and whisker plot showing median, interquartile range, maximum and 
minimum values. P-value calculated using two-tailed Wilcoxon matched pairs test. 
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5.5  DISCUSSION 
The data presented in this chapter demonstrates that peripheral blood neutrophils isolated 
from untreated patients with chronic periodontitis release greater amounts of O2
-
 compared to 
healthy controls in the presence and absence of periodontal pathogens. While greater 
production of O2
-
 by unstimulated neutrophils has been reported (Guarnieri et al. 1991), this is 
the first study to demonstrate neutrophil hyper-reactivity with respect to O2
-
 release following 
stimulation with the periodontal pathogens P. gingivalis and F. nucleatum. The current work 
also demonstrates that successful non-surgical therapy removed this O2
-
 unstimulated hyper-
activity and periodontal pathogen-stimulated hyper-reactivity. Together, the data are 
consistent with current literature demonstrating neutrophil hyperactive and –reactive ROS 
release in the pathogenesis of chronic periodontitis, along with providing supporting data that 
this is corrected following successful periodontal therapy.  
 
Whilst ROS generation is essential for neutrophil host defence, both hyper-active and hyper-
reactive neutrophil ROS release is a well-established pathological feature and is considered 
responsible for causing collateral host tissue damage in the pathogenesis of chronic 
periodontitis (reviewed by Chapple & Matthews 2007). This especially relates to extracellular 
rather than intracellular ROS release, due to the increased risk of collateral host tissue damage 
with extracellular ROS release. The data presented in this thesis is consistent with current 
literature showing hyper-active neutrophil extracellular ROS generation in the absence of 
overt stimulation in chronic periodontitis (Guarnieri et al. 1991, Matthews et al. 2007). Two 
other studies have reported greater O2
-
 release from patient compared to control cells using 
lucigenin-enhanced chemilumuniscence and buffy coat preparations rather than isolated 
neutrophils (Zekonis et al. 2003, Zilinskas et al. 2011). In contrast to the extracellular ROS 
hyperactivity of patient neutrophils, luminol-based studies have failed to detect a significant 
upregulation of unstimulated intracellular ROS generation in chronic periodontitis (Matthews 
et al. 2007).  
 
Greater neutrophil O2
-
 release was observed, for the first time, following stimulation with the 
periodontal pathogens P. gingivalis and F. nucleatum. This represents novel data specific to 
O2
-
 release, and is consistent with neutrophil intra- and extracellular ROS hyper-reactivity 
following F. nucleatum and FcγR stimulation in chronic periodontitis (Gustafsson & Asman 
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1996, 1997, Fredriksson et al. 1998, 1999, 2003, Matthews et al. 2007). This data is similarly 
in agreement with previous studies specifically demonstrating greater O2
-
 release from patient 
compared to control neutrophils following FcγR and E. coli LPS stimulation (Zekonis et al. 
2003, Zilinskas et al. 2011). The lack of difference in O2
-
 release between patient (untreated 
or treated) and control neutrophils following stimulation with PMA presented in this thesis is 
also consistent with the only other study that has investigated this receptor-independent 
activator of protein kinase C (PKC; Guarnieri et al. 1991). Whilst PMA stimulation resulted 
in a 3-6 fold greater superoxide release compared to unopsonised bacterial stimuli,   the lack 
of hyper-reactivity when comparing patient and control responses following PMA stimulation 
contrasts with the hyper-reactivity in the presence of bacterial stimulation with P. gingivalis 
and F. nucleatum. This suggests that dysregulated receptor and downstream signalling 
relating to NADPH and the formation of neutrophil ROS plays a role in the pathogenesis of 
chronic periodontitis rather than solely the NADPH oxidase itself, since PMA bypasses 
receptor signalling with direct stimulation of NADPH via PKC. This is further supported by 
previous data demonstrating no significant difference in neutrophil NADPH phox gene 
expression between patients with chronic periodontitis and healthy controls (Matthews et al. 
2007), whilst NADPH oxidase polymorphisms are considered a risk factor for aggressive 
periodontitis (Nibali et al. 2006).  
 
The data presented here demonstrate that O2
-
 hyperactivity and O2
-
 hyper-reactivity to 
periodontal pathogens exhibited by patient neutrophils was not present after successful 
periodontal tharapy. Whilst it is impossible to compare chemiluminescence data gathered at 
different time points, due to the inherent day-to-day variability in the method, it is not 
unreasonable to suggest that therapy has reduced the O2
-
 responses of patient neutrophils such 
that they are no longer higher than those of cells isolated from matched controls.  There have 
been many studies showing that neutrophils from untreated periodontitis patients consistently 
show significantly higher ROS generation and release than cells isolated from periodontally 
and medically healthy controls (Gustafsson & Asman 1996, Fredriksson et al. 1998, 1999, 
2003, Zekonis & Zekonis 2004, Matthews et al. 2007).  The review data in this study 
therefore strongly suggests that the O2
-
 hyperactivity and hyper-reactivity of peripheral 
neutrophils in periodontitis patients is corrected by successful periodontal therapy. To date 
there has been only one other published longitudinal study investigating the effect of 
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periodontal treatment on neutrophil ROS responses which used luminol and isoluminol 
chemiluminescence methods to detect intra- and extracellular ROS respectively, rather than 
extracellular O2
-
 (Matthews et al. 2007). This latter study demonstrated persistence of 
unstimulated, iso-luminol detectable, extracellular ROS hyperactivity but correction of 
luminol-detectable, FcγR-stimulated intracellular ROS hyper-reactivity following treatment. 
Thus, the data presented in this chapter demonstrating that TLR-stimulated neutrophil O2
-
 
release was similar to that of controls at review following periodontal treatment are similar to 
the corrected FcγR-stimulated total ROS generation previously reported post therapy 
(Matthews et al. 2007). However the unstimulated extracellular O2
-
 release data presented in 
this chapter differs from the previously reported persistent unstimulated extracellular ROS 
release detected by isoluminol, which detects predominantly extracellular, H2O2-derived, 
HOCl (Matthews et al. 2007). One possible explanation may relate to increased intracellular 
levels of H2O2 due to upregulated enzymatic conversion of O2
-
 by intracellular SOD and/or a 
reduction in its intracellular transformation to HOCl and water by MPO and catalase 
respectively (Figure 5.5).  As H2O2 can be transported across cell membranes, increased 
intracellular levels could then result in increased extracellular levels detectable as HOCl in the 
isoluminol assay that was used to show persistent hyperactivity following periodontal 
treatment (Matthews et al. 2007). Whilst MPO and SOD polymorphisms have been identified 
in pancreatic adenocarcinoma (Wheatley-Price et al. 2008) and chronic pelvic pain syndrome 
(Arisan et al. 2006), there are currently no known published studies investigating MPO, SOD 
or catalase activity in patients with chronic periodontitis.  
 
Exaggerated neutrophil extracellular O2
- 
release will have a number of different effects on the 
host response in the pathogenesis of chronic periodontitis. Greater O2
- 
release into the 
surrounding tissue will have the potential to directly cause endothelial cell damage (Droy-
Lefaix et al. 1991), lipid peroxidation (Dix & Aikens 1993) and DNA strand breaks (Dix et 
al. 1996). Furthermore, whilst the O2
-
 radical has relatively little antimicrobial activity and 
toxicity in itself, this is increased by its conversion to downstream H2O2 and HOCl in the 
presence of SOD and MPO respectively (Babior 1999, Dahlgren et al. 1999).  Taken together, 
increased neutrophil ROS release will have the potential to increase NET (Palmer et al. 2012) 
and cytokine release (Ndengele et al. 2005), as well as affecting chemotactic potential (Deitch 
et al. 1990). The median O2
-
 release for unstimulated and F. nucleatum and P. gingivalis 
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stimulated cells, expressed as a percentage of patient compared to matched healthy control 
neutrophils, was 182, 137 and 156% respectively. However, this is likely to be under-
representative of the in-vivo impact regarding the pathogenesis of chronic periodontitis given 
the relatively large numbers of neutrophils recruited as part of the inflammatory-immune 
response. Furthermore, the greater cytokine release from patient neutrophils presented in this 
thesis (Chapter 4) may further exacerbate neutrophil ROS release (Dias et al. 2011, 
Fredriksson et al. 2012, Figure 4.6). The presence of oxidative stress represents an important 
risk factor regarding chronic periodontitis and co-morbidity including type-2 diabetes 
(Karima et al. 2005, Chapple & Genco 2013), atherogenic vascular disease (Dietrich et al. 
2013), rheumatoid arthritis (dePablo et al. 2009) and ischaemic stroke (Scannapieco et al. 
2003). This is further emphasised by the correction of neutrophil extracellular O2
- 
hyper-
activity and –reactivity following periodontal treatment presented in this thesis, in that 
treatment then reduces peripheral blood neutrophil O2
- 
release to that of healthy controls, 
therefore reducing the risk of co-morbidity following periodontal treatment. Furthermore, this 
data adds to our current evidence that chronic periodontitis is a modifiable risk factor for the 
development of other systemic inflammatory diseases where oxidative stress is a pathological 
feature.  
 
The relative contribution of greater neutrophil ROS release to oxidative stress in the 
pathogenesis of chronic periodontitis and systemic disease is further compounded by the 
presence of antioxidants and the redox balance of both the neutrophil and the surrounding 
tissues (Brock et al. 2004, Chapple et al. 2013). The redox state of the neutrophil 
(GSH:GSSG ratio) has been shown to be altered in chronic periodontitis leading to cellular 
stress resulting in the relocation of NADPH oxidase to the outer cell membrane (Dias et al. 
2013) which may partly explain the increased extracellular O2
- 
release in chronic periodontitis 
presented in this thesis. Therefore, the increased release of extracellular O2
- 
may be an 
inherently protective cellular event ensuring neutrophil survival in the presence of oxidative 
stress, with the likely consequence of collateral host tissue damage. The association between 
low antioxidant defence and increased biomarkers of oxidative damage in periodontitis 
plasma has been investigated in several studies (reviewed by Chapple & Matthews 2007). 
Furthermore, the redox disturbances in periodontitis neutrophils are associated with 
dysregulation of the anti-inflammatory transcription factor Nrf2 (Dias et al. 2013). In 
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addition, sulforaphane, which is a natural product found in cruciferous vegetables, has been 
shown to restore cellular glutathione levels and thereby reduce the hyperactivity of 
neutrophils associated with chronic periodontitis highlighting the potential importance of a 
healthy diet and antioxidant intake in the management of chronic periodontitis and also in 
reducing the risk of systemic disease associated with oxidative stress (Chapple et al. 2009, 
Dias et al. 2013).  
 
 
 
 
Figure 5.5. Overview of the neutrophil respiratory burst including generation of O2
- and 
subsequent conversion to downstream ROS. The corrected unstimulated extracellular O2
- 
release hyperactivity presented in this thesis differs from the previously reported persistent 
H2O2-derived HOCl hyperactivity following periodontal treatment (Matthews et al. 2007). One 
possible explanation may relate to increased levels and extracellular release of H2O2 due to 
upregulated enymatic conversion of O2
- by intracellular SOD and/or reduced transformation 
by MPO/catalase.  
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Overall, the neutrophil O2
- 
release data presented in this thesis is consistent with current 
literature with regards to hyperactive and –reactive neutrophil ROS generation in the 
pathogenesis of chronic periodontitis. Taken together with a body of literature demonstrating 
oxidative changes in peripheral blood of patients with systemic diseases such as diabetes 
(Allen et al. 2011), and together with those previously published (Matthews et al. 2007), these 
data suggest that chronic periodontitis is a modifiable risk factor, the successful treatment of 
which has the potential to reduce the risk of co-morbidity associated with oxidative stress due 
neutrophil ROS generation and release. 
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CHAPTER 6 
 RESULTS & DISCUSSION 
 
Case-control study: 
Baseline differences in neutrophil extracellular trap (NET) release 
& chemotactic accuracy in chronic periodontitis 
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6.1 INTRODUCTION 
Isolated neutrophils from untreated patient and healthy control volunteers were cultured in the 
presence and absence of known stimuli for neutrophil extracellular trap (NET; section 2.2.9) 
release (PMA and HOCl) to determine, for the first time, whether dysregulated NET release is 
involved in the pathogenesis of chronic periodontitis. In addition, directional chemotactic 
accuracy of patient and control neutrophils in response to IL-8 and fMLP was determined 
using a novel direct visualisation chemotaxis chamber (section 2.2.10). Although traditional 
“chemotaxis” has been investigated in chronic periodontitis previously, this is the first time 
that this new, directional chemotaxis assay has been applied to the disease. 
 
6.2 NEUTROPHIL EXTRACELLULAR TRAP RELEASE 
Neutrophil extracellular trap (NET) release was confirmed by fluorescence microscopy and 
quantified using a recently developed fluorometric assay (sections 2.2.9.1 & 2).  
 
Extracellular trap release from patient and control neutrophils following stimulation with 
PMA or HOCl is shown in Figure 6.1. Neutrophil extracellular traps were observed to 
confirm their release, with no noticeable visible differences in appearance or quantity between 
patient and control neutrophils. Neutrophil extracellular traps were observed as fluorescent 
streaks alongside non-viable “NETosed” and necrosed neutrophils and cell debris thereby 
making it difficult to quantify NET release using direct observation of Sytox Green stained 
preparations.  A validated fluorometric assay (section 2.2.9.2) was therefore used to quantify 
and determine NET release from patient and control neutrophils. 
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Figure 6.1. Fluorescence microscopy of extracellular traps from patient (A, B) and 
control (C, D) neutrophils stained with Sytox Green following stimulation with (A, C) 
25nM PMA and (B, D) 0.75mM HOCl. Please note the presence of NET-like structures as 
indicated by the arrows consistent with current literature (Brinkmann et al. 2004, Palmer et al. 
2012). However it is impossible to reliably distinguish between NETs, non-viable NETosed 
and necrotic neutrophils/cell debris, thereby making it difficult to accurately determine NET 
quantification using direct observation of Sytox Green stained preparations.  
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Both patient and control cells showed greater NET release following stimulation with PMA 
(P<0.05) and HOCl (P<0.001) compared to RPMI control, demonstrating the effectiveness of 
both agents to stimulate NET production (Table 6.1). Furthermore, greater NET release was 
observed following stimulation with HOCl compared to PMA (P<0.05), a finding consistent 
with recently published data (Palmer et al. 2012).  
 
There were no statistically significant differences in NET release between patient and control 
cells under any of the test conditions (Figure 6.2).  The median and ranges of values were 
similar between groups and there was no tendency for values to be greater in one group 
(Figure 6.2B).  
 
 
NET release 
(AFU) 
 Patient 
 
Control 
 RPMI PMA HOCl 
 
RPMI PMA HOCl 
Median  2,229 6,319 15,318 
 
2,330 6,116 13,705 
Max  8,313 13,720 25,685 
 
8,523 14,383 27,118 
Min  515 2,075 2,700 
 
895 2,053 1,957 
Friedman test   
P<0.0001        
 
      
Dunn’s test   
P<0.05        
 
      
P<0.001        
 
      
P<0.01        
 
      
 
Table 6.1. Neutrophil extracellular trap release from patient and control neutrophils 
(n=20) in the absence (RPMI control) or following stimulation with PMA (25nM) or HOCl 
(0.75mM). Data presented as median, maximum and minimum arbitrary fluorescence units. 
Within patient and control group P-values calculated using Friedman test followed by Dunn’s 
multiple comparisons test (groups compared in table = ).  
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Figure 6.2. Neutrophil extracellular trap release by patient and control neutrophils 
measured by fluorometric quantification (arbitrary fluorescence units; AFU; n=20) in 
the absence (RPMI control) or following stimulation with PMA (25nM) or HOCl 
(0.75mM). (A) Box and whisker plot showing median, interquartile range, maximum and 
minimum values. (B) Line chart showing paired patient and control values. No significant 
differences were detected between patient and control cells using one-tailed Mann-Whitney 
test. 
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6.3 NEUTROPHIL CHEMOTACTIC ACCURACY 
Neutrophil chemotactic accuracy was determined using a novel directional chemotaxis assay 
(section 2.2.10) in the presence of known chemo-attractants, fMLP and IL-8. RPMI was used 
as a negative control.  The data obtained were initially analysed qualitatively using three types 
of graphical plot before determining the chemotactic index, speed and velocity of cells to 
allow direct comparisons between patient and control cell migration.  
 
Examples of individual neutrophil migratory tracks following 20 minutes of phase time-lapse 
recording in the presence of fMLP are shown in Figure 6.3. Subjectively, both patient and 
control neutrophils demonstrated a strong bias for migration toward the source of the 
chemoattractant, along with a lack of directed migration in the presence of additional RPMI as 
a negative control. The lengths of each individual cell track represent the distance moved 
within the 20 minute recordings, with control neutrophils moving a generally greater distance, 
representative of greater speed (section 6.3.2) and velocity (section 6.3.3) of movement 
compared to neutrophils isolated from patients with chronic periodontitis.  
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Figure 6.3. Individual neutrophil migratory tracks towards fMLP (100nM) from a patient 
with chronic periodontitis (A) and healthy control (B). The image shows the final 
neutrophil positions within the Insall chemotaxis chamber after 20 minutes of phase time-
lapse recording. The top of the picture represents the source of the chemotactic signal. The 
coloured tracks indicate the path of migration for each cell analysed; each track begins 
where the cell was positioned at the start of recording and ends where the cell was 
positioned at the end of recording. 
A 
B 
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Individual neutrophil tracks in the presence of fMLP, IL-8 or RPMI control were 
subsequently plotted as spider diagrams calibrated to a central fixed reference point as shown 
in Figure 6.4. These plots confirmed direct observation of individual cell tracks (Figure 6.3), 
clearly showing that both patient and control neutrophil migration demonstrated a strong bias 
towards the chemoattractant source compared to undirected migration in the presence of 
additional RPMI. In addition, and similarly in agreement with the direct observation of 
neutrophil migration, control neutrophils generally moved a greater distance representative of 
greater speed and velocity compared to periodontitis neutrophils. Whilst spider diagrams are a 
useful way of displaying neutrophil migration per individual, the plots become less clear with 
the addition of greater numbers of cell tracks. Therefore, neutrophil migration for all patient 
and control volunteers was displayed as angular histograms and rose plots depicting clusters 
of neutrophil migration, demonstrating the strong bias for migration towards the source of the 
chemo-attractant compared to RPMI control as shown in Figure 6.5.     
   
In order to more clearly display the direction and magnitude of the mean neutrophil migratory 
pattern, resultant vector plots were generated including calculation of the mean resultant 
vector length (section 2.2.10.2; Figure 6.6). Mean resultant vector lengths indicated that 
patient neutrophils, on average, were more accurately directed towards the chemoattractant 
source (90
o
) in the presence of fMLP (92
o
) and IL-8 (92
o
) compared to healthy controls (82
o
 
and 76
o
 for fMLP and IL-8 respectively). However, there was greater variation in neutrophil 
migration in the presence of fMLP and IL-8 for patient compared to control neutrophils as 
shown by the circles on the circumference of the rose plots and larger 95% confidence 
internals (Figure 6.6). Given the greater variation in neutrophil migration, patient neutrophils 
had a shorter mean resultant vector length representative of impaired directional chemotactic 
accuracy (i.e. a smaller proportion of the cell population analysed moving in the direction of 
the vector line) in the presence of fMLP (0.6624) and IL-8 (0.5363) compared to healthy 
control neutrophils (0.8342 and 0.7027 for fMLP and IL-8 respectively; Figure 6.6).  
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Figure 6.4. Spider diagrams representing migration of neutrophils from a patient with 
chronic periodontitis and a healthy control in the presence of RPMI, fMLP (100nM) and 
IL-8 (10nM). Cell tracks representative of individual neutrophil migrations (n=15) calibrated 
from a central fixed reference point (0, 0) from a patient and paired control volunteer. The top 
of the pictures represent the source of the chemotactic signal. Note that the paths of 
individual neutrophils from both patient and control display a bias for migration towards the 
chemo-attractant. 
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Figure 6.5. Angular histograms (rose plots) representing neutrophil migration for 
patient and control neutrophils (n=18 pairs) in the presence of RPMI, fMLP (100nM) 
and IL-8 (10nM). The top of each histogram (90o) represents the source of the chemotactic 
signal. The width and angle of each angular histogram bar represents the proportion and 
migratory directions respectively of groups of neutrophils that are grouped by directionality. 
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Figure 6.6. Resultant vector plots representing neutrophil migration for patient and 
control neutrophils (n=18 pairs) in the presence of RPMI, fMLP (100nM) and IL-8 
(10nM). The top of each histogram (90o) represents the source of the chemotactic signal. 
The red line represents the mean resultant vector highlighting the direction and magnitude of 
the mean cell migration (the longer the red line the stronger the magnitude and direction) 
bounded by the 95% confidence intervals. The circles on the circumference of the rose plots 
represent the individual end-points of neutrophil migration calibrated from the central fixed 
reference point.           
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Whilst the use of spider diagrams, angular histograms and rose plots represent novel methods 
to qualitatively assess cell migration, they cannot be used to objectively compare patient and 
control neutrophil chemotaxis.  Therefore, patient and control chemotactic indices, speed and 
velocity of neutrophil migration were calculated to allow comparisons to be made using 
circular statistics (section 2.2.10.3).  
 
6.3.1 Chemotactic index  
Chemotactic index was calculated (section 2.2.10.3) as a measure of the overall accuracy of 
neutrophil migration towards a chemoattractant source. Patient and control neutrophil 
chemotactic index differed in the presence of fMLP, IL-8 and RPMI as the negative control 
(P<0.0001; Figure 6.7). As expected, neutrophil chemotactic index was greater in the 
presence of fMLP (P<0.001) and IL-8 (P<0.05) compared to RPMI control for both patient 
and control cells. Compared to healthy controls, patient neutrophils had a reduced 
chemotactic index towards fMLP (median 0.43 & 0.63) and IL-8, but this dfference was only 
statistically significant for fLMP (P=0.0022). There was no significant difference in 
chemotactic index in the presence of RPMI as negative control.  
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Chemotactic 
Index  
Patient 
 
Control 
 
RPMI fMLP IL-8 
 
RPMI fMLP IL-8 
Median 
 
0.013 0.433 0.317 
 
-0.004 0.625 0.432 
Max 
 
0.163 0.716 0.597 
 
0.067 0.740 0.711 
Min 
 
-0.154 0.118 0.046 
 
-0.118 0.397 0.060 
Friedman test 
        
P<0.0001 
 
      
 
      
Dunn's test 
        
P<0.001 
 
      
 
      
P<0.05 
 
      
 
      
P<0.05 
 
      
 
      
ns 
 
      
 
      
 
 
 
 
Figure 6.7. Chemotactic index of patient and control neutrophils (n=18) in the 
presence of RPMI, 100nM fMLP and 10nM IL-8. Table (A) presents median, maximum and 
minimum values. Within patient and control group P-values calculated using Friedman test 
followed by Dunn’s multiple comparisons test (groups compared in table = ). Box and 
whisker plot (B) shows median, interquartile range, maximum and minimum values. P-values 
for patient versus control comparisons are calculated using two-tailed Mann-Whitney test.  
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6.3.2 Speed 
The speed of neutrophil movement differed in the presence of fMLP, IL-8 and RPMI for both 
patient and control volunteers (P<0.0173; Figure 6.8). Whilst control neutrophil migration 
speed was greater in the presence of fMLP and IL-8 compared to RPMI control (P<0.05), 
these differences were not significant for patient neutrophils. This was  reflected in the finding 
that patient neutrophils migrated with less speed compared to controls in the presence of 
fMLP (median 2.53 & 3.22µm/min;) and IL-8 (median 1.97 & 2.51µm/min) but this reduction 
was only significant for fMLP (P=0.048). There was no significant difference in neutrophil 
movement speed between patient and control cells in the presence of additional RPMI as 
negative control.  
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Speed 
(µm/min)  
Patient 
 
Control 
 
RPMI fMLP IL-8 
 
RPMI fMLP IL-8 
Median 
 
1.560 2.533 1.968 
 
1.333 3.223 2.514 
Max 
 
2.959 4.226 3.930 
 
2.377 5.907 3.547 
Min 
 
0.692 1.319 1.077 
 
0.692 1.610 1.073 
Friedman test 
        
P<0.0001  
 
      
 
      
P=0.0173         
Dunn's test 
        
ns 
 
      
 
      
P<0.01 
 
      
 
      
ns 
 
      
 
      
P<0.05 
 
      
 
      
ns 
 
      
 
      
 
 
 
 
Figure 6.8. Speed (µm/min) of patient and control neutrophil migration (n=18) in the 
presence of RPMI, 100nM fMLP and 10nM IL-8. Table (A) presents median, maximum and 
minimum values. Within patient and control group P-values calculated using Friedman test 
followed by Dunn’s multiple comparisons test (groups compared in table = ). Box and 
whisker plot (B) showing median, interquartile range, maximum and minimum values. P-
values for patient versus control comparisons are calculated using two-tailed Mann-Whitney 
test.  
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6.3.3 Velocity 
Velocity was calculated as the speed of neutrophil migration in a consistent direction towards 
the source of the chemoattractant (section 2.2.10.3). Patient and control neutrophil velocity 
differed between fMLP, IL-8 and RPMI (P<0.0001; Figure 6.9). Furthermore, neutrophil 
velocity for both patient and control cells was greater in the presence of fMLP (P<0.001) and 
IL-8 (P<0.05) compared to RPMI control. Compared to healthy controls, patient neutrophils 
migrated with reduced velocity in the presence of fMLP (median 1.16 & 1.96µm/min) and IL-
8 (median 0.65 & 1.03µm/min) but, as for chemotactic index and speed, this difference was 
only statistically significant for fMLP (P=0.002).  
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Velocity 
(µm/min)  
Patient 
 
Control 
 
RPMI fMLP IL-8 
 
RPMI fMLP IL-8 
Median 
 
0.053 1.163 0.653 
 
0.020 1.960 1.026 
Max 
 
0.299 2.420 1.848 
 
0.216 4.240 2.298 
Min 
 
-0.377 0.263 0.030 
 
-0.712 0.706 0.100 
Friedman test 
        
P<0.0001 
 
      
 
      
Dunn's test 
        
P<0.001 
 
      
 
      
P<0.05 
 
      
 
      
P<0.05 
 
      
 
      
ns 
 
      
 
      
 
 
 
 
Figure 6.9. Velocity (µm/min; speed in a consistent direction towards the source of the 
chemoattractant) of patient and control neutrophil migration (n=18) in the presence of 
RPMI, 100nM fMLP and 10nM IL-8. Table (A) presents median, maximum and minimum 
values. Within patient and control group P-values calculated using Friedman test followed by 
Dunn’s multiple comparisons test (groups compared in table = ). Box and whisker 
plot (B) showing median, interquartile range, maximum and minimum values. P-values for 
patient versus control comparisons are calculated using two-tailed Mann-Whitney test.  
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6.3.4 Correlation between neutrophil IL-8 release & chemotactic accuracy 
Although not statistically significant, patient neutrophils displayed a lower median 
chemotactic index compared to healthy controls in the presence of IL-8. Data presented in this 
thesis has also demonstrated greater IL-8 release from patient compared to control neutrophils 
(section 4.5.2). Due to the possibility that exaggerated neutrophil IL-8 release by patient 
neutrophils may partly explain their reduced chemotactic accuracy, correlations between 
patient neutrophil IL-8 release and chemotactic index, speed and velocity were determined. 
 
A low but statistically significant correlation was observed between patient neutrophil IL-8 
release (unstimulated, RPMI control; section 4.5.2) and chemotactic index towards fMLP 
only (Figure 6.10). There were no noticeable correlations between patient neutrophil IL-8 
release and either speed or velocity of neutrophil migration in the presence of fMLP and IL-8 
as chemoattractants.  
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Figure 6.10. Correlation (n=16) between patient neutrophil IL-8 release (unstimulated; 
RPMI control) and chemotactic index in response to (A) fMLP and (B) IL-8.  
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6.4 DISCUSSION 
Neutrophil extracellular trap release in chronic periodontitis 
The data presented in this chapter, generated using a recently developed fluorometric 
quantification assay (Palmer et al. 2012) has demonstrated, for the first time, a lack of 
significant differences in NET release from peripheral blood neutrophils from patients with 
chronic periodontitis compared to matched healthy controls. This adds to our current 
understanding of disease pathogenesis because, whilst ROS are essential for NET release 
(Brinkmann et al. 2004, Palmer et al. 2012), neutrophil hyper-active and –reactive ROS 
release (sections 1.6.3, Chapter 5) does not result in detectable differences in NET production.  
 
Neutrophil extracellular trap release was initiated following stimulation with PMA 
(Brinkmann et al. 2004) and HOCl (Palmer et al. 2012), both of which are established NET 
stimuli. Initial studies quantified NETs using cell image counting but such methods are 
subject to observer bias (Brinkmann et al. 2004, Fuchs et al. 2007, Clark et al. 2007, Yost et 
al. 2009) and care is required because NET structures may be artefactual.  For example, it has 
been questioned whether reliable discrimination between NETs and fibrin is possible using 
scanning electron microscopy analyses (Krautgartner et al. 2010). Fluorometric quantification 
of NETs was therefore used in this study to reduce the potential for bias and to obtain more 
objective data. 
 
Neutrophil extracellular trap release is dependent upon neutrophil ROS generation and release 
(Brinkmann et al. 2004, Fuchs et al. 2007) and more specifically HOCl (Palmer et al. 2012). 
The first and subsequent NET studies predominantly used PMA to induce NET formation, 
with approximately one third of PMA-activated neutrophils isolated from human venous 
blood producing NETs in vitro (Brinkmann et al. 2004, Fuchs et al. 2007). Whilst PMA is 
non-physiological, it has the advantage that it causes direct activation of protein kinase C and 
generation of O2
-
, thus bypassing receptor-ligand binding on the neutrophil cell surface and 
subsequent phagocytosis. Data from this chapter has demonstrated that HOCl-stimulated 
neutrophils produce approximately 3 times more NETs compared to PMA, in agreement with 
the first study to demonstrate that NET release is regulated by HOCl (Palmer et al. 2012).  
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Given the requirement for ROS production to initiate NET release, it is interesting to note 
that, whilst the literature and the O2
- 
data presented in this thesis supports neutrophil hyper-
activity and -reactivity regarding ROS release in chronic periodontitis (sections 1.6.3, 5.2 & 
5.3), there were no significant differences in NET release compared to healthy controls. One 
possible explanation may relate to the amount of ROS required, as it has been demonstrated 
that relatively large concentrations of HOCl (>0.5mM) are required to induce NET formation 
(Palmer et al. 2012). The lack of a significant difference in unstimulated NET release between 
patient and control neutrophils is most probably due to insufficient amounts of excess ROS 
associated with the ROS hyper-activity observed in chronic periodontitis to induce NET 
formation per se. This is supported by two observations.  Firstly, hyperactivity in terms of 
ROS generation by unstimulated neutrophils appears to be limited to extracellular release 
rather than raised intracellular levels that would be required for NET release (Matthews et al 
2007). Secondly, the data demonstrate that 5nM PMA stimulates patient neutrophils to 
produce 5.6-7 times the amount of lucigenin detectable O2
- 
than unstimulated cells (Table 5.2; 
Chapter 5) but 25nM PMA is required to induce consistent NET release.  That there were no 
differences in PMA-stimulated NET release is not surprising given the fact that patient 
neutrophils did not exhibit hyper-reactivity to PMA compared to control neutrophils in terms 
of O2
-
 production (Table 5.2 & Figure 5.2; Chapter 5). 
 
While data using PMA appear to indicate that neutrophils from periodontitis patients do not 
differ from those isolated from control individuals, future studies, investigating NET 
formation in chronic periodontitis in response to physiologically-relevant bacterial stimuli 
associated with disease pathogenesis, are still required.  Such studies might also include 
methods of investigating NET release involving multiple stimuli and/or longer, more relevant 
timescales associated with chronic inflammatory diseases such as periodontitis. For example, 
neutrophils from periodontitis patients exhibit ROS hyper-activity and –reactivity as well as 
hyper-reactivity in terms of  IL-8 release following FcγR and F. nucleatum stimulation 
(section 4.5.2), the combination of which may be relevant to disease pathogenesis given that 
IL-8 is also a recognised NET stimulant (Brinkmann et al. 2004). 
 
Following stimulation, NET release requires large-scale decondensation and unfolding of 
nuclear chromatin by PAD-4 activation (Gyorgy et al. 2006, Wang et al. 2009). Interestingly, 
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whilst PAD-4 has been shown to localise to the tertiary granules of neutrophils (Theilgaard & 
Mӧnch 2005), P. gingivalis is currently the only recognised bacterial species to express a 
PAD enzyme (PPAD; Abdullah et al. 2013). There are currently no known published studies 
demonstrating bacterial PAD-induced NET release, however there is evidence that PPAD is 
important in autoantibody formation and the development and progression of rheumatoid 
arthritis (Wegner et al. 2010, Maresz et al. 2013). Given that P. gingivalis is a widely 
recognised periodontal pathogen and can survive and remain viable intra-cellularly (Li et al. 
2008), it is possible that P. gingivalis may play an active role in histone hypercitrullination 
associated with NET formation (section 1.5.4.6) in the pathogenesis of chronic periodontitis. 
 
Neutrophil extracellular trap release is relevant to chronic periodontitis pathogenesis since 
NETs have been visualised from gingival biopsy samples (Vitkov et al. 2009) and within 
purulent GCF exudates from patients with chronic periodontitis (Krautgartner & Vitkov 
2008). In addition, transmission electron microscopic analyses of pocket epithelium biopsies 
from patients with chronic periodontitis have also shown the presence of NETs (Vitkov et al. 
2010). Interestingly, it has been proposed that NETs can become incorporated as part of the 
biofilm structure (Hong et al. 2009). In addition, bacterial nucleic acids have been shown to 
form the framework for the bacterial community within plaque (Jakubovics & Kolenbrander 
2010), although there are currently no known published studies investigating the role of NET 
DNA in the development of the dental plaque biofilm. Furthermore, in relation to the 
pathogenesis of chronic periodontitis, it is also important to appreciate that viable bacteria 
have defensive strategies to combat NET release, with many periodontal pathogens 
expressing extracellular DNases (Palmer et al. 2012) in order to evade NET entrapment.  
Unsurprisingly, bacteria expressing DNases have been shown to demonstrate increased NET 
survival in vitro, along with increased virulence and disease severity in vivo (Bieter et al. 
2006, Buchanan et al. 2006, Berends et al. 2010). Further investigation as to the role of 
bacterial and host-derived DNases will therefore add to our current understanding of the role 
of NETs in the pathogenesis of chronic periodontitis.  
 
Neutrophil extracellular trap release is an important neutrophil defence strategy that has been 
shown to occur in a number of systemic diseases associated with chronic periodontitis 
including rheumatoid arthritis (de Pablo et al. 2009, Routsias et al. 2011, Nesse et al. 2012, 
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Rohrbach et al. 2012, Thomas et al. 2012), renal disease (Palic et al. 2007, Kessenbrock et al. 
2009), respiratory disease (Aulik et al. 2010, Hemmers et al. 2011, Saffarzadeh et al. 2012), 
systemic lupus erythematosus (Garcia-Romo et al. 2011), cerebrovascular inflammation 
(Allen et al. 2012) and atherosclerosis (Doring et al. 2012). The formation of NETs may have 
the potential to further increase the likelihood of collateral host tissue damage in the 
pathogenesis of chronic periodontitis along with increasing the risk of co-morbidity. For 
example NETs have been shown to release cytokines (IL-1β, IL-8 and TNF-α) from platelets 
and the THP-1 monocyte cell line thereby providing evidence of NETs augmenting local 
cytokine networks within tissues (Keshari et al. 2012). It is therefore possible that NET 
release may have the potential to affect the co-ordination of different inflammatory-immune 
responses and therefore the risk of co-morbidity associated with the pathogenesis of chronic 
periodontitis. Furthermore it may be possible that by their very nature as “traps”, local NET 
release may impede other important neutrophil functions such as the diffusion of cytokines 
and also neutrophil chemotaxis. Ineffective removal or delayed neutrophil tissue transit times 
will increase the likelihood of collateral host tissue damage, irrespective of there being no 
detectable differences in NET release in vitro, especially given the hyper-inflammatory 
neutrophil ROS and cytokine phenotype observed in chronic periodontitis.  
 
 
Neutrophil chemotactic accuracy in chronic periodontitis 
Compared to healthy controls, the chemotaxis data presented in this chapter demonstrate 
significantly impaired neutrophil directional chemotactic accuracy (chemotactic index), 
together with reduced velocity and speed of migration towards fMLP. While the medians for 
these parameters were also lower for patient cells using IL-8 as chemoattractant, the 
differences compared to control cells were not statistically significant using 2-tailed Mann-
Whitney analyses. These data were generated using a novel methodology recently developed 
with colleagues at the University of Glasgow, and more accurately represents chemotaxis 
rather than chemokinesis by depicting individual cell movement in relation to chemoattractant 
sources representative of the complexity of neutrophil migration in the pathogenesis of 
chronic periodontitis.  
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The chemotaxis chamber used in the studies reported in this thesis was recently developed as 
an improved chamber for direct visualisation and characterisation of the complex cell 
migratory dynamics representative of chemotaxis (Muinonen-Martin et al. 2010). Previous 
studies investigating “chemotaxis” have used various transwell methods with filters (typically 
5µm for neutrophil studies) including Boyden chambers (Van Dyke et al. 1980, McMullen et 
al. 1981, Coles et al. 1989, Kinane et al. 1989, Champagne et al. 1998, Meyle & Axmann-
Kremar 1999, Shibata et al. 2001, Dias et al. 2008, Yagi et al. 2009, Mizuno et al. 2011), 
Wilkinson’s method (Bhansali et al. 2013) along with in vivo external skin window testing 
(Palmer et al. 1993). Whilst these methods are useful, they only indirectly measure 
unidirectional movement of cells, which is more representative of chemokinesis (i.e. the 
random migration of cells observed in a homogenous solution of an extracellular signal; 
Wells 2000). In contrast, direct visualisation chambers have the advantage of allowing 
individual, real-time, cell migration to be observed using time-lapse microscopy which is 
more representative of chemotaxis (i.e. the process by which the direction of motile cells is 
biased along a concentration gradient of soluble factors and extracellular signals; Insall 2010). 
   
There are many examples of direct visualisation chemotaxis chambers including the Zigmond 
chamber (Zigmond 1977), the Dunn chamber (Zicha et al. 1991), agarose (Kinane et al. 1989, 
Mouynet et al. 1994, Ibarra et al. 2006, Srinivas et al. 2012), pipette (Gerisch & Keller 1981) 
and microfluidic chamber assays (Li Jeon et al. 2002). The new direct visualisation 
chemotaxis chamber used in this thesis (section 2.2.10; Muinonen-Martin et al. 2010) is 
essentially a refined Dunn chemotaxis chamber with a number of published advantages 
including ease of handling, chemoattractant gradients with defined directions along with the 
ability to use #1.5 cover slips thereby allowing the use of high numerical aperture oil 
immersion lenses (Muinonen-Martin et al. 2010). The concurrent use of time-lapse phase 
contrast microscopy also allows tracking of individual cell migration pathways. The 
chemotactic accuracy data presented in this chapter was generated using novel methodology 
providing both qualitative and quantitative measurements of neutrophil chemotaxis in chronic 
periodontitis compared to healthy controls using a novel direct visualisation chemotaxis 
chamber. 
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In terms of periodontitis, the vast majority of studies investigating chemotaxis (or more 
accurately chemokinesis) have been conducted with juvenile/aggressive periodontitis patients 
(reviewed by Ryder 2010), which is relatively uncommon in comparison to chronic 
periodontitis. To date there are only 8 studies investigating peripheral blood neutrophil 
chemokinesis in chronic periodontitis (Van Dyke et al. 1980, McMullen et al. 1981, Altman 
et al. 1985, Zafiropoulos et al. 1991, Mouynet et al. 1994, Kumar & Prakash 2012, Srinivas et 
al. 2012; Table 1.3). The data presented in this chapter demonstrates impaired directional 
chemotaxis, speed and velocity of movement in patients with chronic periodontitis compared 
to controls in agreement with previous literature demonstrating impaired chemokinesis in 
chronic periodontitis (Van Dyke et al. 1980, Zafiropoulos et al. 1991, Kumar & Prakash 
2012). While reduced chemotactic index, speed and velocity of movement of patient cells 
compared to control neutrophils was only significant in the presence of fMLP, median values 
for these parameters were also lower for patient cells in response to IL-8. This lack of 
significance for the IL-8 data may result from the effectiveness of each chemoattractant, as 
fMLP caused significantly greater neutrophil migration and larger differences between patient 
and control cells compared to IL-8. This is particularly pertinent as, assuming that patient 
cells would have defective chemotactic accuracy relative to healthy control cells, 1-tailed 
Mann-Whitney analysis of the IL-8 data shows significant or nearly significant differences 
between patient and control cells for chemotactic index (P=0.0424), speed (P=0.055) and 
velocity (P=0.0484). Although it could be argued that the 1-tailed assumption is acceptable, 
based on data from the current literature, further assays on larger numbers of cell samples are 
required to confirm that the chemotactic accuracy of patient cells to IL-8 is statistically lower 
than that of cells from healthy controls at the 2-tailed level. 
 
Interestingly, reduced neutrophil chemokinesis has also been shown in patients with chronic 
periodontitis with and without diabetes mellitus (McMullen et al. 1981) as well as smokers 
compared to non-smokers with the same periodontal status (Srinivas et al. 2012). Whilst 
defective chemokinesis is recognised in the pathogenesis of chronic periodontitis, the data 
presented in this chapter is the first study to observe and directly measure individual cell 
migratory patterns more accurately representative of directional chemotactic accuracy in the 
pathogenesis of chronic periodontitis. Furthermore, these data highlight the complexity of 
neutrophil directional migratory patterns compared to data collected using indirect 
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unidirectional assays. In addition, the use of time-lapse videomicroscopy and cell-tracking 
allowed the calculation of overall neutrophil directional chemotactic accuracy, speed and 
velocity of movement in relation to individual cell migratory pathways. 
 
The process of neutrophil recruitment to sites of periodontal inflammation initially involves 
endothelial transmigration via diapedesis, along with local generation of chemotactic signals 
(e.g. IL-8, fMLP) which then facilitate neutrophil migration towards sites of infection. 
Neutrophil chemotaxis involves several stages which to date are relatively poorly understood. 
Bacterial formylpeptides are one of the major chemotactic stimuli (Maney & Walters 2009) 
and neutrophils typically express approximately 55,000 G-protein-coupled formylpeptide 
receptors (FPRs) per cell (Pike & Snyderman 1988, Maney & Walters 2009), which when 
activated initiate a cascade of enzymatic reactions resulting in cell polarisation, orientation 
and migration towards the source of the chemoattractant (Snyderman & Goetzl 1981, Springer 
1995, Katanaev 2001, Yagi et al. 2009). Differences in chemotactic cell surface receptors/co-
receptors for chemotactic stimulants such as glycoprotein 110 or CD38 (Van Dyke et al. 
1990) or single nucleotide polymorphisms of FPRs (Perez et al. 1991, Jones et al. 2003, 
Maney & Walters 2009) or a reduced number of FPR receptors (Meyle & Axmann-Kremar 
1999), and/or subsequent pseudopodia generation may offer an explanation for the impaired 
chemotactic accuracy, speed and velocity of movement in periodontitis neutrophils presented 
in this chapter. A defect in pseudopodia activity could result in morphological differences and 
subsequent ability of neutrophils to migrate and their directional chemotactic accuracy. The 
videomicroscopy images of migrating neutrophils, collected in this study, have since been 
used to undertake preliminary elliptical factor analyses by measuring the greatest distance 
between the cell membranes and the perpendicular distance of migrating neutrophils.  These 
analyses have revealed no significant neutrophil shape differences during chemotaxis towards 
fMLP and IL-8 (Appendix III). Interestingly another factor to consider relates to in vitro 
methodology, since neutrophils have been shown to exhibit a reduced number of FPR 
receptors when measured at 22
o
C (Coles et al. 1989). This is important given that studies of 
neutrophil migration do not appear to control or state the temperature with which experiments 
were performed. All of the chemotaxis assays performed in this chapter were performed at 
18.2-23.2
o
C rather than at an in vivo body temperature of ~37
o
C. However both patient and 
control neutrophils were assayed at the same temperature and therefore any differences due to 
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temperature would need to have differentially affected patient cells if this was to contribute to 
the observed defect in neutrophil directional chemotactic accuracy.  
 
With regards to the pathogenesis of periodontitis, it is interesting that data presented in this 
thesis revealed significantly increased cytokine release from periodontitis neutrophils when 
comparing combined data for all stimuli along with several individual stimulatory conditions 
(Tables 4.2, 4.3). It has previously been hypothesised that the biological basis for altered 
neutrophil chemotaxis may not be solely due to an intrinsic cellular defect, but may also in 
part be due to a quantitatively small but biologically significant elevation in serum cytokine 
concentrations (Meyle 1993, Agarwal et al. 1994). This is especially true with regards to the 
increased neutrophil IL-8 cytokine release presented in this thesis (section 4.5.2), which is a 
widely known chemoattractant and was therefore included as a positive chemoattractant 
within the chemotaxis assay metholodology. It was thought that it may be possible that 
neutrophil IL-8 release could effectively result in auto-recruitment and auto-migratory 
patterns resulting in defective directional chemotaxis in periodontitis neutrophils. However a 
moderate positive correlation between neutrophil IL-8 release and chemotactic index towards 
fMLP was observed suggestive that neutrophil IL-8 release may in fact, albeit minimally, 
assist with neutrophil chemotaxis towards bacterial-derived chemoattractants. Another factor 
to consider is that neutrophil activation and subsequent IL-8 release is more likely to occur 
when neutrophils are already at sites of bacterial infiltration and inflammation and is therefore 
more likely to affect surrounding neutrophil chemotaxis though cytokine diffusion rather than 
individual neutrophil IL-8 release and chemotaxis per se. That the correlation was more 
noticeable for fMLP, compared to IL-8 as chemoattractants, may possibly relate to the greater 
chemotactic potential of fMLP, with greater chemotactic index, speed and velocity in the 
presence of fMLP compared to IL-8 presented in this chapter. As such, it is possible that 
neutrophils predominantly migrate towards bacterial components such as fMLP rather than 
host-derived factors, with migrating neutrophils concurrently releasing IL-8 which may 
additionally assist with the overall neutrophil migratory pattern towards the chemoattractant 
source as part of the inflammatory-immune response. Interestingly P. gingivalis has also been 
shown to secrete degradative enzymes (gingipains) that significantly enhance the chemotactic 
activity of IL-877aa released from non-immune cells, but decrease the chemotactic activity of 
IL-872aa released from immune cells, thereby suggesting that during periodontitis secreted 
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gingipains may differentially affect neutrophil chemotaxis in response to IL-8 depending on 
the cellular source of the cytokine (Dias et al. 2008), and this is likely to be important in the 
pathogenesis of chronic periodontitis. 
  
Overall, the NET and chemotaxis data presented in this chapter generated using recently 
developed assays add to our current understanding of the pathogenesis of chronic 
periodontitis. This is the first study to quantify NET release, with a lack of detectable 
differences in unstimulated or PMA- and HOCl-stimulated NET release between patient and 
control neutrophils. In addition, these data more accurately depict reduced chemotactic 
accuracy of peripheral blood neutrophils in chronic periodontitis. Reduced chemotactic 
accuracy of a hyper-inflammatory neutrophil phenotype will increase the likelihood of 
collateral host tissue damage associated with the pathogenesis of chronic periodontitis.  
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CHAPTER 7 
 RESULTS & DISCUSSION 
 
C-reactive protein characterisation & effects of buffer 
constituents on chemiluminescence and the neutrophil respiratory 
burst 
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7.1  INTRODUCTION 
C-reactive protein (CRP) from human plasma was supplied commercially (Sigma C4063) as 
pentameric CRP in 20mM Tris, pH 7.8-8.2, containing 280mM sodium chloride, 5mM 
calcium chloride and 0.1% sodium azide as a preservative. The product specification stated a 
>90% purity determined by SDS electrophoresis. Prior to determining the effects of CRP on 
neutrophil ROS generation and release (Chapter 8) the commercial CRP samples were 
independently characterised to ascertain molecular form and the presence of contaminants 
(section 7.2). The effects of CRP buffer constituents upon cell-free chemiluminescence 
signals (section 7.4) and neutrophil ROS generation (section 7.5) were also measured. In 
addition, the antioxidant capacity of CRP was determined for the first time (section 7.7) as 
this could influence subsequent data interpretation of the effects of CRP upon ex-vivo 
neutrophil ROS generation and release presented in Chapter 8. Furthermore, the molecular 
form of CRP was determined to confirm the presence of soluble pentameric CRP rather than 
altered or modified CRP (mCRP). The latter is insoluble, antigenically distinct and naturally 
expressed at vascular sites, also having been associated with vascular damage and 
cardiovascular disease (Diehl et al. 2000).  
 
7.2 C-REACTIVE PROTEIN CHARACTERISATION 
The purity and molecular weight of the commercial CRP samples were determined using 
liquid chromatography tandem mass spectrometry (section 2.2.11.3) and analytical 
ultracentrifugation (AUC; section 2.2.11.4).  
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7.2.1  Liquid chromatography tandem mass spectrometry 
Analysis of protein peptide sequences confirmed the predominant presence of isoform 1 CRP 
(>98%) plus 21 microcontaminant proteins, 11 of which were derived from epidermis or 
saliva (Table 7.1).  These latter components are commonly present in proteins purified from 
biological samples due to the extensive laboratory processes required for purification. Isoform 
1 of CRP was characterised by 23 peptides, which were consistent with being derived from 
monomeric CRP units of molecular weight 25,023Da containing 224 amino acids. The 
intensity of the peptide precursor ions identified from the CRP samples were compared to 
those of peptide ions from contaminants.  Contaminant intensity was <2% of the CRP signal, 
based upon intensity analyses of the major peptides, demonstrating CRP purity was >98% 
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Accession # Coverage # Peptides #AAs MW [Da] Score Description 
IPI:IPI00022389.1 29.02 23 224 25023 621.96 Isoform 1 of C-reactive protein 
IPI:IPI00009865.4 23.29 12 584 58792 465.21 Keratin, type I cytoskeletal 10                                                      * 
IPI:IPI00220327.4 17.24 11 644 65999 376.98 Keratin, type II cytoskeletal 1                                                       * 
IPI:CON_00745872.2 12.15 7 609 69321 245.90 Isoform 1 of Serum albumin precursor                                        * 
IPI:CON_00021304.1 5.43 3 645 65825 142.01 Keratin, type II cytoskeletal 2 epidermal                                      * 
IPI:IPI00853045.1 15.81 2 234 25682 135.41 Anti-RhD monoclonal T125 kappa light chain 
IPI:CON_00019359.3 4.65 2 623 62092 122.33 Keratin, type I cytoskeletal 9                                                        * 
PROT:P00761 16.45 4 231 24394 119.36 Trypsin - Sus scrofa (Pig). - [TRYP_PIG] 
IPI:CON_00714876.1 5.45 3 606 63127 105.07 ENSEMBL:ENSBTAP00000038253 (Bos taurus) 63 kDa protein 
IPI:IPI00922744.1 4.24 1 354 38114 100.77 Complement protein C4B frameshift mutant (Fragment)             * 
IPI:IPI00646265.1 7.08 1 226 25554 99.59 Amylase, alpha 1B                                                                       * 
IPI:IPI00830047.2 17.99 2 139 14669 75.34 IGL@ protein 
IPI:IPI00789295.1 14.71 1 102 11154 71.91 11 kDa protein 
IPI:IPI00293665.9 3.37 2 564 60030 70.89 Keratin, type II cytoskeletal 6B                                                     * 
IPI:IPI00431645.1 4.27 1 281 31362 61.95 HP protein 
IPI:IPI00442911.1 6.73 1 208 22212 59.23 CDNA FLJ26266 fis, clone DMC05613 
IPI:IPI00382804.1 4.85 1 227 24181 56.25 EEF1A protein (Fragment) 
IPI:IPI00397801.4 0.50 1 2391 247928 47.81 Filaggrin-2                                                                                    * 
IPI:IPI00871949.1 4.97 1 965 102093 43.85 PREDICTED: filaggrin variant                                                      * 
IPI:IPI00027547.2 10.00 1 110 11277 42.70 Dermcidin                                                                                     * 
IPI:IPI00791348.1 5.73 1 192 19583 42.22 20 kDa protein 
IPI:IPI00514530.5 5.54 1 289 32254 41.59 Putative uncharacterized protein ACTA1 
 
Table 7.1. Liquid chromatography tandem mass spectrometry MS/MS analysis of commercial CRP sample (Sigma C4063). 
Protein peptide sequences confirm the predominant presence (>98%) of isoform 1 CRP plus 21 microcontaminant proteins, 11 of which 
are derived from epidermis or saliva (*). 
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7.2.2 Analytical ultracentrifugation 
Analytical ultracentrifugation analysis of the commercial CRP sample, under non-dissociating 
conditions, revealed a sedimentation coefficient of ~6.2S consistent with a molecular mass of 
~117kDa and corresponding to native, pentameric CRP (Okemefuna et al. 2010; Figure 7.1).  
 
 
 
 
Figure 7.1. A SEDFIT c(M) deconvolution of sedimentation velocity analytical 
ultracentrifugation data collected on a dialysed and filtered commercial CRP sample. 
Please note the presence of 1 peak corresponding to ~117kDa consistent with pentameric 
CRP. Data was collected in triplicate on a Beckman XL-I proteome lab at 20,000rpm with 
particle migration monitored by scanning the cells at 280nm.  
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7.3 ANALYTICAL ULTRACENTRIFUGATION OF UNHEATED AND HEATED 
IgG SAMPLES 
The formation of heat-aggregated IgG (section 2.2.5.1) was confirmed by analytical 
ultracentrifugation prior to its inclusion as a stimulus in the ROS assays that aimed to 
investigate the effects of CRP on the neutrophil respiratory burst presented in Chapter 8. 
Analytical ultracentrifugation of unheated IgG samples (freeze-dried IgG purified from 
human serum (Sigma I4506), reconstituted in 150mM NaCl) revealed two bands with  
sedimentation coefficients of ~6.5S (166kDa; IgG monomer) and 9.8S (300kDa; IgG dimer) 
corresponding to ~89% and ~11% of the protein analysed. Heated IgG (63
o
C for 60 minutes) 
also gave two bands with sedimentation coefficients of ~6.1S (134kDa; monomer-like) and 
~10S (300kDa; dimer) but these only accounted for ~35% and ~5% of the protein sedimented.  
Approximately 60% of the heated IgG sample failed to sediment indicating a molecular 
weight of >500kDa consistent with the presence of IgG aggregates (Figure 7.2).  
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Figure 7.2. A SEDFIT c(M) deconvolution of sedimentation velocity analytical 
ultracentrifugation data collected on unheated and heated IgG samples. Unheated IgG 
revealed 2 peaks (~6.5S;(166kDa; monomer & 9.8S; (300kDa; dimer) corresponding to 
~100% of the protein analysed. Heated IgG also gave 2 peaks (~6.1S; 134kDa; monomer-
like & ~10S; 300kDa; dimer) that accounted for ~40% of the protein sedimented.  
Approximately 60% of the heated IgG sample failed to sediment indicating a molecular 
weight of >500kDa. Data was collected in triplicate on a Beckman XL-I proteome lab at 
20,000rpm with particle migration monitored by scanning the cells at 280nm. 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0 100000 200000 300000 400000 500000
c
(M
) 
Mass (Da) 
 IgG 
- - - - - IgG heated 63
o
C 
for 60mins 
 181 
7.4 EFFECT OF TRIS BUFFER ON LUMINOL, ISOLUMINOL & LUCIGENIN-
ENHANCED CHEMILUMINESCENCE 
The ability of Tris buffer, equivalent to that in which the commercial CRP was supplied and 
stored but without sodium azide, -to directly cause chemiluminescence (section 2.2.11.5), or 
alter the chemiluminescence signal generated following addition of H2O2, was determined  for 
luminol, isoluminol and lucigenin test systems (section 2.2.11.6), as described below. 
 
7.4.1 Direct effect of Tris buffer on luminol, isoluminol and lucigenin-enhanced 
chemiluminescence 
There were no discernable direct effects of Tris buffer on luminol, isoluminol or lucigenin-
enhanced chemiluminescence at the concentrations tested (Figure 7.3), other than occasional 
peaks of light output resulting from the initial minor environmental disturbance due to the 
injection of Tris buffer.  
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Figures 7.3. Lack of a direct effect of 0.25, 0.5, 1, 2, 4, 10 & 25mM Tris buffer on 
luminol, isoluminol and lucigenin chemiluminescence (cell-free system). Light output 
was monitored before (2s), during and after (10s) automatic injection of freshly prepared Tris 
buffer diluted in distilled water. Data presented as mean relative light units (RLU) and is 
representative of a single experiment performed in quadruplicate. Please note the occasional 
“peak” in light output at 2s due to the minor environmental disturbance caused by the 
injection of Tris buffer. 
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7.4.2 Effect of Tris buffer on H2O2-induced luminol, isoluminol and lucigenin-
enhanced chemiluminescence 
The presence of Tris buffer resulted in significant changes in H2O2-induced luminol, 
isoluminol and lucigenin-enhanced chemiluminescence (Friedman P<0.0001). Addition of all 
tested concentrations of Tris buffer (0.25-25mM) resulted in significant increases in luminol, 
isoluminol and lucigenin enhanced chemiluminescence (Dunn’s multiple comparison’s test 
P<0.05; Figure 7.4).  The one exception to this was 2mM Tris, which had no significant effect 
on  isoluminol and lucigenin chemiluminescence and had less effect on luminol light emission 
than 0.25mM Tris, suggesting that there may have been an error in its preparation . Moderate 
and strong significant positive correlations were observed between Tris buffer concentration 
(including the 2mM Tris data) and H2O2-induced chemiluminescence (Figure 7.5).   
 
The addition of 1mM Tris, equivalent to that used in the enhanced chemiluminescence assays 
to determine the effects of CRP on neutrophil ROS generation and release (section 2.2.11.8; 
Chapter 8), resulted in significant increases in chemiluminescence compared to PBS control 
in the presence of luminol (17,957 & 8,343RLU; 215.2%; P<0.001), isoluminol (2,172 & 
750RLU; 289.6%, P<0.001) and lucigenin (463 & 54RLU; 857.4%, P<0.001).   
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Figure 7.4. Enhancement of hydrogen peroxide induced light output caused by the 
presence of 0.25, 0.5, 1, 2, 4, 10 and 25mM Tris buffer using luminol, isoluminol and 
lucigenin chemiluminescence substrates (cell-free system). Light output was monitored 
before (2s), during and after (10s) automatic injection of freshly prepared H2O2 solution. Data 
presented as mean relative light units (RLU) and representative of a single experiment 
performed in sextuplicate. 
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Figure 7.5. Correlations between Tris buffer concentration and maximal H2O2-induced 
luminol, isoluminol and lucigenin enhanced chemiluminescence. Data representative of 
a single experiment performed in sextuplicate.  
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7.5 EFFECT OF SODIUM AZIDE ON NEUTROPHIL ROS GENERATION 
The commercial CRP contained 0.1% (1mg/ml) sodium azide (NaN3) as a preservative, which 
is known to inhibit MPO, catalase and HRP activities (Ortiz de Montellano et al. 1988, 
VanUffelen et al. 1998). Concentrations of sodium azide (0.05, 0.5 and 1.5µg/ml) equivalent 
to those that would be present in the neutrophil enhanced-chemiluminescence assays when 
examining the effects of 0.1, 1 and 3µg/ml CRP were analysed to determine their potential 
effects on neutrophil ROS generation and release, as described below. 
 
7.5.1 Effect of sodium azide on unstimulated neutrophil ROS generation 
Addition of sodium azide significantly altered neutrophil ROS generation determined by 
luminol (P=0.0012) and isoluminol (P=0.0157) chemiluminescence that detect predominantly 
intra and extracellular HOCl respectively (Figure 7.6). 1.5µg/ml and 0.5µg/ml sodium azide 
significantly reduced neutrophil ROS generation detected by luminol compared to vehicle 
control (P<0.05). In addition, 1.5µg/ml sodium azide significantly reduced neutrophil 
extracellular ROS detected by isoluminol (P<0.05). In contrast, addition of sodium azide did 
not significantly affect neutrophil extracellular O2
-
 detected by lucigenin at the concentrations 
tested (P=0.07). 
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Figure 7.6. Effect of sodium azide on unstimulated neutrophil ROS generation 
detected by luminol, isoluminol and lucigenin enhanced chemiluminescence. Data 
presented as mean peak relative light units (RLU) + standard deviation, and representative of 
a single experiment performed in octuplicate. P-values for comparisons with buffer/0µg/ml 
azide-treated cells determined by Bonferroni multiple comparisons test, *P<0.05, ***P<0.001. 
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7.5.2 Effect of sodium azide on stimulated neutrophil ROS generation 
Neutrophil stimulation was performed following pre-incubation and in the presence of sodium 
azide. Data is representative of a single experiment performed in triplicate for opsonised S. 
aureus and F. nucleatum, and in duplicate for PMA stimulation. Given the obvious effects, 
despite the limitations of the data, indicative statistical analyses were performed. 
 
Sodium azide significantly reduced, in a dose-dependent manner, PMA, FcγR and TLR 
stimulated neutrophil ROS generation detected by luminol chemiluminescence detecting 
predominantly intracellular HOCl (Figure 7.7). Mean levels of luminol chemiluminescence 
following FcγR and TLR stimulation was significantly lower in the presence of all tested 
concentrations of sodium azide (0.05-1.5µg/ml; P<0.01) with 71.5% and 84.8% reductions in 
the presence of 1.5µg/ml sodium azide respectively. Similarly, 0.5µg/ml and 1.5µg/ml sodium 
azide significantly reduced PMA stimulated luminol-detected intracellular HOCl generation 
by 58.2% and 69.0% respectively (P<0.01). 
 
There were no significant differences in FcγR stimulated neutrophil extracellular HOCl 
release detected by isoluminol in the presence of sodium azide at the concentrations tested 
(0.05-1.5µg/ml; Figure 7.8). Furthermore, whilst the mean PMA stimulated neutrophil 
extracellular ROS detected by isoluminol and lucigenin was reduced in a dose-dependent 
manner in the presence of sodium azide, this was not statistically significant (Figures 7.8 & 
7.9). Fusobacterium nucleatum stimulated isoluminol-detectable extracellular HOCl showed a 
mean decrease of 45.8% due to sodium azide at all concentrations tested (P<0.001 for 0.05-
1.5µg/ml). In contrast, FcγR and TLR stimulated extracellular O2
-
 release detected by 
lucigenin significantly differed in the presence of sodium azide, plateauing with 82.8% and 
55.8% increases in the presence of 0.5µg/ml sodium azide respectively (P<0.001; Figure 7.9). 
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Figure 7.7. Luminol-detected neutrophil ROS (detected predominantly as intracellular 
HOCl) generation following 30 minute pre-incubation with sodium azide and 
subsequent stimulation with PMA (5nM), opsonised S. aureus (MOI 300:1) and F. 
nucleatum (MOI 100:1). Data presented as mean peak relative light units (RLU) + standard 
deviation  and representative of a single experiment performed in triplicate for opsonised S. 
aureus and F. nucleatum, and in duplicate for PMA stimulation. P-values for comparisons 
with buffer/0µg/ml azide-treated cells determined by Bonferroni multiple comparisons test: 
**P<0.01, ***P<0.001. 
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Figure 7.8. Isoluminol-detected neutrophil ROS (detected predominantly as 
extracellular HOCl) generation following 30 minute pre-incubation with sodium azide 
and subsequent stimulation with PMA (5nM), opsonised S. aureus (MOI 300:1) and F. 
nucleatum (MOI 100:1). Data presented as mean peak relative light units (RLU) + standard 
deviation and and representative of a single experiment performed in triplicate for opsonised 
S. aureus and F. nucleatum, and in duplicate for PMA stimulation. P-values for comparisons 
with buffer/0µg/ml azide-treated cells determined by Bonferroni multiple comparisons test: 
**P<0.01, ***P<0.001. 
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Figure 7.9.  Lucigenin-detected neutrophil ROS (detected predominantly as 
extracellular superoxide) generation following 30 minute pre-incubation with sodium 
azide and subsequent stimulation with PMA (5nM), opsonised S. aureus (MOI 300:1) 
and F. nucleatum (MOI 100:1). Data presented as mean peak relative light units (RLU) + 
standard deviation and and representative of a single experiment performed in triplicate for 
opsonised S. aureus and F. nucleatum, and in duplicate for PMA stimulation. P-values for 
comparisons with buffer/0µg/ml azide-treated cells determined by Bonferroni multiple 
comparisons test: *P<0.05, **P<0.01, ***P<0.001. 
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7.6 NEUTROPHIL VIABILITY IN THE PRESENCE OF CRP CONTAINING 
AZIDE 
Addition of 1 and 6µg/ml commercial CRP (i.e. containing 0.5 and 3µg/ml sodium azide) 
significantly affected neutrophil viability following a 30 minute incubation (P=0.0007; Table 
7.2). Neutrophil viability was significantly reduced by 8% and 5% in the presence of 1µg/ml 
and 6µg/ml commercial CRP respectively (P<0.01).  
 
 
RLU Buffer 
CRP (µg/ml) 
1 6 
Mean 283886 262293 268226 
SD 14585 14559 6364 
Repeated measures ANOVA 
P=0.0007       
Bonferroni multiple comparisons test 
P<0.001       
P<0.01       
ns       
 
Table 7.2. Neutrophil viability following 30 minute incubation with 1 and 6µg/ml CRP 
determined using Cell-Titre Glo. Data presented as relative light units (RLU; mean and 
standard deviation), and representative of 2 experiments performed in triplicate. P-values 
calculated using repeated measures ANOVA followed by Bonferroni multiple comparisons 
test (groups compared in table= ; ns = not significant).   
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7.7 ANTIOXIDANT CAPACITY OF CRP 
Whilst in the total antioxidant capacity assay employed the recovery time to T10% is 
traditionally used as the index for calculating antioxidant capacity (Brock et al. 2004; Chapple 
et al. 2007), light output was not inhibited sufficiently to obtain a T10%. Therefore the 
potential antioxidant capacity of azide-free CRP was calculated as the percentage reduction in 
light output compared with vehicle control (azide-free Tris buffer; section 2.2.11.1). 0.2µg/ml 
and 4µg/ml azide-free CRP resulted in a 0.45+2.5% and 0.78+1.08% reduction in light output 
respectively (Figure 7.10).  
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Figure 7.10. Typical recovery curves after addition of vehicle control (sodium azide-
free Tris buffer; (A) and 4µg/ml dialysed CRP (B) in the chemiluminescence assay to 
determine antioxidant capacity. 
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7.8 DISCUSSION 
The experiments performed to characterise the commercial CRP samples as part of this 
chapter confirmed the presence of pentameric CRP using analytical ultracentrifugation along 
with 98% sample purity determined by mass spectrometry. Whilst Tris buffer did not have 
any direct effect on luminol, isoluminol and lucigenin chemiluminescence, significant 
increases were detected with regards to H2O2-induced chemiluminescence using a cell-free 
system. In addition, equivalent concentrations of sodium azide to those found in the 
commercial CRP samples had a number of significant effects on unstimulated and FcγR, TLR 
and PMA stimulated neutrophil ROS generation and release. Furthermore, pre-incubation 
with commercial CRP (1 & 6g/ml) containing sodium azide (0.5 and 3g/ml) caused a small 
but significant reduction in neutrophil viability. 
 
Human CRP used for in-vitro studies may be obtained from a number of different sources 
including recombinant (Tanaka et al. 2002, Pepys et al. 2005, Fujii et al. 2006), malignant 
ascetic fluid (Blizniukov et al. 2003, Clapp et al. 2005, Pepys et al. 2005), pleural fluids (Du 
Clos et al. 1991, Zeller & Sullivan 1992, Stein et al. 2000) and commercial samples (Khreiss 
et al. 2002, 2005, Verma et al. 2002, Hart et al. 2005, Biro et al. 2007). CRP samples are 
occasionally documented as being characterised before use in in-vitro methodology, however 
the majority of studies do not publish details of protein characterisation or buffer contents 
which is important regarding the accuracy of in-vitro methodology and also when comparing 
datasets. Indeed, it has been postulated that different buffer constituents may be responsible 
for producing artefactual data as a result of CRP buffer constituents rather than due to the 
CRP itself (Ginsburg et al. 1993, Zouki et al. 2001, Khreiss et al. 2002, 2005, Fujii et al. 
2006, Freitas et al. 2009). 
 
It is therefore disappointing that many authors do not completely reveal the composition 
and/or concentrations of incubation buffers when publishing in vitro methodology and this is 
not solely limited to studying the effects of CRP. This is a potentially very important issue 
especially when studying respiratory burst activity since it has been known for several years 
that components of buffer media alone have the potential to influence the chemiluminescent 
signals independently of the presence and number of cells included within the assay (Nelson 
et al. 1977). Therefore all subsequent CRP experiments performed within this thesis (Chapter 
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8) were controlled within the assay itself with the addition of CRP samples alongside dialysed 
buffer minus CRP as vehicle control, given that Tris buffer alone increases the H2O2-induced 
chemiluminescence signal as presented in this chapter. The CRP samples used in this thesis 
were commercially supplied in the presence of a Tris buffer (Bleich & Schmartz 1966) 
containing 280mM sodium chloride, 5mM calcium chloride and 0.1% sodium azide as a 
preservative. Whilst the addition of Tris buffer minus sodium azide did not directly affect the 
luminol, isoluminol and lucigenin induced chemiluminescent signal using a cell-free system, 
in agreement with studies investigating the role of buffers on neutrophil chemiluminescence 
(Ginsburg et al. 1993), it did cause a small but noticeable increase in H2O2-induced 
chemiluminscent signal. Furthermore, a significant moderate positive correlation between Tris 
buffer concentration and H2O2-induced luminol, isoluminol and lucigenin chemiluminescence 
were demonstrated. 
 
Along with the effects of buffer constituents, there is emerging awareness of the use of 
commercial sample preparations for in vitro studies, with many of these samples both 
incompletely defined and/or subsequently found to contain additional biologically active 
agents such as sodium azide which is a commonly used sample preservative. The presence of 
concurrent sodium azide is of particular interest and importance when investigating neutrophil 
biology given that it is known to inhibit important neutrophil enzymes including MPO and 
catalase activity (Ortiz de Montellano et al. 1988, Van Uffelen et al. 1998). The data 
presented in this chapter demonstrates that sodium azide inhibits both unstimulated as well as 
FcγR and TLR stimulated neutrophil ROS generation in agreement with previous studies 
investigating neutrophil luminol chemiluminescent responses (Bednar et al. 1996, Hasegawa 
et al. 1997, Hitzfeld et al. 1997, Razumovitch et al. 2004). Furthermore, luminol 
chemiluminescence has been shown to be completely inhibited by 0.3mM sodium azide 
(Razumovitch et al. 2004), and this is likely to be due to reduced conversion of H2O2 to HOCl 
following inhibition of neutrophil MPO by sodium azide, although there are currently no 
known studies confirming the ability of sodium azide to traverse cell membranes of viable 
neutrophils. In contrast to luminol and isoluminol chemiluminescence, the data presented in 
this chapter also demonstrated greater FcγR and TLR, but with no significant differences in 
PMA stimulated lucigenin-detected neutrophil O2
-
 release. This is in agreement with previous 
studies showing that sodium azide enhances lucigenin chemiluminescence, although with a 
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differential effect following PMA stimulation (Hasegawa et al. 1997, Allen 1986). It is 
possible that the elevated lucigenin-enhanced chemiluminescence reflects increased 
accumulation of O2
-
 due to blockade of O2
-
 and H2O2 consumption by sodium azide inhibition 
of MPO thereby leading to increased extracellular O2
-
 release (Figure 5.5). The contrasting, 
albeit not significant, reduction in PMA stimulated O2
-
 release may relate to a previously 
reported increase in PMA-activated neutrophil apoptosis in the presence of sodium azide 
(Lundqvist-Gustafsson & Bengtsson 1999). 
 
It is therefore possible that additional sample constituents have biological effects on 
neutrophil function and interestingly CRP-induced in vitro vasorelaxation is now thought to 
be artefactual and caused by the concurrent presence of sodium azide (van den Berg et al. 
2004, Liu et al. 2005, Swafford et al. 2005). It has also been reported that the biological 
effects of commercial CRP preparations could be completely abrogated by dialysis to remove 
contaminating sodium azide, and also that the inclusion of azide at equivalent concentrations 
completely reinstated all of the commercial preparation effects in vitro (Liu et al. 2005). In 
addition, many of the proinflammatory, proapoptotic, antiproliferative, antimigratory and 
antiangiogenic effects attributed to CRP have similarly been associated with the presence of 
sodium azide and/or contaminating LPS (Schwedler et al. 2006, Liu et al. 2005, Taylor et al. 
2005, Yeh 2005). Whilst a number of studies include the removal of sodium azide by dialysis 
or specifically state buffers to be free of sodium azide (Hart et al. 2005, Khreiss et al. 2005, 
Pepys et al. 2005, Fujii et al. 2006), others, using commercial CRP samples, do not address 
the problems associated with the presence of sodium azide. The data presented in this chapter 
is in agreement with Liu and co-workers (2005) who suggest that future studies with 
commercial CRP should be performed following CRP separation from sodium azide, 
authentication of biological findings with use of azide concentrations equal to those found in 
commercial preparation, or alternatively, the use of a recombinant CRP source that should be 
sterile and not require addition of preservative. 
 
Many studies investigating CRP do not test its effect on cell viability, particularly when using 
concentrations that are towards the higher end of those that are physiologically relevant. This 
is important given that any observed changes in neutrophil function in the presence of CRP 
may otherwise be due to cell necrosis or apoptosis, rather than an alteration in viable cell 
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physiology. However, the data presented in this thesis demonstrated that <6µg/ml CRP had a 
negligible effect on neutrophil viability in agreement with a previous study showing that 
<50µg/ml CRP has no effect of neutrophil viability measured by trypan blue dye exclusion 
(Zhong et al. 1998). 
 
The antioxidant effects of physiologically-relevant concentrations of CRP were also 
investigated and presented in this chapter. Given the published reports investigating the 
effects of CRP on the respiratory burst, it is interesting that there are currently no known 
published studies investigating the antioxidant potential of CRP. The CRP antioxidant data 
presented in this thesis therefore represents novel data that is relevant to data interpretation 
when investigating the effects of CRP on neutrophil ROS generation presented in Chapter 8. 
The data confirms that the antioxidant capacity of CRP, as measured using this validated 
assay is negligible and unlikely to have any significant in vivo relevance in itself.  
 
Overall, the data presented in this chapter confirmed the presence of pentameric CRP within 
the commercial CRP sample, along with determining the effect of CRP on neutrophil viability 
and antioxidant potential for the first time. Furthermore, the data presented in this Chapter 
demonstrate the importance of characterising protein content, and concurrent buffer 
constituents with in-vitro methodologies. For example, the effects of Tris buffer on cell-free 
H2O2-induced chemiluminescence demonstrate the importance of incorporating a vehicle 
control with in vitro methodology. In addition, the effects of equivalent concentrations of 
sodium azide highlighted the need for sample dialysis (section 2.2.11.2) prior to investigating 
the effects of CRP on the neutrophil respiratory burst presented in Chapter 8.  
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CHAPTER 8 
 RESULTS & DISCUSSION 
 
Effects of C-reactive protein on the neutrophil respiratory burst 
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8.1 INTRODUCTION 
The effects of physiologically-relevant concentrations of CRP on the neutrophil respiratory 
burst were determined using chemiluminescence methods. Having demonstrated that some 
components within the buffer in which commercial CRP is supplied alter chemiluminescence 
assays, CRP samples were extensively dialysed to remove sodium azide and filter-sterilised 
(section 2.2.11.2).  Furthermore, all CRP assays included vehicle controls containing identical 
amounts of dialysed Tris buffer. The C-reactive protein concentrations tested were chosen to 
include the systemic concentrations identified from the patient volunteers diagnosed with 
chronic periodontitis recruited as part of the longitudinal interventional case controlled study 
(section 3.2) and those associated with cardiovascular disease risk (Ridker et al. 2005). The 
aim was to contribute to our current understanding of neutrophil function in relation to 
systemic inflammatory markers that are associated with both chronic periodontitis and 
systemic disease.  
 
8.2 EFFECTS OF CRP ON NEUTROPHIL ROS GENERATION 
Unstimulated and stimulated neutrophil ROS generation was determined  in the presence and 
absence of pentameric CRP (1, 3 and 10µg/ml)  using luminol, isoluminol and lucigenin-
enhanced chemiluminescence (section 2.2.11.8).  
 
8.2.1 Unstimulated ROS generation in the presence of CRP 
Addition of 1, 3 and 10µg/ml CRP significantly altered neutrophil ROS generation detected 
by all 3 chemiluminescent substrates in a dose-dependent manner compared to vehicle control 
(20mM Tris buffer; P<0.0006; Figure 8.1). 10µg/ml CRP significantly reduced neutrophil 
ROS generation detected by luminol, isoluminol and lucigenin-enhanced chemiluminescence 
compared to vehicle control (P<0.01). The mean percentage reductions in unstimulated ROS 
with 10µg/ml CRP were 41.8%, 11.9% and 28.8% for luminol, isoluminol and lucigenin 
respectively. In addition, 3µg/ml CRP also significantly reduced neutrophil intracellular 
HOCl and extracellular O2
-
 release detected by luminol and lucigenin respectively (P<0.05; 
Figures 8.1).     
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Figure 8.1. The effect of CRP on unstimulated ROS generation detected by luminol, 
isoluminol and lucigenin. Peak chemiluminescence (median, interquartile range, 
maximum and minimum RLU; n=14) attained during the 30 minutes after addition of 
CRP (1, 3 & 10µg/ml) or vehicle control (0µg/ml CRP). Significant differences from vehicle 
control-treated cells determined using Dunn’s multiple comparisons test: *P<0.05, **P<0.01, 
***P<0.001. 
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8.2.2 Confirmation of increased neutrophil ROS generation after neutrophil FcγR and 
TLR-stimulation. 
Neutrophils were stimulated after an initial 30 minute baseline resting period and an 
additional 30 minutes following addition of dialysed Tris buffer (CRP vehicle control). 
Addition of IgG-opsonised S. aureus (MOI 300:1), F. nucleatum (MOI 100:1) and aggregated 
IgG (600µg/ml final well concentration) significantly increased neutrophil ROS generation 
detected by all 3 chemiluminescent substrates (P=0.0001; Figure 8.2). Stimulation of luminol 
detectable ROS generation was significantly higher following addition of opsonised S. aureus 
compared to aggregated IgG (P<0.05) and, whereas median levels of isoluminol and lucigenin 
detectable ROS release were also greater after stimulation with opsonised S. aureus, the 
difference between these two FcR stimuli were not statistically significant.  
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Figure 8.2. Neutrophil ROS generation and release after a 30 minute pre-incubation 
with Tris buffer (CRP vehicle control) and subsequent stimulation with opsonised S. 
aureus (ops Sa; MOI 300:1), F. nucleatum (Fn; MOI 100:1) and aggregated IgG (aggIgG; 
600µg/ml final well concentration) detected by luminol, isoluminol and lucigenin. 
Significant differences from baseline chemiluminescence determined using Dunn’s multiple 
comparisons test: *P<0.05, **P<0.01, ***P<0.001. 
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8.2.3 Stimulated ROS generation in the presence of CRP 
Neutrophil stimulation was performed following a 30 minute baseline resting period and a 30 
minute pre-incubation with CRP. There was no clear relationship between FcγR-stimulated 
neutrophil ROS generation in the presence of CRP detected by luminol and isoluminol 
chemiluminescence (Figures 8.3 & 8.4). Whilst median levels of luminol-detected 
intracellular HOCl following stimulation with IgG-opsonised S. aureus were higher in the 
presence of CRP, this was only significant for 3µg/ml CRP, and was not present following 
stimulation with aggregated IgG. In contrast, a small dose-dependent decrease in neutrophil 
O2
-
 release detected by lucigenin was observed, which was significant in the presence of 
10µg/ml CRP following FcγR-stimulation with both IgG-opsonised S. aureus (13.9% 
reduction; P<0.001) and aggregated IgG (17.9% reduction; P<0.05).  
 
F. nucleatum TLR-stimulated neutrophil ROS generation was significantly altered in the 
presence of CRP as detected by all 3 chemiluminescent substrates (P<0.0359; Figures 8.3, 8.4 
& 8.5). There was a small dose-dependent decrease in TLR-stimulated neutrophil intracellular 
HOCl detected by luminol that was significant in the presence of 10µg/ml CRP (13.4% 
reduction; P<0.05). However, the predominant effect of CRP related to TLR-stimulated 
extracellular ROS detected by isoluminol and lucigenin (Figures 8.4 & 8.5). There was a 
significant reduction in TLR-stimulated extracellular ROS detected by isoluminol in the 
presence of 3 and 10µg/ml CRP reducing H2O2/HOCl release by 22.5% and 19.2% 
respectively (P<0.01; Figure 8.4). In contrast, CRP increased TLR-stimulated neutrophil O2
-
 
release detected by lucigenin at all concentrations tested, with a mean increase of 21.5% 
(P<0.05 for 1 and 3µg/ml CRP; P<0.001 for 10µg/ml CRP; Figure 8.5).  
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Figure 8.3. Luminol-detected neutrophil ROS (detected predominantly as intracellular 
HOCl) generation following 30 minute pre-incubation with CRP and subsequent 
stimulation with IgG-opsonised S. aureus (MOI 300:1), F. nucleatum (MOI 100:1) and 
aggregated IgG (600µg/ml final well concentration). Peak chemiluminescence (median, 
interquartile range, maximum and minimum RLU; n=14) attained after stimulation. 
Significant differences from vehicle control-treated cells determined using Dunn’s multiple 
comparisons test: *P<0.05. 
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Figure 8.4. Isoluminol-detected neutrophil ROS (detected predominantly as 
extracellular HOCl) generation following 30 minute pre-incubation with CRP and 
subsequent stimulation with IgG-opsonised S. aureus (MOI 300:1), F. nucleatum (MOI 
100:1) and aggregated IgG (600µg/ml final well concentration). Peak 
chemiluminescence (median, interquartile range, maximum and minimum RLU; n=14) 
attained after stimulation. Significant differences from vehicle control-treated cells 
determined using Dunn’s multiple comparisons test: **P<0.01. 
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Figure 8.5. Lucigenin-detected neutrophil ROS (detected as extracellular superoxide) 
generation following 30 minute pre-incubation with CRP and subsequent stimulation 
with IgG-opsonised S. aureus (MOI 300:1), F. nucleatum (MOI 100:1) and aggregated 
IgG (600µg/ml final well concentration). Peak chemiluminescence (median, 
interquartile range, maximum and minimum RLU; n=14) attained after stimulation. 
Significant differences from vehicle control-treated cells determined using Dunn’s multiple 
comparisons test: *P<0.05, ***P<0.001. 
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8.3  DISCUSSION 
The data presented within this chapter demonstrates, for the first time, that physiologically-
relevant (<10µg/ml) concentrations of pentameric CRP have the ability to reduce 
unstimulated neutrophil ROS generation. Furthermore, CRP reduced FcγR stimulated 
neutrophil O2
-
 release and, whilst decreasing TLR stimulated HOCl generation, increased 
TLR stimulated extracellular O2
-
 release. 
 
Systemic CRP concentrations are raised in a number of inflammatory conditions, including 
cardiovascular disease (Ridker et al. 2005) and chronic periodontitis (Paraskevas et al. 2008), 
and are widely used medically as a gauge of systemic inflammation (Ballou & Kushner 1992). 
Serum CRP concentrations may increase to >500mg/l within 24-74 hours as part of the 
systemic inflammatory response to infection or tissue damage (Pepys & Hirschfield 2003). 
Serum CRP levels are also of prognostic value in predicting acute cardiovascular events 
(Ridker et al. 1997, 2005). Greater plasma CRP concentrations were identified in patients 
compared to the healthy control volunteers recruited for the longitudinal intervention case-
control clinical study presented in this thesis. The median plasma CRP concentration in 
patients was 2.15mg/l CRP (section 3.4) and in agreement with 1-4mg/l CRP previously 
reported in chronic periodontitis (Paraskevas et al. 2008). Thus, equivalent CRP 
concentrations were therefore utilised in this chapter to determine its effect upon neutrophil 
ROS generation. 
 
There is evidence that CRP concentrations progressively increase in periodontal health 
through to chronic gingivitis and chronic periodontitis. Serum, salivary and GCF CRP 
concentrations have all been shown to be higher in patients with chronic gingivitis compared 
to healthy controls, albeit not significantly (Herrera et al. 2007, Alzahrani et al. 2013, Patil & 
Desai 2013, Shojaee et al. 2013) possibly relating to the lack of systemic involvement in 
chronic gingivitis. Similarly, there were no significant differences in serum CRP 
concentrations detected during a 21-day model of experimental gingivitis (Wahaidi et al. 
2011), possibly relating to acute-onset rather than chronic inflammation associated with 
clinically-diagnosed chronic gingivitis.  
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Increased neutrophil ROS release, collateral host tissue damage and the formation of 
oxidative stress are established pathological features of chronic periodontitis and are 
associated with systemic disease (Chapple & Matthews 2007). C-reactive protein has the 
potential to modify a number of different neutrophil functions since CRP accumulates at sites 
of inflammation associated with infiltrating neutrophils (Shephard et al. 1990). Furthermore, 
CRP concentrations are raised in conditions associated with oxidative stress, including 
cardiovascular disease (Ridker et al. 2005) and chronic periodontitis (Paraskevas et al. 2008). 
The data presented in this chapter demonstrates, for the first time, that CRP, at concentrations 
equivalent to those found in the plasma of chronic periodontitis patients, significantly reduce 
unstimulated neutrophil ROS release, with a 12-42% reduction in unstimulated neutrophil 
ROS detected with all 3 chemiluminescent substrates. This suggests a protective role for CRP 
in reducing the excess hyperactive neutrophil ROS generation and release observed in patients 
with chronic periodontitis (Matthews et al. 2007; Chapter 5), reducing the risk of collateral 
tissue damage and also co-morbidity associated with the presence of oxidative stress. 
 
The negligible antioxidant properties of CRP, as measured by luminol chemiluminescence 
(<1% reduction in chemiluminescence signal; section 7.7), cannot account for the reduction in 
unstimulated neutrophil ROS generation presented in this chapter. Furthermore, reduced 
luminol-detected intracellular HOCl generation cannot be due to simple protein scavenging 
since CRP is unable to enter the cell (Bottazzi et al. 2010). Therefore, it is possible that the 
reduction in unstimulated neutrophil ROS generation results from a reduction in NADPH 
oxidase activation in the cell membrane and intracellular granule membrane resulting from a 
CRP-FcγR interaction (Heuertz et al. 2005).  
 
The presence of CRP also had a number of significant effects on stimulated neutrophil ROS 
generation, which varied according to the stimuli and nature of the ROS measured. This is the 
first study to measure FcγR-stimulated neutrophil ROS release using physiologically-relevant 
stimuli in the presence of physiologically-relevant concentrations of CRP. C-reactive protein 
had no consistent effects on FcγR stimulated intra- or extracellular HOCl generation but 
significantly reduced O2
-
 release. That the data for isoluminol-detectable extracellular HOCl 
showed no significant differences in the presence of CRP may reflect the fact that 
extracellular HOCl is derived from both membrane-released O2
-
 and diffusion of H2O2 from 
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within the cell, with the latter masking the small changes in the former seen with lucigenin. 
The reduction in FcγR-stimulated O2
-
 release caused by low levels of CRP is consistent with 
current literature demonstrating that high concentrations (>50mg/l) inhibit PMA-, conA and 
fMLP-stimulated neutrophil O2
-
 release (Buchta et al. 1987, Shephard et al. 1990, Dobrinich 
& Spagnuolo 1991, Ratnam & Mookerjea 1998, Mortensen & Zhong 2000). The reduction in 
FcγR-stimulated O2
-
 presented in this chapter may be the result of receptor 
blocking/competition since CRP is known to bind to FcγRs (Heuertz et al. 2005, Khreiss et al. 
2005). However this does not completely explain the data given the reported reduction in 
PMA, conA and fMLP stimulated O2
-
 release, which do not activate neutrophils by FcγRs, 
along with a lack of consistent effect on FcγR-stimulated intra- and extracellular HOCl 
generation. It is possible that this attenuation of neutrophil ROS generation is a means to 
minimize tissue damage in vivo at sites where CRP accumulates. Furthermore, that the 
reduced O2
-
 release was not reflected in reduced intracellular luminol-detected HOCl levels 
suggests retention of neutrophil defence functions requiring intracellular ROS such as 
phagocytosis (Winterbourn & Kettle 2013) and NET production (Palmer et al. 2012).  
 
The ability of physiologically relevant concentrations of CRP to enhance F. nucleatum TLR 
stimulated neutrophil extracellular O2
-
 release, despite a reduction in intra- and extracellular 
HOCl, is a novel finding reported in this chapter and may represent an important contributing 
factor in the pathogenesis of chronic periodontitis. The consistent increase in neutrophil 
extracellular O2
-
 release, despite a reduction in intra- and extracellular HOCl generation 
following F. nucleatum TLR stimulation, could be due to activation and relocation of 
NADPH oxidase to the neutrophil cell surface. This would result in an increase in 
extracellular O2
-
 release (detected by lucigenin), with a concurrent decrease in intracellular 
O2
-
 and generation/release of H2O2 detected predominantly as HOCl by luminol and 
isoluminol respectively. Furthermore, it is unlikely that CRP would affect SOD and MPO 
enzyme activities given that they’re predominantly intracellular and CRP is unable to enter 
the cell, with 50µg/ml CRP having been shown to have no significant effect on neutrophil 
membrane expression of MPO (Xu et al. 2012). Interestingly NADPH oxidase relocation to 
the outer cell membrane has been demonstrated in peripheral blood neutrophils from patients 
with chronic periodontitis (Dias et al. 2013) of which F. nucleatum is a widely recognised 
pathogen.  
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The increased F. nucleatum-stimulated O2
-
 release was consistent, even at the lowest (1µg/ml) 
CRP concentration tested, and may be the result of FcγR/TLR cross-linking in the presence of 
both CRP and F. nucleatum. C-reactive protein binds predominantly to phosphorylcholine in 
the presence of Ca
2+
, which is present on a number of different host and bacterial cells, 
including F. nucleatum (Gmur et al. 1999, Schenkein et al. 2001). It is therefore likely that 
during stimulation with F. nucleatum in the presence of CRP, neutrophil receptor cross-
linking could occur with TLR binding F. nucleatum and adjacent FcγR binding with CRP 
thereby potentially up-regulating the downstream activation events leading to increased 
translocation of NADPH oxidase to the cell surface and observed increase in O2
-
 release. 
Furthermore, TLR-FcγR interactions have been shown to be important in the activation of 
neutrophils, macrophages and dendritic cells (Rittirsch et al. 2009, den Dunnen et al. 2012).  
 
Pentameric CRP has also been shown to dissociate and aggregate under certain conditions 
including heat, acid and urea dissociation and chelation (Potempa et al. 1987) thereby forming 
modified CRP (mCRP) which is insoluble and antigenically distinct. Furthermore, mCRP has 
been recently shown to be generated on cell membranes of activated platelets  associated with 
vascular injury (Ji et al. 2007, Eisenhardt et al. 2009) with its occurrence being considered 
responsible for the pathological features associated with atherosclerosis (Diehl et al. 2000, 
Khreiss et al. 2004). All procedures undertaken as part of this thesis were therefore 
undertaken in Ca
2+
-containing buffers to prevent spontaneous dissociation of pentameric CRP 
and generation of mCRP. Furthermore, the native pentameric structure of CRP was confirmed 
(section 7.2) prior to investigating the effects of  CRP on the neutrophil respiratory burst. 
Pentameric and mCRP have different biological properties and differentially bind to human 
neutrophils, with pentameric CRP binding to FcγRI (CD64) and FcγRIIa (CD32) and mCRP 
binding to FcγRIII (CD16) respectively (Khreiss et al. 2005). With regards to the effects of 
mCRP on the neutrophil respiratory burst, evidence from a single research group indicates 
that mCRP has no direct effect on baseline neutrophil ROS generation.  However, at high 
concentrations (>50µg/ml), mCRP appeared to increase ROS generation in response to 
aggregated IgG but not PMA or opsonised zymosan (Zeller et al. 1986, 1992).  
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Overall, the data obtained show that physiologically-relevant concentrations of CRP decrease 
unstimulated and FcγR-stimulated O2
-
 release by neutrophils potentially offering some degree 
of host protection by minimising the effects of oxidative stress, systemic inflammation and 
associated risk of co-morbidity. By contrast, CRP enhanced TLR stimulated neutrophil O2
-
 
release that has the potential to increase both oxidative stress and the risk of collateral host 
tissue damage in chronic periodontitis, as well as host protection during the transition from 
gingivitis to periodontitis when acquired immunity had not been developed.  
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CHAPTER 9 
 
 CONCLUDING REMARKS 
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9.1 SUMMARY OF MAIN FINDINGS 
The overall aim of this thesis was to contribute to our current understanding of the role of the 
neutrophil in the pathogenesis of chronic periodontitis, along with possible associations with 
systemic disease in which raised systemic CRP concentrations are present.  
 
In order to study novel aspects of neutrophil function in chronic periodontitis patients, a 
longitudinal intervention case-control clinical study was undertaken (section 2.1.1). Peripheral 
blood neutrophil cytokine (section 2.2.7) and superoxide (section 2.2.8) release were 
measured both pre- and post-therapy in patients and matched healthy controls. In addition, 
NET release (section 2.2.9) and directional chemotactic accuracy (section 2.2.10) were also 
determined using recently developed assays. An overview of the neutrophil functions studied 
in relation to the pathogenesis of chronic periodontitis is shown in Figure 9.1.  
 
The neutrophil cytokine release data (Chapter 4) have reaffirmed that neutrophils do not 
solely function antimicrobially but are also actively involved in co-ordinating the 
inflammatory-immune response with the hierarchical release of IL-8, IL-6, IL-1β and TNF-α 
respectively. Furthermore the data demonstrated, for the first time, that peripheral blood 
neutrophils from patients with chronic periodontitis release greater amounts of IL-8, IL-6, IL-
1β and TNF-α, compared with healthy controls both pre- and post-therapy. Specifically, 
patient neutrophils were hyper-reactive regarding FcγR-stimulated IL-8, IL-6, IL-1β and 
TNF-α and P. gingivalis (TLR)-stimulated IL-1β release both before and after periodontal 
therapy. In contrast, the hyper-reactive, F. nucleatum (TLR)-stimulated IL-6, IL-8 and TNF-α 
release displayed by patient neutrophils was not present at post-periodontal treatment review. 
Dysregulated neutrophil cytokine release is of significant in vivo relevance given that 
cytokines regulate many different aspects of the inflammatory-immune response, including 
neutrophil ROS and NET release as well as chemotactic potential (Figure 9.1).  
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Figure 9.1. Overview of the role of the neutrophil in the pathogenesis of chronic periodontitis, including associations with 
systemic CRP concentrations. Please note individual thesis chapters (highlighted) relating to specific neutrophil functions associated 
with the pathogenesis of chronic periodontitis, with neutrophil cytokine release relating to data presented in Chapter 4. Abbreviations: 
LPS, lipopolysaccharide; TLR, toll-like receptor; CR, complement receptor; IL, interleukin; C, complement; TNF, tumour necrosis factor; 
CRP, C-reactive protein; FcγR, Fcγ-receptor; ROS, reactive oxygen species; NET, neutrophil extracellular trap; PDL, periodontal 
ligament.
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Neutrophil hyper-activity and –reactivity regarding ROS generation is a well-established 
feature in the pathogenesis of chronic periodontitis (section 1.6.3). Data presented in this 
thesis have demonstrated patient neutrophil O2
-
 hyperactivity along with P. gingivalis and F. 
nucleatum (TLR)-stimulated hyper-reactivity, with no significant periodontitis-associated 
difference in PMA stimulated extracellular O2
-
 release (Chapter 5). Furthermore, patient 
neutrophil O2
-
 hyper-activity and P. gingivalis and F. nucleatum (TLR)-stimulated hyper-
reactivity were not present at review, post-treatment. The finding that neutrophil O2
-
 hyper-
activity and –reactivity, along with F. nucleatum (TLR)-stimulated IL-6, IL-8 and TNF-α 
hyper-reactivity, were not present at review may possibly be suggestive of acquired rather 
than constitutional defects in neutrophil function. Acquired defects are likely to result from 
the permeable nature of the junctional epithelium with periodontal bacteria and their products 
having the potential to enter the surrounding tissues and vasculature (Loos 2005, Seymour et 
al. 2007) resulting in a systemic inflammatory-immune response. Therefore, the data suggest 
that removal of supra- and subgingival plaque deposits results in a reduction in peripheral 
blood neutrophil priming/activation by bacterial plasma-borne components and a consequent 
correction of the observed neutrophil hyperactivity and –reactivity. 
 
A dysregulated inflammatory-immune response is considered responsible for the majority of 
disease pathogenesis associated with chronic periodontitis (Page et al. 1997; section 1.2.2) 
however the exact mechanisms remain to be fully elucidated. Dysregulated neutrophil 
function has the potential to cause collateral host tissue damage as well as delayed bacterial 
clearance from the gingival crevice resulting in potentiation of a chronic inflammatory lesion. 
The finding that hyper-reactive, F. nucleatum (TLR)-stimulated IL-6, IL-8 and TNF-α and O2
-
 
release was absent at review, whereas FcγR-stimulated IL-8, IL-6, IL-1β and TNF-α and P. 
gingivalis (TLR)-stimulated IL-1β hyper-reactivity persisted post-therapy, is suggestive that 
both constitutional and acquired defects may underlie the dysregulated peripheral blood 
neutrophil phenotype in chronic periodontitis. Constitutional defects may involve any aspect 
of neutrophil function, including FcγR and P. gingivalis TLR stimulated cytokine generation 
and release. These may represent significant genetic risk factors for chronic periodontitis 
(Michalowicz 1994). For example several constitutional defects in intracellular signal 
transduction responsible for chemotaxis and O2
-
 generation have been identified in the 
pathogenesis of localised aggressive periodontitis (Gronert et al. 2004). As a result, 
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constitutional defects would remain inherent to neutrophil function irrespective of 
intervention in terms of periodontal treatment. 
 
In addition to acquired and constitutional defects in neutrophil function, recent evidence has 
also demonstrated that extravasated neutrophils may re-enter the vasculature in a process 
called “reverse migration” (Mathias et al. 2006, Elks et al. 2011, Woodfin et al. 2011). It is 
therefore possible that neutrophils recruited to sites of periodontal inflammation may become 
primed or activated by periodontal bacteria and their products within the inflamed gingival 
tissues, and then re-enter the circulation resulting in a hyperactive and –reactive peripheral 
blood neutrophil phenotype. Neutrophil transmigration, contributing 1-2% of the peripheral 
blood population, has been identified in rheumatoid arthritis (Buckley et al. 2006) but has yet 
to be investigated in chronic periodontitis. It is possible that neutrophil transmigration will 
have in vivo relevance in the pathogenesis of chronic periodontitis given the large surface area 
of exposed connective tissues and thus vasculature, and the chronic, often long-term nature of 
disease. However, this is unlikely to be solely responsible for the differences in ROS and 
cytokine release, presented in this thesis, given the probability that transmigrating cells form a 
minor population of peripheral blood neutrophils. Whilst neutrophil reverse migration may be 
beneficial to the host in preserving cells when needed to protect against infection, activated 
neutrophils re-entering the circulation could disseminate the inflammatory response 
throughout the body leading to systemic and/or chronic inflammation, and therefore provide a 
causal link between chronic periodontitis and systemic disease. 
 
Neutrophil extracellular trap (NET) formation is a recently discovered neutrophil 
antimicrobial mechanism (Brinkmann et al. 2004) and considered important in the 
pathogenesis of chronic periodontitis (reviewed by Cooper et al. 2013). Neutrophil 
extracellular trap release is triggered by ROS, specifically HOCl (Palmer et al. 2012). 
Therefore, given the well-established hyperactive and hyper-reactive ROS generation by 
neutrophils in periodontitis (section 1.6.3, Chapter 5) NET release was measured, for the first 
time, using a recently developed fluorometric quantification assay (section 2.2.9). Whilst NET 
release was confirmed following stimulation with established NET agonists (PMA & HOCl), 
there were no significant differences in NET release between patient and control cells 
(Chapter 6). This suggests that the ability to release NETs is unaffected in periodontitis 
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following direct stimulation, however it remains to be elucidated how this may translate to 
NET release in response to periodontally-relevant bacteria, and within periodontal tissues. 
 
Impaired neutrophil chemotaxis has previously been reported in the pathogenesis of chronic 
periodontitis (section 1.6.2).  This was confirmed and more accurately characterised by the 
data reported here, generated using a novel directional chemotaxis assay recently developed in 
collaboration with colleagues at the University of Glasgow (section 2.2.10.1). Patient 
neutrophils demonstrated impaired directional chemotactic accuracy, speed and velocity of 
migration towards recognised chemoattractants (fMLP and IL-8). The case-control study 
presented in this thesis represents novel and unique data in that a number of different 
neutrophil functions have been measured from the same patient and control volunteers. 
Neutrophil IL-8 release was greater from the patient compared to control neutrophils (Chapter 
4) and IL-8 is a widely recognised chemoattractant used within the directional chemotaxis 
assay (section 2.2.10). It was therefore postulated that the amount of neutrophil IL-8 release 
by patients’ neutrophils may negatively correlate with directional chemotactic accuracy and 
provide a causal mechanism for the observed defective neutrophil chemotaxis in chronic 
periodontitis (Chapter 6). If neutrophil IL-8 release was responsible for the defective 
chemotaxis observed, one would expect a negative correlation between neutrophil IL-8 and 
concurrent chemotactic index. However, in contrast, there was a moderately significant 
positive correlation between neutrophil IL-8 release and chemotactic accuracy towards fMLP 
(Chapter 6). Neutrophils are the predominant leucocyte of the innate immune system and, as 
such, will be recruited following initiation of an inflammatory-immune response and probably 
actively participate in the recruitment of distant inflammatory cells, including additional 
neutrophils. This is of in vivo relevance and important in disease pathogenesis given that 
greater neutrophil recruitment, albeit with impaired chemotactic accuracy, of a hyper-active 
and hyper-reactive neutrophil phenotype, will increase the probability of collateral host tissue 
damage. Reduced neutrophil chemotactic accuracy is unlikely to result in a significant delay 
in bacterial clearance from the gingival crevice given the large number of neutrophils present. 
However, greater tissue transit times would lead to increased release of potentially damaging 
neutrophil pro-inflammatory mediators, including cytokines, ROS and antimicrobial peptides 
(section 1.5.4), due to relatively erratic migratory pathways whilst travelling towards host and 
plaque-derived chemoattractants within the periodontal tissues.  
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Chronic periodontitis results in a systemic inflammatory-immune response with greater 
plasma C-reactive protein (CRP) concentrations compared to healthy controls (Paraskevas et 
al. 2008; Chapter 3). This was thought to be potentially due to hyper-reactive neutrophil IL-6 
release (Chapter 4), since IL-6 is a primary trigger for CRP synthesis and release from liver 
hepatocytes (Gauldie et al. 1987, Gabay & Kushner 1999). However there was no correlation 
between unstimulated patient neutrophil IL-6 release and plasma CRP concentration 
(R
2
=0.03; P=0.5; data not shown). Nonetheless, given the large numbers of neutrophils and 
their central role in the inflammatory-immune response, it remains possible that increased 
neutrophil IL-6 release may contribute in part to the systemic inflammatory response and 
increased systemic CRP concentrations observed in chronic periodontitis. However, currently 
the consensus from the 2012 European and American workshop on periodontal and systemic 
diseases is that periodontally-derived bacteraemia likely drives the acute-phase CRP response 
reported in periodontitis patients (Tonetti & Van Dyke 2013) 
 
The effects of physiologically relevant concentrations of CRP, equivalent to those identified 
in chronic periodontitis (Chapter 3) and used as an indicator for cardiovascular disease risk 
(Ridker et al. 2002, 2005), on the neutrophil respiratory burst of control neutrophils from 
periodontally and systemically healthy volunteers were determined (Chapter 8). Unstimulated 
neutrophil HOCl and O2
-
 generation and release, F. nucleatum stimulated HOCl and FcγR-
stimulated O2
-
 release were all significantly inhibited in the presence of CRP. Raised systemic 
CRP concentrations may therefore be beneficial to the host in helping to reduce the oxidative 
stress associated with chronic periodontitis and systemic disease, and minimise the risk of co-
morbidity. However, in contrast, increased F. nucleatum stimulated extracellular O2
-
 release 
was observed in the presence of CRP. Whilst enhanced TLR-mediated O2
-
 release from 
neutrophils may be beneficial in aiding host protection from infection in situations where 
acquired immunity has not yet been developed, this may also contribute to and exacerbate 
collateral host tissue damage in chronic periodontitis. Furthermore, greater F. nucleatum 
(TLR)-stimulated O2
-
 in the presence of physiologically-relevant concentrations of CRP, even 
at the lowest 0.1µg/ml CRP concentration tested, may also represent a risk factor for systemic 
disease associated with oxidative stress in the presence of chronic periodontitis. 
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Fusobacterium nucleatum is a key periodontal pathogen, and periodontal bacteria and their 
products have the potential to enter the surrounding tissue and vasculature (Loos 2005, 
Seymour et al. 2007). As a result, it is likely that both F. nucleatum and increased 
concentrations of CRP are present in the peripheral blood of periodontitis patients.  It is 
therefore interesting that there was a moderate, significant positive correlation between 
plasma CRP concentration of patient volunteers and their corresponding ex vivo neutrophil 
O2
-
 release in the absence of overt stimulation (Figure 9.2). Thus it is possible that, in 
periodontitis, peripheral blood neutrophils in the presence of elevated CRP concentrations 
(Paraskevas et al. 2008; Chapter 3) and systemic circulating periodontal pathogens, including 
F. nucleatum, could be partly responsible for the observed neutrophil ROS hyper-activity 
following isolation from peripheral blood. This therefore highlights the importance of plaque 
control through oral hygiene and active periodontal treatment in reducing the potential for 
systemic F. nucleatum-CRP interaction resulting in the hyperactive and –reactive neutrophil 
phenotype in the pathogenesis of chronic periodontitis.     
 
 
 
 
Figure 9.2. Correlation (n=19) between unstimulated patient neutrophil O2
- release and 
plasma hsCRP concentration (mg/l).  Superoxide detected by lucigenin in the absence of 
CRP (mean relative light units; RLU). Omission of the high outlying 20.8mg/l plasma hsCRP 
concentration results in a Pearson correlation of 0.591 (R2 = 0.3493; P<0.01). 
 
 
 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0.00 5.00 10.00 15.00 20.00 25.00
R
L
U
 
Plasma CRP (mg/l) 
R2 = 0.5415 
P=0.0003 
 221 
Furthermore, in relation to the in vivo pathogenesis of chronic periodontitis, once neutrophil 
functions have been fulfilled in the tissues they undergo apoptosis to prevent the uncontrolled 
release of toxic cell contents (Fox et al. 2010). Apoptotic-specific cell changes promote the 
recognition and uptake of cells by phagocytes such as macrophages involving exposure of 
phosphorylcholine that becomes accessible to CRP only in apoptotic cells, and is therefore 
important in scavenging cellular debris and extracellular matrix components (Pepys & Baltz 
1983, Szalai et al. 1999). It is therefore plausible that the greater systemic CRP concentrations 
in chronic periodontitis and systemic disease relate to the greater need for removal of 
apoptotic neutrophils during the inflammatory-immune response whilst, at the same time, also 
having both anti- and pro-inflammatory effects on viable neutrophil function. These include 
the aforementioned reduction in unstimulated and F. nucleatum-stimulated HOCl and FcγR-
stimulated O2
-
 release, along with greater F. nucleatum stimulated O2
-
 release by neutrophils 
in the presence of CRP.  
 
Overall, this thesis presents novel data that adds to our current understanding of neutrophil 
function and the host inflammatory-immune response in the pathogenesis of chronic 
periodontitis. Whilst the clinical relevance of this research may not be immediately apparent, 
it is hoped that greater understanding of the pathogenesis of chronic periodontitis will 
ultimately lead to improved preventative, diagnostic and treatment strategies in the future. 
Although oral hygiene, plaque control and elimination of periodontal risk factors (e.g. 
smoking), along with regular dental/periodontal examination, will remain the mainstay of  
prevention and therapy for periodontitis, it is possible that re-balancing the pro-inflammatory 
neutrophil phenotype through local or systemic adjunctive treatments may also be beneficial 
and improve periodontal treatment outcome in high risk patients. Moreover, greater 
understanding of neutrophil function in the presence of systemic inflammatory markers such 
as CRP increases the scientific evidence of the impact of systemic inflammation upon 
neutrophil function and risk of co-morbidity. This further adds to our current understanding of 
the associations between periodontal and systemic disease. It is therefore hoped that the risk 
of co-morbidity will be reduced in the future through greater understanding of the host 
response in chronic periodontitis, and ultimately improved periodontal risk assessment, 
diagnosis and treatment strategies in the future. 
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9.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
The data presented in this thesis fulfil the aim of contributing to our current understanding of 
the role of the neutrophil in the pathogenesis of chronic periodontitis. However a number of 
additional questions have not been addressed within this thesis, which will further contribute 
to our current understanding of the role of the host response in the pathogenesis of chronic 
periodontitis. Therefore recommendations for future research include:  
 
 Performance of gene expression analyses on the stored neutrophil cell pellets 
following 18 hour culture in the presence and absence of periodontally relevant 
bacteria (section 2.2.6). This would provide novel information as to the transcriptional 
responses of neutrophils in response to periodontal bacteria to support the neutrophil 
cytokine release data (Chapter 4). 
 
 A study of NET formation in response to periodontally-relevant bacteria from patients 
with chronic periodontitis and healthy controls following on from the PMA and 
HOCl-stimulated NET data presented in this thesis (Chapter 6). Whilst no significant 
differences in PMA and HOCl-stimulated NET release were detected in the current 
studies, this may be due to the NET stimuli used.  For example, even the well-
established neutrophil hyper-reactivity in chronic periodontitis in response to TLR and 
FcR stimulation is not observed following PMA stimulation (Chapter 5). It is 
therefore possible that physiologically-relevant stimuli may result in differences in 
NET release not detected using PMA and HOCl. Moreover, the subsequent effect of 
non-surgical periodontal therapy could also be studied by performing an additional 
case controlled longitudinal intervention study.  
 
 Assessment of the effect of non-surgical periodontal therapy on the impaired 
neutrophil directional chemotactic accuracy, speed and velocity of movement (Chapter 
6). This data has already been collected and analysed as part of a collaborative project 
with H. Roberts (section 2.2). 
 
 Determination of the effect of physiologically relevant concentrations of CRP on NET 
and cytokine release and directional chemotactic accuracy. 
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9.3 CONCLUSION 
This thesis has investigated a number of key neutrophil functions in chronic periodontitis, 
namely IL-8, IL-6, IL-1β, TNF-α, O2
-
 and NET release along with directional chemotactic 
accuracy. In addition, the effects of physiologically relevant concentrations of CRP on the 
neutrophil respiratory burst were investigated. Taken together, this thesis further supports 
current evidence demonstrating that a number of different neutrophil functions are 
dysregulated in chronic periodontitis. In addition, the effects of CRP on neutrophil respiratory 
burst activity further emphasise the impact of chronic periodontitis and systemic disease on 
the systemic inflammatory-immune response and subsequent risk of co-morbidity. 
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APPENDIX I 
Medical history questionnaire 
 
Are you:  Yes No Details 
1. Receiving medical or hospital treatment at present?    
2. Taking any tablets, medicines or any other substance e.g. 
inhalers? 
   
3. Allergic to any tablets, medicines or any other substance 
e.g. Penicillin/Latex (rubber)? 
   
4. Are you pregnant? (if appropriate)    
5. Have you ever had a heart murmur, rheumatic fever or 
any other problem with your heart? 
   
6. Have you ever had raised blood pressure, angina, heart 
attack or thrombosis e.g. CVA, DVT? 
   
7. Have you ever had hepatitis, jaundice or been diagnosed 
with HIV disease? 
   
8. Have you ever had any chest problems e.g. 
asthma/bronchitis or tuberculosis? 
   
9. Have you ever had an operation or illness treated in 
hospital? 
   
10. Have you ever been diagnosed with epilepsy?    
11. Have you ever been diagnosed with diabetes?    
12. Have you ever undergone brain surgery, received 
growth hormone treatment before the mid 1980’s or do 
you have a close relative with CJD? 
   
13. Have you ever had prolonged bleeding following a tooth 
extraction or other surgery? 
   
14. Have you ever had a problem with LA or GA?    
15. Are there any other problems that may be relevant?    
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APPENDIX II 
Patient volunteer information leaflet 
 
 
SCHOOL OF DENTISTRY 
 
VOLUNTEER INFORMATION SHEET (GROUP 2) 
Version 1.1 (2
nd
 September 2010) 
 
Study Title: Analysis of neutrophil response in chronic periodontitis study 
Sponsor Reference: RG_10-077 
NHS R&D Reference: R&D1398 
REC Reference Number: 10/H1208/48 
 
Researcher: Mr Martin Ling (PhD thesis) 
Contact Telephone No.  
Contact Email:  
Research Sponsor: University of Birmingham 
Sponsor Reference: RG_10-077 
Research Supervisor: Professor Iain Chapple 
Contact Telephone No.  
Contact Email:  
Research site: Birmingham Dental Hospital & School 
NHS R&D Reference R&D1398 
Research Ethics 
Committee: 
West Midlands REC 
REC Reference Number: 10/H1208/48 
 
 
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you wish.  
 
Please feel free to ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
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WHAT IS THE PURPOSE OF THE STUDY? 
Recent scientific evidence suggests that the defence cells of the body (neutrophils) behave differently 
in patients with gum disease, namely how they interact with bacteria and their role in defence systems 
of the body. There is also evidence that gum disease is related to other important diseases such as 
diabetes and rheumatoid arthritis. The aim of the study is to look at behavior patterns of these defence 
cells in relation to volunteers without gum disease. As a result we aim to learn more about the 
condition and hopefully develop new methods to treat or possibly even prevent the disease in the 
future. 
 
WHY HAVE I BEEN INVITED TO TAKE PART? 
You have been invited to take part in the study because you have good general health and require 
treatment for gum disease and your dentist has requested your treatment be performed at the Dental 
Hospital. This study will have two parallel groups, one test (gum disease) and two separate controls 
(no gum disease and one group with chronic granulomatous disease as a negative control). 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
If you decide to take part in this study you will be treated in exactly the same manner as all our 
patients who suffer from gum disease apart from some additional sampling procedures. These will 
include taking routine clinical measurements of your teeth and gums during two visits with the 
collection of gum fluid (which is painless to collect and takes 30 seconds) and a blood sample. We 
will also take two tissue samples from your gums on two of your four treatment visits in order to look 
at the cells under a microscope and from which some cells will be grown, stored until use and their 
behaviour tested against different challenges. These biopsies will be extremely small, approximately 
the size of a needle-head and will heal uneventfully within days with no detrimental effects to you or 
they way that your disease is managed whatsoever. There will be only one additional appointment 
(approx 20 minutes) for you to attend and treatment appointments will be slightly longer than normal 
(by approximately 30 minutes) so that the measurements and samples can be taken. 
 
DO I HAVE TO TAKE PART IN THE STUDY? 
It is up to you to decide whether or not to take part and is entirely voluntary. If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care you receive. 
 
WHAT HAPPENS IF I WISH TO WITHDRAW FROM THE STUDY? 
Participation in the study is entirely voluntary and you may withdraw at any time. If you wish to 
withdraw from the study then you are free to do so without question and without giving a reason. To 
do this you will need to contact either Martin Ling (Researcher) on 0121 237 2806 or 
M.R.Ling@bham.ac.uk, or alternatively Professor Iain Chapple (Research Supervisor) on 0121 237 
2808 or I.L.C.Chapple@bham.ac.uk. In the event of a volunteer wishing to withdraw from the 
research then all samples will be identified by the Researcher, destroyed and data deleted. Any 
samples already analysed would have been done so by study number only and as such will be non-
identifiable to any other staff other than the Researcher. All data will be utilized in a non-identifiable 
manner. 
 
WILL MY TAKING PART IN THE RESEARCH BE CONFIDENTIAL? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. Your name will not be identified with the data collected other than by a code. Results 
collected will be expressed as an average for all volunteers participating in the research with no 
identifiable details whatsoever. Individual volunteer data will not be used in the publication of results.  
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WHAT WILL I HAVE TO DO? 
You are asked to read this Information Sheet, ask any questions you may have about the study and, if 
you wish to take part, sign the consent form. You will then be asked to fill out a separate medical 
questionnaire that will be used to help decide whether or not you meet the study requirements. 
 
All information gathered about you will be treated in strict confidence. It may be made available to 
Regulatory Authorities, Auditors, the Ethics Review Group or the Study Monitors in order to check 
the quality of the data. If it is to be used for scientific purposes your name will not be disclosed. 
 
There will be one extra appointment over standard treatment (approximately 20 minutes), and the first 
and review appointments will be slightly longer as will two of the four treatment visits. We expect the 
additional time taken will be approximately 1 hour (20 minutes per appointment). In addition the gum 
tissue samples will be taken during two out of your four treatment visits and we expect the additional 
time for these visits will again be approximately 1 hour (30 minutes per appointment). All study 
procedures will take place at the Dental Hospital.  
 
VISIT 1: Identification and information presentation 
 You will have been identified as a potential patient volunteer for the study and you will have 
been given verbal and written information about participation in the study. 
 
VISIT 2: Recruitment and GCF sampling 
You must not drink anything, brush your teeth or chew gum within 2 hours as this may affect 
our results. 
 A separate appointment will then be arranged for you to ask any further questions and 
complete a medical history form, during which time we will assess whether you are suitable 
for the study. 
 If you are suitable for the study we will answer any questions you may have and if you are 
willing to participate we will ask you to sign a consent form. 
 If so we will complete some basic measurements of your gums, identically as if you weren’t 
participating in the study as this forms part of your clinical care. This appointment will take 
approximately 20 minutes. 
 We will collect gum fluid samples which will take approximately 5 minutes. 
 
VISIT 3: Blood sampling 
 We will collect gum fluid samples which will take approximately 5 minutes 
 We will take a blood sample (approximately ten teaspoons) which will take a couple of 
minutes. 
 You will then proceed to have intensive oral hygiene instruction by a dedicated Staff 
Hygienist which will form your preliminary treatment visit, which would occur regardless of 
your participation in the study. 
 
VISIT 4: First treatment visit and 1
st
 set of gingival biopsy sampling  
 We will begin gum treatment in the first of four corners of the mouth, with treatment 
completed over four visits, which is exactly as it would be done if you were not enrolled in the 
study. 
 We will use a local anaesthetic prior to treatment, exactly as we would if you were not 
enrolled in the study, and whilst anaesthetized we will collect two small gum tissue samples 
which will be approximately the size of a small needle-head immediately before commencing 
treatment, and whilst covered by the anaesthetic and will take approximately 20 minutes in 
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addition to your treatment. These are extremely small and will heal uneventfully within days 
with no detrimental effect on your treatment whatsoever.  
 We will then continue your gum treatment exactly as we would were you not enrolled in the 
study. 
 
VISIT 5: Second treatment visit and 2
nd
 set of gingival biopsy sampling 
 We will continue your gum treatment in the second of four corners of the mouth exactly as if 
you were not enrolled in the study. 
 We will again use a local anaesthetic prior to treatment, and whilst anaesthetized we will 
collect an additional two small gum tissue samples in another corner of the mouth. These will 
again be approximately the size of a small needle-head and collected immediately before 
treatment whilst covered by the anaesthetic and will take approximately 20 minutes in 
addition to your treatment. These are extremely small and will heal uneventfully within days 
with no detrimental effect on your treatment whatsoever. 
 We will then continue your gum treatment exactly as we would were you not enrolled in the 
study. 
 
VISIT 6: Third treatment visit (routine) 
 This will be an entirely routine gum treatment visit in the third of four corners of the mouth 
with the use of a local anaesthetic. 
 
VISIT 7: Fourth routine treatment visit (routine) 
 This will be an entirely routine gum treatment visit in the final corner of the mouth with the 
use of a local anaesthetic. 
 
VISIT 8: Three-month follow-up after treatment (routine) and additional blood/GCF sampling. 
You must not drink anything, brush your teeth or chew gum within 2 hours as this may affect 
our results. 
 
 We will take some routine measurements of your teeth and gums which will take 
approximately 20 minutes in order to assess your response to treatment as we would do were 
you not enrolled in the study. 
 During this visit we will collect an additional sample of gum fluid which will take 5 minutes. 
 We will also take an additional blood sample (approximately ten teaspoons) which will take a 
couple of minutes. 
 We will then ask you to complete a feedback form so that we can gain your thoughts on 
participation in the study. 
 
At this point you will then exit the study and continue with your clinical care regardless of whether 
or not you have participated in the study. 
 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING PART? 
There are no disadvantages to taking part, except that 2 of your visits will be approximately 20 
minutes longer and you will need blood and gum fluid samples taking at these visits.  In addition, two 
of your four treatment visits will take approximately 30 minutes longer whilst we collect two small 
tissue samples from around your gums. 
 
Venepuncture is a procedure where we obtain blood from the vein on the anterior forearm (the side 
within the fold of the elbow). This is a safe and commonly performed procedure although may result 
in minor discomfort and/or bruising which, if occurs, heals uneventfully. In addition there is a minor 
chance of infection at the site of blood collection, although this has never been experienced within the 
department in over twenty years. Blood will be taken by a suitably qualified member of clinical staff 
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and as such these risks are extremely minimal. All blood taken will be in accordance with the 
University of Birmingham “Blood Taking from Volunteers for Research” Health and Safety Policy 
document. 
 
The tissue samples collected will be extremely small (2mm
2
 – approximately the size of a needle-
head) that will be taken from the gums surrounding two teeth during the first two out of four standard 
treatment visits. These will be the equivalent of creating a small ulcer at the site of treatment that will 
heal uneventfully within days with no detrimental effects whatsoever and will not affect the treatment 
received or its outcome in any way.   
 
ARE THERE ANY SIDE EFFECTS OF THE TREATMENT? 
The gum disease treatment you will receive is entirely that which you would routinely need. Although 
this in itself may make your gums shrink back a little, this happens with all gum treatments and is 
unavoidable if you want the disease treated. The additional tests you will require as part of the study 
(i.e. providing blood, gum fluid and gum tissue samples) have no side effects. 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
You will benefit by taking part because your treatment will be by an experienced member of staff 
rather than a student, which is the normal practice at the Dental Hospital. The treatment will therefore 
take less time than if you did not take part.  
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
At the end of the study, you will enter a normal review process and any further treatment needed will 
be arranged with a member of staff or your dentist as is normal practice.  
 
WHAT IF SOMETHING GOES WRONG? 
We do not expect you to experience any problems as a result of taking part in this study. However, 
should you have any concerns then you should contact the study team on 0121 237-2792 or -2793 and 
ask to speak to someone involved in the Neutrophil Response (NR) study. If you have any general 
questions about the study please call Martin Ling on 0121 237-2806 or -2808 (office hours). 
 
If you are harmed due to someone’s negligence, then you may have grounds for a legal action but you 
may have to pay for it. Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms will be available to you. ‘The sponsor’ will not 
compensate you where such injury results from any procedure carried out which is not in accordance 
with the protocol for the study. Your right at law to claim compensation for injury where you can 
prove negligence is not affected. 
 
WILL I BE INFORMED OF THE RESULTS OF THE STUDY? 
Participants will not be individually informed of their results. However it is the aim to publish results 
of the research in peer-reviewed journals and as part of a PhD thesis, which will be freely available for 
access. However, if you wish to know results out of scientific interest then we will be happy to give 
you a copy of the final study report and also of any resulting publications. 
 
WHO IS ORGANIZING AND FUNDING THE RESEARCH? 
This study has been organized through The University of Birmingham as ‘Sponsor’, and has been 
planned within the Periodontal Research Group at the School of Dentistry. Funding has been secured 
through successful research grants awarded from the Oral and Dental Research Trust and the Royal 
College of Surgeons of England. 
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WHO HAS REVIEWED THIS STUDY? 
All research in the NHS is looked at by an independent Research Ethics Committee to protect your 
safety, rights, wellbeing and dignity. This study has been reviewed and given favourable ethical 
opinion by the West Midlands Research Ethics Committee. 
 
CONTACT FOR FURTHER INFORMATION? 
If you need further information please phone 0121 237-2792 or -2793 and ask to speak to someone 
involved in the “Neutrophil Response (NR)” study. This will be Martin Ling or one of the study team. 
Alternatively, general independent advice about taking part in research can be obtained from our 
PALS spokesman Derek de Faye on 0121 237 2836. 
 
Thank you for taking the time to read this information sheet 
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APPENDIX III 
Neutrophil elliptical factor analysis 
Neutrophils identified previously by Martin Ling & Helen Roberts were analysed to calculate 
their elliptical factor. Following consultation with Dr. Joshua Rappoport five images were 
used for the elliptical factor analysis (t=0 s, 300 s, 600 s, 900 s, 1170 s). The elliptical factors 
were calculated by measuring the greatest distance between the cell membranes (or 
observable edges) and the perpendicular distance (at 90 ° and midpoint), as shown below: 
 
 
 
Up to 15 cells were analysed for each dataset (i.e. patient or paired control), depending on the 
ability to successfully identify the elliptical factor throughout the time course (e.g. if any cell 
moved partially off screen this cell would not be analysed).  
A total of five paired patients and controls were analysed, and the mean elliptical factor of 
each patient and control sample was calculated. These mean values (n=5) were analysed with 
the use of Friedman and Wilcoxon tests (shown overleaf). As it can be seen, no statistical 
significance is identified between t=0 s and 1170 s (Wilcoxon test) or between patient and 
control samples.  
The Wilcoxon test shows that for fMLP the control cells have a greater elliptical factor at 
t=1170 s in comparison to the patient sample (P=0.125 in comparison to P=0.1875), whereas 
for IL-8 and RPMI the values are much lower for the patient. It is difficult to explain this 
finding, but it did appear that the cells were much more mobile (for both control and patient) 
when stimulated with fMLP than IL-8. As such it is possible that due to the increased 
chemotaxis (especially for the control sample) and high cell density the cells were 
increasingly interacting and moving around other cells, which would explain why they would 
be more elongated. With respect to IL-8 and RPMI, no statistical significance is identified, 
although in both cases the p value is approximately half of the control sample, which may 
suggest that if a greater n were analysed then significance may be seen. 
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APPENDIX IV 
Research conference presentations 
 
Ling MR. Chemotactic Accuracy of Peripheral Blood Neutrophils in Chronic Periodontitis 
using a Novel Direct Visualisation Chemotaxis Chamber. University of Birmingham College 
of Medical & Dental Sciences Festival of Graduate Research, 8
th
 April 2014. 
 
Ling MR. Cytokine release from peripheral blood neutrophils in chronic periodontitis. 
Periodontal Research Group, 13
th
 March 2014. 
 
Ling MR. Chemotactic Accuracy of Peripheral Blood Neutrophils in Chronic Periodontitis 
using a Novel Direct Visualisation Chemotaxis Chamber. Birmingham Inflammation Group, 
7
th
 March 2014. 
 
Ling MR. Chemotactic Accuracy of Peripheral Blood Neutrophils in Chronic Periodontitis 
using a Novel Direct Visualisation Chemotaxis Chamber. University of Birmingham School 
of Dentistry Science Lunchtime Seminar, 21
st
 February 2014. 
 
Ling MR, Roberts HM, Matthews JB, Grant MM, Chapple IL. Chemotactic Accuracy of 
Peripheral Blood Neutrophils in Chronic Periodontitis using a Novel Direct Visualisation 
Chemotaxis Chamber. British Society of Periodontology Sir Wilfred Fish Research 
Presentation, The Royal College of Surgeons of England, London, October 2013. 
 
Ling MR, Chapple IL, Matthews JB. Effects of C-Reactive Protein on the Neutrophil 
Respiratory Burst In Vitro. College of Medical & Dental Sciences, University of Birmingham, 
March 2013.  
 
Ling MR, Matthews JB, Chapple IL. An Investigation into the Chemotactic Accuracy of 
Peripheral Blood Neutrophils from Patients with Chronic Periodontitis. The Alpha Omega 
London Chapter and Charitable Trust, London, UK, November 2012. 
 
Ling MR, Chapple IL, Matthews JB. C-Reactive Protein Modulation of Peripheral Blood 
Neutrophil Response. Birmingham Inflammation Group, University of Birmingham, March 
2012. 
 
Ling MR, Matthews JB, Chapple IL. Enhanced Chemiluminescence Assays to Measure 
Neutrophil Reactive Oxygen Species. West Midlands Primary Immunodeficiency Group, 
University of Birmingham, November 2011.  
 
Ling MR, Chapple IL, Matthews JB. Effect of C-Reactive Protein on Neutrophil ROS 
Production. The Royal College of Surgeons of England, London, UK, November 2011. 
 
Ling MR, Chapple IL, Matthews JB. Effect of C-Reactive Protein on Neutrophil ROS 
Production. British Society for Oral and Dental Research, Sheffield, UK, September 2011. 
 
Ling MR, Chapple IL, Matthews JB. C-Reactive Protein Modulation of Peripheral Blood 
Neutrophil Response (ID 207). International Association for Dental Research, San Diego, 
California, USA, March 2011. 
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APPENDIX V 
Research papers published in peer-reviewed journals 
 
Roberts HM, Ling MR, Insall R, Kalna G, Grant MM, Chapple IL (2014). Neutrophil 
chemotaxis in chronic periodontitis. Submitted to J Clin Periodontol 
 
Ling MR, Chapple IL, Creese AJ, Matthews JB (2014). Effects of C-reactive protein on 
the neutrophil respiratory burst in vitro. Innate Immun; 20(4): 339-349 
 
Matthews JB, Chen FM, Milward MR, Ling MR, Chapple IL (2012). Neutrophil 
superoxide production in the presence of cigarette smoke extract, nicotine and cotinine. J Clin 
Periodontol; 39(7): 626-634 
 
Palmer LJ, Cooper PR, Ling MR, Wright HJ, Huissoon A, Chapple IL (2012). 
Hypochlorous acid regulates neutrophil extracellular trap release in humans. Clin Exp 
Immunol; 167(2): 261-268 
 
Grant MM, Creese AJ, Barr G, Ling MR, Scott AE, Matthews JB, Griffiths HR, Cooper 
HJ, Chapple IL (2010). Proteomic analysis of a noninvasive human model of acute 
inflammation and its resolution: the twenty-one day gingivitis model. J Proteome Res; 9(9): 
4732-4744 
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APPENDIX VI 
Research grants 
 
Birmingham & the Black Country Comprehensive Local Research Network funding 
allocation 
£15,938.00 
May 2012 
 
The Royal College of Surgeons of England Faculty of Dental Surgery Research Grant 
£9,200.00 
November 2010 
 
Oral & Dental Research Trust Glaxo Smith Kline Research Grant 
£6,273.00 
August 2010 
 
British Society of Periodontology Research Grant 
£4,444.00 
April 2010 
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APPENDIX VII 
Research prizes & awards 
 
Sir Wilfred Fish Research Prize 
British Society of Periodontology 
October 2013 
 
Highly Commended Award for doctoral research poster presentation 
The University of Birmingham College of Medical & Dental Sciences Festival of Graduate 
Research 
March 2013 
 
Inaugural Dr John Zamet Memorial Prize in Periodontal Research 
The Alpha Omega London Chapter & Charitable Trust 
November 2012 
 
 
 
